snps	chr	pos	r2	dist	referenz	snp_vereinzelt_gwas	snps_gwas	phenotype_gwas	pval_details_gwas	pval_gwas	reported_genes_gwas	fa_gwas	date_gwas	pmid_gwas
1:2470675:T:C	1	2470675	0.859211	30663	ref1: TG phase3 v5	rs10797432	rs10797432	Ulcerative colitis	""	3e-12	MMEL1, PLCH2, TNFRSF14	Jostins L	2012-11-01	23128233
1:2470675:T:C	1	2470675	0.859211	30841	ref1: TG phase3 v5	rs10910092	rs10910092	Ulcerative colitis	(EA)	1e-11	NR	Liu JZ	2015-07-20	26192919
1:2470675:T:C	1	2470675	0.846809	42541	ref1: TG phase3 v5	rs734999	rs734999	Ulcerative colitis	""	3e-09	MMEL1, PLCH2, C1orf93, TNFRSF14	Anderson CA	2011-02-06	21297633
1:2470675:T:C	1	2470675	0.83166	20530	ref1: TG phase3 v5	rs2234161	rs2234161	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	2e-11	TNFRSF14	Ellinghaus D	2016-03-14	26974007
1:2470675:T:C	1	2470675	0.790635	32105	ref1: TG phase3 v5	rs6667605	rs6667605	Inflammatory bowel disease	(EA)	1e-06	NR	Liu JZ	2015-07-20	26192919
1:2470675:T:C	1	2470675	0.790635	32105	ref1: TG phase3 v5	rs6667605	rs6667605	Ulcerative colitis	(EA)	3e-10	NR	Liu JZ	2015-07-20	26192919
1:2470675:T:C	1	2470675	0.39248	82949	ref1: TG phase3 v5	rs3890745	rs3890745	Rheumatoid arthritis	""	1e-07	MMEL1, TNFRSF14	Raychaudhuri S	2008-09-14	18794853
1:2470675:T:C	1	2470675	0.39248	82949	ref1: TG phase3 v5	rs3890745	rs3890745	Rheumatoid arthritis	""	4e-06	TNFRSF14	Stahl EA	2010-05-09	20453842
1:2470675:T:C	1	2470675	0.38622	238489	ref1: TG phase3 v5	rs4648356	rs4648356	Multiple sclerosis	""	1e-14	MMEL1	Sawcer S	2011-08-11	21833088
1:2470675:T:C	1	2470675	0.364026	56071	ref1: TG phase3 v5	rs3748816	rs3748816	Celiac disease	""	3e-09	MMEL1, TNFRSF14	Dubois PC	2010-02-28	20190752
1:2470675:T:C	1	2470675	0.356323	49852	ref1: TG phase3 v5	rs6670198	rs6670198	Multiple sclerosis	""	2e-36	FAM213B	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs142706819:2575297:A:C	1	2575297			LD kl min R2									
rs2379156:11503660:G:T	1	11503660			LD kl min R2									
rs2817618:11603207:A:G	1	11603207	0.649853	144	ref1: TG phase3 v5	rs2817619	rs2817619	Attention deficit hyperactivity disorder (inattention symptoms)	""	6e-07	PTCHD2	Kweon K	2018-04-01	32595297
rs5068:11905974:A:G	1	11905974	0.937106	29312	ref1: TG phase3 v5	rs17376328	rs17376328	Diastolic blood pressure	""	3e-06	CLCN6	Kulminski AM	2018-03-01	29615537
rs5068:11905974:A:G	1	11905974	0.937106	29312	ref1: TG phase3 v5	rs17376328	rs17376328	Systolic blood pressure	""	7e-06	CLCN6	Kulminski AM	2018-03-01	29615537
rs5068:11905974:A:G	1	11905974	0.865716	53458	ref1: TG phase3 v5	rs17375901	rs17375901	Atrial fibrillation	""	6e-07	NPPA, MTHFR	Benjamin EJ	2009-07-13	19597492
rs5068:11905974:A:G	1	11905974	0.376843	43196	ref1: TG phase3 v5	rs17367504	rs17367504	Systolic blood pressure	""	2e-13	NPPA, CLCN6, NPPB, AGTRAP, MTHFR	Newton-Cheh C	2009-05-10	19430483
rs5068:11905974:A:G	1	11905974	0.376843	43196	ref1: TG phase3 v5	rs17367504	rs17367504	Blood pressure	(Mean Arterial Pressure)	2e-16	NPPB, MTHFR	Wain LV	2011-09-11	21909110
rs5068:11905974:A:G	1	11905974	0.376843	43196	ref1: TG phase3 v5	rs17367504	rs17367504	Diastolic blood pressure	""	3e-09	MTHFR	Kulminski AM	2018-03-01	29615537
rs5068:11905974:A:G	1	11905974	0.376843	43196	ref1: TG phase3 v5	rs17367504	rs17367504	Hypertension	""	4e-34	MTHFR	German CA	2019-12-26	31879980
rs5068:11905974:A:G	1	11905974	0.369296	45131	ref1: TG phase3 v5	rs17037390	rs17037390	Diastolic blood pressure	""	1e-23	MTHFR, NPPB	Ehret GB	2016-09-12	27618452
rs5068:11905974:A:G	1	11905974	0.369296	45131	ref1: TG phase3 v5	rs17037390	rs17037390	Systolic blood pressure	""	6e-29	MTHFR, NPPB	Ehret GB	2016-09-12	27618452
rs198379:11915467:T:C	1	11915467	0.981907	3804	ref1: TG phase3 v5	rs198389	rs198389	NT-proBNP levels in acute coronary syndrome	""	1e-15	NPPB	Johansson A	2016-01-21	26908625
rs198379:11915467:T:C	1	11915467	0.981907	3804	ref1: TG phase3 v5	rs198389	rs198389	B-type natriuretic peptide levels	""	1e-09	NPPB	Musani SK	2015-01-05	25561047
rs198379:11915467:T:C	1	11915467	0.907963	628	ref1: TG phase3 v5	rs549596	rs549596	Blood protein levels in cardiovascular risk	""	2e-14	NPPB	Folkersen L	2017-04-03	28369058
rs198379:11915467:T:C	1	11915467	0.402637	16434	ref1: TG phase3 v5	rs1023252	rs1023252	Natriuretic peptide levels	""	4e-16	CLCN6	Del Greco M F	2011-01-27	21273288
rs198389:11919271:A:G	1	11919271	1	0	ref1: TG phase3 v5	rs198389	rs198389	NT-proBNP levels in acute coronary syndrome	""	1e-15	NPPB	Johansson A	2016-01-21	26908625
rs198389:11919271:A:G	1	11919271	1	0	ref1: TG phase3 v5	rs198389	rs198389	B-type natriuretic peptide levels	""	1e-09	NPPB	Musani SK	2015-01-05	25561047
rs198389:11919271:A:G	1	11919271	0.890342	3176	ref1: TG phase3 v5	rs549596	rs549596	Blood protein levels in cardiovascular risk	""	2e-14	NPPB	Folkersen L	2017-04-03	28369058
rs198389:11919271:A:G	1	11919271	0.418354	20238	ref1: TG phase3 v5	rs1023252	rs1023252	Natriuretic peptide levels	""	4e-16	CLCN6	Del Greco M F	2011-01-27	21273288
rs144069283:11923781:G:T	1	11923781			LD kl min R2									
rs4654770:22147077:G:A	1	22147077			LD kl min R2									
rs4654995:22234654:C:T	1	22234654			LD kl min R2									
rs78078784:55030678:T:C	1	55030678			LD kl min R2									
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	LDL cholesterol	""	1e-10	PCSK9	Waterworth DM	2010-09-23	20864672
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	LDL cholesterol	""	4e-11	PCSK9	Willer CJ	2008-01-13	18193043
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	Myocardial infarction (early onset)	""	1e-08	PCSK9	Kathiresan S	2009-02-08	19198609
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	Coronary heart disease	""	9e-08	PCSK9	Schunkert H	2011-03-06	21378990
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	LDL cholesterol	""	4e-08	PCSK9	Kathiresan S	2008-12-07	19060906
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	Coronary artery disease	""	2e-08	PCSK9	Nikpay M	2015-09-07	26343387
rs11206510:55496039:T:C	1	55496039	1	0	ref1: TG phase3 v5	rs11206510	rs11206510	Myocardial infarction	""	7e-07	PCSK9	Nikpay M	2015-09-07	26343387
rs11206510:55496039:T:C	1	55496039	0.306688	9408	ref1: TG phase3 v5	rs45448095	rs45448095	Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	""	4e-12	PCSK9	Pott J	2018-05-01	29748315
rs11206510:55496039:T:C	1	55496039	0.306688	9408	ref1: TG phase3 v5	rs45448095	rs45448095	Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	(statin-free)	3e-08	PCSK9	Pott J	2018-05-01	29748315
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	LDL cholesterol	""	2e-44	PCSK9	Kathiresan S	2008-01-13	18193044
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	LDL cholesterol	""	2e-92	PCSK9	Surakka I	2015-05-11	25961943
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Response to statins (LDL cholesterol change)	(baseline LDL-C)	5e-09	PCSK9	Chasman DI	2012-02-13	22331829
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Low density lipoprotein cholesterol levels (on statin treatment)	(EA)	8e-10	PCSK9	Oni-Orisan A	2020-01-16	31969989
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(Serum_C)	1e-18	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_LDL_C)	5e-20	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_LDL_CE)	2e-18	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(L_LDL_FC)	1e-24	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(FreeC)	4e-23	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(XS_VLDL_L)	1e-08	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(LDL_C)	2e-08	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(Serum_C)	3e-08	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(XS_VLDL_CE)	4e-12	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(Remnant_C)	9e-18	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(S_HDL_PL)	7e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(L_LDL_PL)	4e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(XS_VLDL_C)	4e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(L_LDL_L)	7e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_HDL_PL)	3e-17	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_HDL_C)	9e-11	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(S_VLDL_CE)	1e-12	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(L_LDL_CE)	7e-25	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_LDL_FC)	4e-20	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(L_LDL_PL)	4e-22	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(XS_VLDL_C)	3e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(L_LDL_L)	7e-26	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(L_LDL_FC)	4e-11	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(FreeC)	6e-11	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(XS_VLDL_PL)	8e-12	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(Remnant_C)	3e-08	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(S_VLDL_CE)	9e-08	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_HDL_P)	2e-17	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(S_LDL_L)	2e-19	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_HDL_CE)	5e-11	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(S_LDL_P)	1e-16	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(S_LDL_FC)	2e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(IDL_L)	5e-17	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(IDL_PL)	2e-21	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(IDL_P)	3e-21	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(XS_VLDL_FC)	4e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(L_LDL_C)	3e-16	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(ApoB_ApoA1)	7e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(IDL_P)	4e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(IDL_FC)	4e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(XS_VLDL_CE)	2e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(L_LDL_C)	3e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(IDL_FC)	4e-20	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(S_HDL_PL)	8e-19	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(L_LDL_CE)	8e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(L_LDL_P)	1e-09	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(M_LDL_FC)	7e-07	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(ApoB_ApoA1)	4e-16	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(L_LDL_P)	3e-23	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(M_LDL_C)	1e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(M_LDL_CE)	1e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(M_LDL_L)	2e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(XS_VLDL_P)	4e-09	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(M_LDL_PL)	3e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(ApoB)	3e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(M_LDL_P)	3e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(S_LDL_C)	4e-06	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(IDL_C)	7e-14	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(IDL_CE)	1e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(IDL_L)	2e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(IDL_PL)	2e-13	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(XS_VLDL_P)	9e-16	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(XS_VLDL_L)	2e-14	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(LDL_C)	1e-24	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	LDL cholesterol x physical activity interaction (2df test)	""	6e-158	NR	Kilpelainen TO	2019-01-22	30670697
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels	(XS_VLDL_FC)	2e-07	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(M_LDL_PL)	8e-20	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(VLDL_C)	6e-11	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(IDL_C)	8e-16	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(IDL_CE)	1e-17	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Serum metabolite levels (CMS)	(XS_VLDL_PL)	1e-16	PCSK9	Gallois A	2019-10-21	31636271
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Apolipoprotein A1 levels	""	1e-12	PCSK9	Richardson TG	2020-03-23	32203549
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	""	2e-17	PCSK9	Pott J	2018-05-01	29748315
rs11591147:55505647:G:T	1	55505647	1	0	ref1: TG phase3 v5	rs11591147	rs11591147	Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	(statin-free)	6e-16	PCSK9	Pott J	2018-05-01	29748315
rs11591147:55505647:G:T	1	55505647	0.373466	79197	ref1: TG phase3 v5	rs191448950	rs191448950	Cholesterol, total	""	6e-73	PCSK9	Surakka I	2015-05-11	25961943
rs7525407:55522425:G:A	1	55522425	0.363143	1316	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels	(XL_HDL_FC)	2e-06	PCSK9	Gallois A	2019-10-21	31636271
rs7525407:55522425:G:A	1	55522425	0.363143	1316	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels (CMS)	(XXL_VLDL_CE)	2e-10	PCSK9	Gallois A	2019-10-21	31636271
rs7525407:55522425:G:A	1	55522425	0.363143	1316	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels (CMS)	(XL_HDL_FC)	6e-10	PCSK9	Gallois A	2019-10-21	31636271
rs565436:55524601:G:A	1	55524601	0.362264	3492	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels	(XL_HDL_FC)	2e-06	PCSK9	Gallois A	2019-10-21	31636271
rs565436:55524601:G:A	1	55524601	0.362264	3492	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels (CMS)	(XXL_VLDL_CE)	2e-10	PCSK9	Gallois A	2019-10-21	31636271
rs565436:55524601:G:A	1	55524601	0.362264	3492	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels (CMS)	(XL_HDL_FC)	6e-10	PCSK9	Gallois A	2019-10-21	31636271
rs11583974:55551718:G:A	1	55551718			LD kl min R2									
rs1165285:55556428:T:A	1	55556428	0.524043	35319	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels	(XL_HDL_FC)	2e-06	PCSK9	Gallois A	2019-10-21	31636271
rs1165285:55556428:T:A	1	55556428	0.524043	35319	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels (CMS)	(XXL_VLDL_CE)	2e-10	PCSK9	Gallois A	2019-10-21	31636271
rs1165285:55556428:T:A	1	55556428	0.524043	35319	ref1: TG phase3 v5	rs693668	rs693668	Serum metabolite levels (CMS)	(XL_HDL_FC)	6e-10	PCSK9	Gallois A	2019-10-21	31636271
rs1165285:55556428:T:A	1	55556428	0.364008	37961	ref1: TG phase3 v5	rs2495477	rs2495477	Serum metabolite levels (CMS)	(EstC)	5e-15	PCSK9	Gallois A	2019-10-21	31636271
rs1165285:55556428:T:A	1	55556428	0.364008	37961	ref1: TG phase3 v5	rs2495477	rs2495477	Serum metabolite levels	(EstC)	6e-08	PCSK9	Gallois A	2019-10-21	31636271
rs79494709:55608984:G:C	1	55608984			LD kl min R2									
rs116264584:55725045:G:C	1	55725045			LD kl min R2									
rs10888908:55726519:T:C	1	55726519			LD kl min R2									
rs11206619:56024421:C:G	1	56024421	0.400603	84183	ref1: TG phase3 v5	rs1165472	rs1165472	Paclitaxel-induced neuropathy	""	4e-06	RP11-466L17.1	Leandro-Garcia LJ	2013-06-17	23776197
rs145534566:153886345:G:A	1	153886345			LD kl min R2									
rs113191295:153912623:G:A	1	153912623	0.904187	70591	ref1: TG phase3 v5	rs111237020	rs111237020	C-reactive protein levels	""	2e-16	NR	Han X	2020-01-03	31900758
rs115199989:153924297:C:A	1	153924297			LD kl min R2									
rs2230324:153954646:C:T	1	153954646			LD kl min R2									
rs41265211:153963749:G:T	1	153963749			LD kl min R2									
rs141372821:154044909:T:C	1	154044909			LD kl min R2									
rs137945133:154047416:T:G	1	154047416			LD kl min R2									
rs55675282:154167180:A:C	1	154167180			LD kl min R2									
rs114772434:154182928:C:G	1	154182928			LD kl min R2									
rs113618762:154199049:A:G	1	154199049			LD kl min R2									
rs114779784:154239549:G:C	1	154239549			LD kl min R2									
rs12742691:154258864:C:T	1	154258864			LD kl min R2									
rs10908804:154262857:A:C	1	154262857	0.790576	8020	ref1: TG phase3 v5	rs3103309	rs3103309	Blood protein levels	(IL6R)	2e-07	NR	Sun W	2016-08-17	27532455
rs10908804:154262857:A:C	1	154262857	0.341929	120949	ref1: TG phase3 v5	rs4845364	rs4845364	Leisure sedentary behaviour (television watching)	""	1e-12	NR	van de Vegte YJ	2020-04-21	32317632
rs3103309:154270877:C:T	1	154270877	1	0	ref1: TG phase3 v5	rs3103309	rs3103309	Blood protein levels	(IL6R)	2e-07	NR	Sun W	2016-08-17	27532455
rs56367957:154283217:A:G	1	154283217	0.417882	76698	ref1: TG phase3 v5	rs12077265	rs12077265	C-reactive protein levels	""	2e-78	NR	Han X	2020-01-03	31900758
rs1931299:154283831:G:T	1	154283831	0.387735	76084	ref1: TG phase3 v5	rs12077265	rs12077265	C-reactive protein levels	""	2e-78	NR	Han X	2020-01-03	31900758
rs115165870:154303228:G:A	1	154303228			LD kl min R2									
rs147889978:154303783:G:A	1	154303783			LD kl min R2									
rs12077870:154305190:G:C	1	154305190	0.995175	13232	ref1: TG phase3 v5	rs35950207	rs35950207	Parkinson's disease progression (motor)	""	5e-06	AQP10	Tan MMX	2020-10-28	33111402
rs12077870:154305190:G:C	1	154305190	0.334379	54725	ref1: TG phase3 v5	rs12077265	rs12077265	C-reactive protein levels	""	2e-78	NR	Han X	2020-01-03	31900758
rs150779199:154307776:C:T	1	154307776			LD kl min R2									
rs41310887:154321623:G:A	1	154321623	0.451647	194074	ref1: TG phase3 v5	rs114697636	rs114697636	C-reactive protein levels	""	3e-08	NR	Han X	2020-01-03	31900758
rs56258967:154334023:C:T	1	154334023			LD kl min R2									
rs75432579:154340929:G:A	1	154340929			LD kl min R2									
rs79438587:154342517:C:T	1	154342517			LD kl min R2									
rs12735458:154361406:A:G	1	154361406	1	0	ref1: TG phase3 v5	rs12735458	rs12735458	C-reactive protein levels	""	1e-10	NR	Han X	2020-01-03	31900758
rs12132326:154376896:G:A	1	154376896			LD kl min R2									
rs57569414:154380419:C:A	1	154380419	0.789918	27061	ref1: TG phase3 v5	rs11579718	rs11579718	Metabolite levels	(salicylurate)	9e-06	ATP8B2	Rhee EP	2013-07-02	23823483
rs7525477:154394297:G:A	1	154394297	0.307609	1649	ref1: TG phase3 v5	rs6689306	rs6689306	Coronary artery disease	""	3e-09	IL6R	Nikpay M	2015-09-07	26343387
rs116037345:154404454:C:T	1	154404454			LD kl min R2									
rs186110340:154415848:C:G	1	154415848			LD kl min R2									
rs61812598:154420087:G:A	1	154420087	1	0	ref1: TG phase3 v5	rs61812598	rs61812598	Fibrinogen levels	""	3e-36	IL6R	de Vries PS	2015-11-10	26561523
rs61812598:154420087:G:A	1	154420087	1	0	ref1: TG phase3 v5	rs61812598	rs61812598	C-reactive protein levels	""	0	NR	Han X	2020-01-03	31900758
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs2228145	rs2228145	Rheumatoid arthritis	(EA)	5e-06	IL6R	Okada Y	2013-12-25	24390342
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs2228145	rs2228145	Rheumatoid arthritis	""	4e-09	IL6R	Okada Y	2013-12-25	24390342
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs2228145	rs2228145	Hay fever and/or eczema	""	7e-13	NR	Johansson A	2019-07-30	31361310
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs2228145	rs2228145	Allergic disease (asthma, hay fever or eczema)	""	1e-12	NR	Johansson A	2019-07-30	31361310
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	C-reactive protein levels	""	2e-48	IL6R	Dehghan A	2011-02-07	21300955
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	Protein quantitative trait loci	(sIL-6R)	2e-57	IL6R	Melzer D	2008-05-09	18464913
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	Pulmonary function	(ppFEF)	7e-06	IL6R	Wilk JB	2007-09-19	17903307
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	9e-18	IL6R	Ellinghaus D	2016-03-14	26974007
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	Asthma	""	2e-08	IL6R	Ferreira MA	2011-09-10	21907864
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	Fibrinogen	(EA)	6e-27	IL6R	Sabater-Lleal M	2013-08-22	23969696
rs61812598:154420087:G:A	1	154420087	0.995763	6177	ref1: TG phase3 v5	rs4129267	rs4129267	Blood protein levels in cardiovascular risk	""	2e-297	IL6R	Folkersen L	2017-04-03	28369058
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs8192284	rs8192284	Fibrinogen	""	2e-11	IL6R	Danik JS	2009-04-01	20031577
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs8192284	rs8192284	C-reactive protein	""	2e-08	IL6R	Ridker PM	2008-04-24	18439548
rs61812598:154420087:G:A	1	154420087	0.995763	6883	ref1: TG phase3 v5	rs8192284	rs8192284	Blood protein levels	(IL6R)	8e-194	NR	Sun W	2016-08-17	27532455
rs61812598:154420087:G:A	1	154420087	0.939143	1208	ref1: TG phase3 v5	rs4537545	rs4537545	C-reactive protein	""	2e-14	IL6R	Elliott P	2009-07-01	19567438
rs61812598:154420087:G:A	1	154420087	0.938315	15063	ref1: TG phase3 v5	rs56383622	rs56383622	Interleukin-6 levels	""	1e-22	IL6R	Russell AE	2020-05-28	32473944
rs61812598:154420087:G:A	1	154420087	0.928285	1672	ref1: TG phase3 v5	rs11265613	rs11265613	Protein quantitative trait loci	(IL-6 sRa)	5e-93	NR	Ruffieux H	2020-06-03	32492067
rs61812598:154420087:G:A	1	154420087	0.451191	22671	ref1: TG phase3 v5	rs12118721	rs12118721	Myocardial infarction	""	1e-07	IL6R	Nikpay M	2015-09-07	26343387
rs61812598:154420087:G:A	1	154420087	0.424381	24141	ref1: TG phase3 v5	rs6689306	rs6689306	Coronary artery disease	""	3e-09	IL6R	Nikpay M	2015-09-07	26343387
rs113580743:154420333:G:A	1	154420333	0.333601	292784	ref1: TG phase3 v5	rs114697636	rs114697636	C-reactive protein levels	""	3e-08	NR	Han X	2020-01-03	31900758
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs2228145	rs2228145	Rheumatoid arthritis	(EA)	5e-06	IL6R	Okada Y	2013-12-25	24390342
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs2228145	rs2228145	Rheumatoid arthritis	""	4e-09	IL6R	Okada Y	2013-12-25	24390342
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs2228145	rs2228145	Hay fever and/or eczema	""	7e-13	NR	Johansson A	2019-07-30	31361310
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs2228145	rs2228145	Allergic disease (asthma, hay fever or eczema)	""	1e-12	NR	Johansson A	2019-07-30	31361310
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	C-reactive protein levels	""	2e-48	IL6R	Dehghan A	2011-02-07	21300955
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	Protein quantitative trait loci	(sIL-6R)	2e-57	IL6R	Melzer D	2008-05-09	18464913
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	Pulmonary function	(ppFEF)	7e-06	IL6R	Wilk JB	2007-09-19	17903307
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	9e-18	IL6R	Ellinghaus D	2016-03-14	26974007
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	Asthma	""	2e-08	IL6R	Ferreira MA	2011-09-10	21907864
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	Fibrinogen	(EA)	6e-27	IL6R	Sabater-Lleal M	2013-08-22	23969696
rs12126142:154425456:G:A	1	154425456	1	808	ref1: TG phase3 v5	rs4129267	rs4129267	Blood protein levels in cardiovascular risk	""	2e-297	IL6R	Folkersen L	2017-04-03	28369058
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs8192284	rs8192284	Fibrinogen	""	2e-11	IL6R	Danik JS	2009-04-01	20031577
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs8192284	rs8192284	C-reactive protein	""	2e-08	IL6R	Ridker PM	2008-04-24	18439548
rs12126142:154425456:G:A	1	154425456	1	1514	ref1: TG phase3 v5	rs8192284	rs8192284	Blood protein levels	(IL6R)	8e-194	NR	Sun W	2016-08-17	27532455
rs12126142:154425456:G:A	1	154425456	0.995763	5369	ref1: TG phase3 v5	rs61812598	rs61812598	Fibrinogen levels	""	3e-36	IL6R	de Vries PS	2015-11-10	26561523
rs12126142:154425456:G:A	1	154425456	0.995763	5369	ref1: TG phase3 v5	rs61812598	rs61812598	C-reactive protein levels	""	0	NR	Han X	2020-01-03	31900758
rs12126142:154425456:G:A	1	154425456	0.935323	6577	ref1: TG phase3 v5	rs4537545	rs4537545	C-reactive protein	""	2e-14	IL6R	Elliott P	2009-07-01	19567438
rs12126142:154425456:G:A	1	154425456	0.934404	20432	ref1: TG phase3 v5	rs56383622	rs56383622	Interleukin-6 levels	""	1e-22	IL6R	Russell AE	2020-05-28	32473944
rs12126142:154425456:G:A	1	154425456	0.924225	7041	ref1: TG phase3 v5	rs11265613	rs11265613	Protein quantitative trait loci	(IL-6 sRa)	5e-93	NR	Ruffieux H	2020-06-03	32492067
rs12126142:154425456:G:A	1	154425456	0.445231	28040	ref1: TG phase3 v5	rs12118721	rs12118721	Myocardial infarction	""	1e-07	IL6R	Nikpay M	2015-09-07	26343387
rs12126142:154425456:G:A	1	154425456	0.418768	29510	ref1: TG phase3 v5	rs6689306	rs6689306	Coronary artery disease	""	3e-09	IL6R	Nikpay M	2015-09-07	26343387
rs12739228:154426190:G:A	1	154426190	0.302	66275	ref2: TG phase1 v3	rs12077265	rs12077265	C-reactive protein levels	""	2e-78	NR	Han X	2020-01-03	31900758
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs2228145	rs2228145	Rheumatoid arthritis	(EA)	5e-06	IL6R	Okada Y	2013-12-25	24390342
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs2228145	rs2228145	Rheumatoid arthritis	""	4e-09	IL6R	Okada Y	2013-12-25	24390342
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs2228145	rs2228145	Hay fever and/or eczema	""	7e-13	NR	Johansson A	2019-07-30	31361310
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs2228145	rs2228145	Allergic disease (asthma, hay fever or eczema)	""	1e-12	NR	Johansson A	2019-07-30	31361310
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	C-reactive protein levels	""	2e-48	IL6R	Dehghan A	2011-02-07	21300955
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	Protein quantitative trait loci	(sIL-6R)	2e-57	IL6R	Melzer D	2008-05-09	18464913
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	Pulmonary function	(ppFEF)	7e-06	IL6R	Wilk JB	2007-09-19	17903307
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	9e-18	IL6R	Ellinghaus D	2016-03-14	26974007
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	Asthma	""	2e-08	IL6R	Ferreira MA	2011-09-10	21907864
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	Fibrinogen	(EA)	6e-27	IL6R	Sabater-Lleal M	2013-08-22	23969696
rs4129267:154426264:C:T	1	154426264	1	0	ref1: TG phase3 v5	rs4129267	rs4129267	Blood protein levels in cardiovascular risk	""	2e-297	IL6R	Folkersen L	2017-04-03	28369058
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs8192284	rs8192284	Fibrinogen	""	2e-11	IL6R	Danik JS	2009-04-01	20031577
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs8192284	rs8192284	C-reactive protein	""	2e-08	IL6R	Ridker PM	2008-04-24	18439548
rs4129267:154426264:C:T	1	154426264	1	706	ref1: TG phase3 v5	rs8192284	rs8192284	Blood protein levels	(IL6R)	8e-194	NR	Sun W	2016-08-17	27532455
rs4129267:154426264:C:T	1	154426264	0.995763	6177	ref1: TG phase3 v5	rs61812598	rs61812598	Fibrinogen levels	""	3e-36	IL6R	de Vries PS	2015-11-10	26561523
rs4129267:154426264:C:T	1	154426264	0.995763	6177	ref1: TG phase3 v5	rs61812598	rs61812598	C-reactive protein levels	""	0	NR	Han X	2020-01-03	31900758
rs4129267:154426264:C:T	1	154426264	0.935323	7385	ref1: TG phase3 v5	rs4537545	rs4537545	C-reactive protein	""	2e-14	IL6R	Elliott P	2009-07-01	19567438
rs4129267:154426264:C:T	1	154426264	0.934404	21240	ref1: TG phase3 v5	rs56383622	rs56383622	Interleukin-6 levels	""	1e-22	IL6R	Russell AE	2020-05-28	32473944
rs4129267:154426264:C:T	1	154426264	0.924225	7849	ref1: TG phase3 v5	rs11265613	rs11265613	Protein quantitative trait loci	(IL-6 sRa)	5e-93	NR	Ruffieux H	2020-06-03	32492067
rs4129267:154426264:C:T	1	154426264	0.445231	28848	ref1: TG phase3 v5	rs12118721	rs12118721	Myocardial infarction	""	1e-07	IL6R	Nikpay M	2015-09-07	26343387
rs4129267:154426264:C:T	1	154426264	0.418768	30318	ref1: TG phase3 v5	rs6689306	rs6689306	Coronary artery disease	""	3e-09	IL6R	Nikpay M	2015-09-07	26343387
rs140393337:154428309:G:T	1	154428309			LD kl min R2									
rs142712385:154431123:T:A	1	154431123			LD kl min R2									
rs147140395:154433897:G:A	1	154433897			LD kl min R2									
rs114445392:154438143:C:T	1	154438143			LD kl min R2									
rs147700711:154445362:G:T	1	154445362			LD kl min R2									
1:154445635:C:T	1	154445635			snp not in any Ref									
rs41269913:154461480:C:T	1	154461480			LD kl min R2									
rs35013837:154480123:C:T	1	154480123	0.319876	120208	ref2: TG phase1 v3	rs12077265	rs12077265	C-reactive protein levels	""	2e-78	NR	Han X	2020-01-03	31900758
rs116059394:154483655:A:G	1	154483655			LD kl min R2									
rs78664422:154499246:G:A	1	154499246			LD kl min R2									
rs77994623:154505106:C:T	1	154505106			LD kl min R2									
rs147830103:154509061:G:A	1	154509061			LD kl min R2									
rs76289529:154516404:C:T	1	154516404			LD kl min R2									
rs4845649:154533617:C:A	1	154533617	0.375286	131938	ref1: TG phase3 v5	rs8192282	rs8192282	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)	(Hispanic)	5e-06	IL6R	Leger PD	2014-02-20	24554482
rs12072348:154547292:A:C	1	154547292			LD kl min R2									
rs11264224:154568086:A:C	1	154568086	0.310248	21879	ref2: TG phase1 v3	rs9426827	rs9426827	Apolipoprotein A1 levels	""	3e-18	ADAR	Richardson TG	2020-03-23	32203549
rs9427097:154568683:T:G	1	154568683			LD kl min R2									
rs12139887:154573139:A:C	1	154573139	0.37637	112402	ref1: TG phase3 v5	rs16830122	rs16830122	Alzheimer's disease in APOE e4- carriers	""	2e-06	KCNN3	Jun G	2015-03-17	25778476
rs148657418:154602770:TAATA:T	1	154602770			LD kl min R2									
rs61811397:154606846:G:A	1	154606846			LD kl min R2									
rs9427109:154609009:A:G	1	154609009	0.809195	19044	ref1: TG phase3 v5	rs9426827	rs9426827	Apolipoprotein A1 levels	""	3e-18	ADAR	Richardson TG	2020-03-23	32203549
rs9427109:154609009:A:G	1	154609009	0.745716	52346	ref1: TG phase3 v5	rs1127311	rs1127311	C-reactive protein levels or triglyceride levels (pleiotropy)	""	6e-09	ADAR	Ligthart S	2016-06-10	27286809
rs9427109:154609009:A:G	1	154609009	0.321562	21489	ref1: TG phase3 v5	rs10796927	rs10796927	Blood protein levels	(IL6R)	2e-17	NR	Sun W	2016-08-17	27532455
rs76401668:154610358:G:A	1	154610358	0.655642	193553	ref1: TG phase3 v5	rs139952834	rs139952834	C-reactive protein levels	""	2e-09	NR	Han X	2020-01-03	31900758
rs201012281:154631628:ACTGCG:A	1	154631628			LD kl min R2									
1:154650470:C:T	1	154650470			LD kl min R2									
rs7554871:154650598:G:A	1	154650598	0.490208	60633	ref1: TG phase3 v5	rs9426827	rs9426827	Apolipoprotein A1 levels	""	3e-18	ADAR	Richardson TG	2020-03-23	32203549
rs7554871:154650598:G:A	1	154650598	0.454919	93935	ref1: TG phase3 v5	rs1127311	rs1127311	C-reactive protein levels or triglyceride levels (pleiotropy)	""	6e-09	ADAR	Ligthart S	2016-06-10	27286809
rs7554871:154650598:G:A	1	154650598	0.403341	6377	ref1: TG phase3 v5	rs3856270	rs3856270	C-reactive protein levels	""	3e-17	NR	Han X	2020-01-03	31900758
rs7554871:154650598:G:A	1	154650598	0.360062	20100	ref1: TG phase3 v5	rs10796927	rs10796927	Blood protein levels	(IL6R)	2e-17	NR	Sun W	2016-08-17	27532455
rs6426875:154650870:T:C	1	154650870			LD kl min R2									
rs11264239:154653052:G:A	1	154653052			LD kl min R2									
rs6701860:154653632:A:G	1	154653632			LD kl min R2									
rs12069266:154664175:G:T	1	154664175	0.628939	7200	ref1: TG phase3 v5	rs3856270	rs3856270	C-reactive protein levels	""	3e-17	NR	Han X	2020-01-03	31900758
rs12069266:154664175:G:T	1	154664175	0.305646	74210	ref1: TG phase3 v5	rs9426827	rs9426827	Apolipoprotein A1 levels	""	3e-18	ADAR	Richardson TG	2020-03-23	32203549
rs4845663:154692088:T:C	1	154692088			LD kl min R2									
rs7528919:154699134:C:G	1	154699134			LD kl min R2									
rs78651737:154716887:C:T	1	154716887			LD kl min R2									
rs137881298:154722040:G:A	1	154722040			LD kl min R2									
rs6667045:154726567:C:T	1	154726567			LD kl min R2									
rs74859699:154739875:G:A	1	154739875			LD kl min R2									
rs12406117:154740879:G:A	1	154740879			LD kl min R2									
rs12728678:154764715:C:T	1	154764715			LD kl min R2									
rs11577297:154766100:C:T	1	154766100			LD kl min R2									
rs1777931:154767833:C:G	1	154767833			LD kl min R2									
rs150147842:154768942:AC:A	1	154768942			LD kl min R2									
rs11804928:154786262:C:T	1	154786262			LD kl min R2									
rs10752609:154791128:G:A	1	154791128			LD kl min R2									
rs1218601:154791676:G:A	1	154791676			LD kl min R2									
rs111992259:154797987:G:A	1	154797987			LD kl min R2									
rs11264270:154802379:A:G	1	154802379			LD kl min R2									
rs74414495:154803854:G:T	1	154803854			LD kl min R2									
rs76102976:154816174:G:A	1	154816174			LD kl min R2									
rs4845395:154824792:A:G	1	154824792			LD kl min R2									
rs12044470:154826061:G:A	1	154826061	0.524327	23710	ref1: TG phase3 v5	rs12069356	rs12069356	Schizophrenia	""	2e-06	NR	Goes FS	2015-07-21	26198764
rs12044470:154826061:G:A	1	154826061	0.462635	8122	ref1: TG phase3 v5	rs1218582	rs1218582	Prostate cancer	""	2e-08	ADAM15, ADAR, CKS1B, DCST1, DCST2, EFNA3, EFNA4, LOC10050, FLAD1, KCNN3, LENEP, LOC100505666, MIR4258, PBXIP1, DPM3, PYGO2, EFNA1, SHC1, SLC50A1, ZBTB7B, PMVK	Eeles RA	2013-04-01	23535732
rs12044470:154826061:G:A	1	154826061	0.462635	8122	ref1: TG phase3 v5	rs1218582	rs1218582	Prostate cancer	""	1e-08	NR	Schumacher FR	2018-06-11	29892016
rs71628635:154834546:A:C	1	154834546			LD kl min R2									
rs143522632:154873864:C:T	1	154873864	0.545179	64798	ref1: TG phase3 v5	rs8191979	rs8191979	Hemoglobin levels	""	4e-23	SHC1	Oskarsson GR	2020-04-23	32327693
rs77715381:154888198:A:G	1	154888198	0.512467	50464	ref1: TG phase3 v5	rs8191979	rs8191979	Hemoglobin levels	""	4e-23	SHC1	Oskarsson GR	2020-04-23	32327693
rs1320965:169114635:T:A	1	169114635			LD kl min R2									
rs9332575:169527101:T:C	1	169527101	0.975285	36850	ref1: TG phase3 v5	rs6136	rs6136	Soluble levels of adhesion molecules	(P-Selectin)	4e-61	SELP	Barbalic M	2010-02-18	20167578
rs6136:169563951:T:G	1	169563951	1	0	ref1: TG phase3 v5	rs6136	rs6136	Soluble levels of adhesion molecules	(P-Selectin)	4e-61	SELP	Barbalic M	2010-02-18	20167578
rs3917727:169581258:A:G	1	169581258	0.531446	968	ref1: TG phase3 v5	rs2235302	rs2235302	Soluble levels of adhesion molecules	(P-Selectin)	4e-16	SELP	Barbalic M	2010-02-18	20167578
rs3917727:169581258:A:G	1	169581258	0.360734	27659	ref1: TG phase3 v5	rs1569476	rs1569476	Total ventricular volume	""	3e-07	SELP	Furney SJ	2010-11-30	21116278
rs185343911:170039329:T:A	1	170039329			LD kl min R2									
rs4950789:202682802:G:A	1	202682802			LD kl min R2									
rs12239558:202713809:G:A	1	202713809			LD kl min R2									
rs115942617:202741695:C:A	1	202741695			LD kl min R2									
rs11337396:202744192:AC:A	1	202744192			LD kl min R2									
rs4498856:202784295:T:C	1	202784295			LD kl min R2									
rs75168337:202833174:C:T	1	202833174			LD kl min R2									
rs200955105:202839985:A:AT	1	202839985			LD kl min R2									
rs12094889:202842333:C:T	1	202842333			LD kl min R2									
rs12043834:202875654:T:C	1	202875654			LD kl min R2									
rs61822683:202940589:G:A	1	202940589			LD kl min R2									
rs782789:202978809:A:C	1	202978809			LD kl min R2									
rs10920550:203003641:C:T	1	203003641			LD kl min R2									
rs71635601:203019091:G:A	1	203019091			LD kl min R2									
rs12742983:203024421:A:T	1	203024421			LD kl min R2									
rs17462322:203034015:G:A	1	203034015			LD kl min R2									
rs12064527:203046340:G:A	1	203046340			LD kl min R2									
rs10753935:203054310:G:A	1	203054310	0.333536	36964	ref1: TG phase3 v5	rs903361	rs903361	Asthma	""	4e-12	ADORA1	Johansson A	2019-07-30	31361310
rs10753935:203054310:G:A	1	203054310	0.323811	38891	ref1: TG phase3 v5	rs12023876	rs12023876	Asthma (childhood onset)	""	7e-12	NR	Zhu Z	2019-10-24	31669095
rs4950877:203055101:A:G	1	203055101			LD kl min R2									
rs2886116:203060608:T:G	1	203060608	0.916088	32593	ref1: TG phase3 v5	rs12023876	rs12023876	Asthma (childhood onset)	""	7e-12	NR	Zhu Z	2019-10-24	31669095
rs2886116:203060608:T:G	1	203060608	0.882739	30666	ref1: TG phase3 v5	rs903361	rs903361	Asthma	""	4e-12	ADORA1	Johansson A	2019-07-30	31361310
rs57229101:203071897:A:G	1	203071897			LD kl min R2									
rs3898276:203073796:A:C	1	203073796	0.389063	19145	ref1: TG phase3 v5	rs61745017	rs61745017	Height	""	8e-09	""	Kichaev G	2018-12-27	30595370
rs1494485:203101232:A:T	1	203101232	0.304563	8031	ref2: TG phase1 v3	rs12023876	rs12023876	Asthma (childhood onset)	""	7e-12	NR	Zhu Z	2019-10-24	31669095
rs75683960:203102206:T:C	1	203102206			LD kl min R2									
rs33996239:203109801:C:T	1	203109801			LD kl min R2									
rs17511046:203110045:C:T	1	203110045			LD kl min R2									
rs12565957:203113189:T:C	1	203113189			LD kl min R2									
rs10399916:203115403:T:A	1	203115403			LD kl min R2									
rs1845466:203120143:G:T	1	203120143			LD kl min R2									
rs903359:203146749:T:G	1	203146749			LD kl min R2									
rs17531168:203147846:A:C	1	203147846			LD kl min R2									
rs111768615:203155412:G:A	1	203155412			LD kl min R2									
rs7515776:203155703:A:T	1	203155703			LD kl min R2									
rs4950928:203155882:G:C	1	203155882	1	0	ref1: TG phase3 v5	rs4950928	rs4950928	YKL-40 levels	""	1e-13	CHI3L1	Ober C	2008-04-09	18403759
rs4950928:203155882:G:C	1	203155882	0.874219	12592	ref1: TG phase3 v5	rs2153101	rs2153101	Blood protein levels in cardiovascular risk	""	2e-236	CHI3L1	Folkersen L	2017-04-03	28369058
rs2364574:203159706:A:G	1	203159706			LD kl min R2									
rs35534609:203161576:C:A	1	203161576			LD kl min R2									
rs34697712:203164724:C:T	1	203164724			LD kl min R2									
rs2486064:203168764:T:C	1	203168764	0.341944	290	ref1: TG phase3 v5	rs2153101	rs2153101	Blood protein levels in cardiovascular risk	""	2e-236	CHI3L1	Folkersen L	2017-04-03	28369058
rs2486064:203168764:T:C	1	203168764	0.315963	12882	ref2: TG phase1 v3	rs4950928	rs4950928	YKL-40 levels	""	1e-13	CHI3L1	Ober C	2008-04-09	18403759
rs946264:203169492:A:C	1	203169492			LD kl min R2									
rs871799:203169871:C:G	1	203169871			LD kl min R2									
rs2486950:203174670:G:C	1	203174670			LD kl min R2									
rs10920581:203176399:T:C	1	203176399			LD kl min R2									
rs12140418:203180724:C:T	1	203180724			LD kl min R2									
rs111467700:203181560:C:T	1	203181560	0.616201	13086	ref1: TG phase3 v5	rs2153101	rs2153101	Blood protein levels in cardiovascular risk	""	2e-236	CHI3L1	Folkersen L	2017-04-03	28369058
rs111467700:203181560:C:T	1	203181560	0.553186	25678	ref1: TG phase3 v5	rs4950928	rs4950928	YKL-40 levels	""	1e-13	CHI3L1	Ober C	2008-04-09	18403759
rs4950937:203182292:G:A	1	203182292			LD kl min R2									
rs11586183:203183572:A:T	1	203183572			LD kl min R2									
rs74969659:203189350:G:A	1	203189350			LD kl min R2									
rs10920585:203190663:C:A	1	203190663			LD kl min R2									
rs56152830:203191527:C:T	1	203191527			LD kl min R2									
rs3216011:203192448:GC:G	1	203192448			LD kl min R2									
rs2486070:203195689:G:A	1	203195689			LD kl min R2									
rs17533071:203200196:T:C	1	203200196	0.398665	60304	ref1: TG phase3 v5	rs4543864	rs4543864	Multiple sclerosis	""	3e-06	LINC01353	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs74650977:203200560:T:C	1	203200560			LD kl min R2									
rs2486073:203203701:C:T	1	203203701	0.669677	56799	ref1: TG phase3 v5	rs4543864	rs4543864	Multiple sclerosis	""	3e-06	LINC01353	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs12747110:203206245:C:T	1	203206245			LD kl min R2									
rs7547716:203209481:T:G	1	203209481			LD kl min R2									
rs144654447:203213834:C:T	1	203213834			LD kl min R2									
rs12564942:203214009:C:T	1	203214009			LD kl min R2									
rs2486948:203222108:G:A	1	203222108			LD kl min R2									
rs12116451:203226902:G:C	1	203226902	0.487726	33598	ref1: TG phase3 v5	rs4543864	rs4543864	Multiple sclerosis	""	3e-06	LINC01353	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs12116451:203226902:G:C	1	203226902	0.313698	54273	ref1: TG phase3 v5	rs17534202	rs17534202	Mean corpuscular volume	""	3e-27	BTG2	Astle WJ	2016-11-17	27863252
rs17534048:203275407:C:G	1	203275407	0.639386	5768	ref1: TG phase3 v5	rs17534202	rs17534202	Mean corpuscular volume	""	3e-27	BTG2	Astle WJ	2016-11-17	27863252
rs4605:203309966:G:C	1	203309966	0.313452	28791	ref1: TG phase3 v5	rs17534202	rs17534202	Mean corpuscular volume	""	3e-27	BTG2	Astle WJ	2016-11-17	27863252
rs10920615:203317676:A:G	1	203317676			LD kl min R2									
rs10920618:203324697:A:T	1	203324697			LD kl min R2									
rs12145660:203326475:C:T	1	203326475			LD kl min R2									
rs10920620:203334839:T:G	1	203334839			LD kl min R2									
rs1891175:203335702:G:A	1	203335702			LD kl min R2									
rs11581135:203341531:C:A	1	203341531	0.49454	4723	ref1: TG phase3 v5	rs10800919	rs10800919	Attention deficit hyperactivity disorder (inattention symptoms)	""	4e-07	PRELP, FMOD	Kweon K	2018-04-01	32595297
rs4081379:203348910:G:A	1	203348910			LD kl min R2									
rs145626592:203512319:C:T	1	203512319			LD kl min R2									
rs4951337:203638770:G:T	1	203638770			LD kl min R2									
rs149524838:203647359:C:T	1	203647359			LD kl min R2									
rs77031439:102113116:A:G	2	102113116			LD kl min R2									
rs76873700:102129588:C:T	2	102129588			LD kl min R2									
rs10496356:102183590:A:G	2	102183590			LD kl min R2									
rs6758958:102188319:C:T	2	102188319			LD kl min R2									
rs368413571:102192079:A:G	2	102192079			LD kl min R2									
rs6543079:102196491:A:G	2	102196491			LD kl min R2									
rs76619743:102198112:AC:A	2	102198112			LD kl min R2									
rs28639701:102233171:G:A	2	102233171			LD kl min R2									
rs192040890:102234070:G:A	2	102234070			LD kl min R2									
rs4850985:102243065:T:C	2	102243065			LD kl min R2									
rs148826515:102254725:T:A	2	102254725			LD kl min R2									
rs77489518:102265874:T:C	2	102265874			LD kl min R2									
rs76515411:102265880:C:T	2	102265880			LD kl min R2									
rs62155066:102265890:A:C	2	102265890			LD kl min R2									
rs13004743:102267780:G:A	2	102267780			LD kl min R2									
rs59265382:102282980:G:A	2	102282980			LD kl min R2									
rs112161923:102320308:A:G	2	102320308			LD kl min R2									
rs11695637:102350714:A:G	2	102350714			LD kl min R2									
rs78302706:102369606:T:G	2	102369606			LD kl min R2									
rs78013647:102430369:T:C	2	102430369			LD kl min R2									
rs79238918:102506218:C:T	2	102506218			LD kl min R2									
rs6543102:102513194:T:C	2	102513194	0.38701	154860	ref1: TG phase3 v5	rs6650791	rs6650791	Height	""	1e-13	""	Kichaev G	2018-12-27	30595370
rs5832990:102515376:C:CAGTT	2	102515376	0.38701	157042	ref1: TG phase3 v5	rs6650791	rs6650791	Height	""	1e-13	""	Kichaev G	2018-12-27	30595370
rs150279884:102552547:A:G	2	102552547			LD kl min R2									
rs147521239:102561925:G:GTC	2	102561925	0.301653	101703	ref1: TG phase3 v5	rs2310173	rs2310173	Ankylosing spondylitis	""	5e-07	IL1R2	Reveille JD	2010-01-10	20062062
rs147521239:102561925:G:GTC	2	102561925	0.301653	101703	ref1: TG phase3 v5	rs2310173	rs2310173	Ulcerative colitis	""	3e-12	IL1R2	Anderson CA	2011-02-06	21297633
rs147521239:102561925:G:GTC	2	102561925	0.301653	101703	ref1: TG phase3 v5	rs2310173	rs2310173	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	(Modelling analysis)	3e-06	MAP4K4, IL1R2	Smoller JW	2013-02-27	23453885
rs112746404:102569928:A:T	2	102569928			LD kl min R2									
rs76168489:102587156:G:A	2	102587156			LD kl min R2									
rs192374608:102591479:C:T	2	102591479			LD kl min R2									
rs113168341:102597045:A:G	2	102597045			LD kl min R2									
rs114568704:102606101:G:T	2	102606101			LD kl min R2									
rs4141134:102606526:G:A	2	102606526	0.482032	56362	ref1: TG phase3 v5	rs10185424	rs10185424	Ulcerative colitis	(EA)	1e-14	NR	Liu JZ	2015-07-20	26192919
rs4141134:102606526:G:A	2	102606526	0.482032	56362	ref1: TG phase3 v5	rs10185424	rs10185424	Crohn's disease	(EA)	3e-09	NR	Liu JZ	2015-07-20	26192919
rs4141134:102606526:G:A	2	102606526	0.471274	57102	ref1: TG phase3 v5	rs2310173	rs2310173	Ankylosing spondylitis	""	5e-07	IL1R2	Reveille JD	2010-01-10	20062062
rs4141134:102606526:G:A	2	102606526	0.471274	57102	ref1: TG phase3 v5	rs2310173	rs2310173	Ulcerative colitis	""	3e-12	IL1R2	Anderson CA	2011-02-06	21297633
rs4141134:102606526:G:A	2	102606526	0.471274	57102	ref1: TG phase3 v5	rs2310173	rs2310173	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	(Modelling analysis)	3e-06	MAP4K4, IL1R2	Smoller JW	2013-02-27	23453885
rs4141134:102606526:G:A	2	102606526	0.316304	40774	ref2: TG phase1 v3	rs4851529	rs4851529	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	1e-14	IL1R2	Ellinghaus D	2016-03-14	26974007
rs4141134:102606526:G:A	2	102606526	0.310632	248192	ref1: TG phase3 v5	rs6650791	rs6650791	Height	""	1e-13	""	Kichaev G	2018-12-27	30595370
rs75227546:102609356:C:T	2	102609356			LD kl min R2									
rs4851524:102614602:A:T	2	102614602			LD kl min R2									
rs2310170:102616154:T:G	2	102616154	0.405611	46734	ref1: TG phase3 v5	rs10185424	rs10185424	Ulcerative colitis	(EA)	1e-14	NR	Liu JZ	2015-07-20	26192919
rs2310170:102616154:T:G	2	102616154	0.405611	46734	ref1: TG phase3 v5	rs10185424	rs10185424	Crohn's disease	(EA)	3e-09	NR	Liu JZ	2015-07-20	26192919
rs2310170:102616154:T:G	2	102616154	0.399415	47474	ref1: TG phase3 v5	rs2310173	rs2310173	Ankylosing spondylitis	""	5e-07	IL1R2	Reveille JD	2010-01-10	20062062
rs2310170:102616154:T:G	2	102616154	0.399415	47474	ref1: TG phase3 v5	rs2310173	rs2310173	Ulcerative colitis	""	3e-12	IL1R2	Anderson CA	2011-02-06	21297633
rs2310170:102616154:T:G	2	102616154	0.399415	47474	ref1: TG phase3 v5	rs2310173	rs2310173	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	(Modelling analysis)	3e-06	MAP4K4, IL1R2	Smoller JW	2013-02-27	23453885
rs112143646:102617045:G:A	2	102617045	0.34613	4032	ref2: TG phase1 v3	rs4321386	rs4321386	Hormone measurements	(Testosterone)	9e-08	NR	Chen Z	2013-09-18	24049095
rs3218875:102628958:T:G	2	102628958	0.804288	15945	ref1: TG phase3 v5	rs4321386	rs4321386	Hormone measurements	(Testosterone)	9e-08	NR	Chen Z	2013-09-18	24049095
rs78714574:102637685:G:C	2	102637685			LD kl min R2									
rs28385684:102638848:C:T	2	102638848			LD kl min R2									
rs2241082:102642128:T:C	2	102642128			LD kl min R2									
rs733498:102643525:C:T	2	102643525	0.625151	30512	ref1: TG phase3 v5	rs4321386	rs4321386	Hormone measurements	(Testosterone)	9e-08	NR	Chen Z	2013-09-18	24049095
rs144931540:102647239:AGT:A	2	102647239			LD kl min R2									
rs112003178:102650613:T:C	2	102650613			LD kl min R2									
rs34292511:102661833:C:A	2	102661833			LD kl min R2									
rs10185424:102662888:T:G	2	102662888	1	0	ref1: TG phase3 v5	rs10185424	rs10185424	Ulcerative colitis	(EA)	1e-14	NR	Liu JZ	2015-07-20	26192919
rs10185424:102662888:T:G	2	102662888	1	0	ref1: TG phase3 v5	rs10185424	rs10185424	Crohn's disease	(EA)	3e-09	NR	Liu JZ	2015-07-20	26192919
rs10185424:102662888:T:G	2	102662888	0.91898	740	ref1: TG phase3 v5	rs2310173	rs2310173	Ankylosing spondylitis	""	5e-07	IL1R2	Reveille JD	2010-01-10	20062062
rs10185424:102662888:T:G	2	102662888	0.91898	740	ref1: TG phase3 v5	rs2310173	rs2310173	Ulcerative colitis	""	3e-12	IL1R2	Anderson CA	2011-02-06	21297633
rs10185424:102662888:T:G	2	102662888	0.91898	740	ref1: TG phase3 v5	rs2310173	rs2310173	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	(Modelling analysis)	3e-06	MAP4K4, IL1R2	Smoller JW	2013-02-27	23453885
rs10185424:102662888:T:G	2	102662888	0.50725	15588	ref1: TG phase3 v5	rs4851529	rs4851529	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	1e-14	IL1R2	Ellinghaus D	2016-03-14	26974007
rs10203724:102688158:C:A	2	102688158			LD kl min R2									
rs72817883:102688200:G:T	2	102688200			LD kl min R2									
rs7569218:102690578:A:C	2	102690578	0.408787	45128	ref1: TG phase3 v5	rs1004548	rs1004548	Nonatopic asthma	""	7e-11	NR	Zhu Z	2019-10-24	31669095
rs71827660:102698744:ATAT:A	2	102698744	0.682999	32852	ref1: TG phase3 v5	rs1007027	rs1007027	Asthma (childhood onset)	""	6e-14	NR	Zhu Z	2019-10-24	31669095
rs71827660:102698744:ATAT:A	2	102698744	0.388704	36962	ref1: TG phase3 v5	rs1004548	rs1004548	Nonatopic asthma	""	7e-11	NR	Zhu Z	2019-10-24	31669095
rs113112517:102699635:G:T	2	102699635			LD kl min R2									
rs11694915:102710068:T:A	2	102710068	0.70232	21528	ref1: TG phase3 v5	rs1007027	rs1007027	Asthma (childhood onset)	""	6e-14	NR	Zhu Z	2019-10-24	31669095
rs11694915:102710068:T:A	2	102710068	0.389143	25638	ref1: TG phase3 v5	rs1004548	rs1004548	Nonatopic asthma	""	7e-11	NR	Zhu Z	2019-10-24	31669095
rs933493:102711031:C:T	2	102711031	0.468073	48262	ref1: TG phase3 v5	rs1800919	rs1800919	C-reactive protein levels	""	4e-18	NR	Han X	2020-01-03	31900758
rs933493:102711031:C:T	2	102711031	0.462096	20660	ref1: TG phase3 v5	rs1558643	rs1558643	Fibrinogen levels	""	3e-10	IL1R1	de Vries PS	2015-11-10	26561523
rs933493:102711031:C:T	2	102711031	0.445291	15630	ref1: TG phase3 v5	rs12712127	rs12712127	Fibrinogen	(EA)	3e-08	IL1R1, IL1R2	Sabater-Lleal M	2013-08-22	23969696
rs933493:102711031:C:T	2	102711031	0.369235	24675	ref1: TG phase3 v5	rs1004548	rs1004548	Nonatopic asthma	""	7e-11	NR	Zhu Z	2019-10-24	31669095
rs12471980:102721463:G:T	2	102721463			LD kl min R2									
rs6729953:102723094:A:C	2	102723094	0.426992	8502	ref1: TG phase3 v5	rs1007027	rs1007027	Asthma (childhood onset)	""	6e-14	NR	Zhu Z	2019-10-24	31669095
rs1030023:102732274:T:C	2	102732274	0.697128	5613	ref1: TG phase3 v5	rs12712127	rs12712127	Fibrinogen	(EA)	3e-08	IL1R1, IL1R2	Sabater-Lleal M	2013-08-22	23969696
rs1030023:102732274:T:C	2	102732274	0.68648	583	ref1: TG phase3 v5	rs1558643	rs1558643	Fibrinogen levels	""	3e-10	IL1R1	de Vries PS	2015-11-10	26561523
rs1030023:102732274:T:C	2	102732274	0.429726	27019	ref1: TG phase3 v5	rs1800919	rs1800919	C-reactive protein levels	""	4e-18	NR	Han X	2020-01-03	31900758
rs1030023:102732274:T:C	2	102732274	0.30331	678	ref1: TG phase3 v5	rs1007027	rs1007027	Asthma (childhood onset)	""	6e-14	NR	Zhu Z	2019-10-24	31669095
rs1967313:102735435:T:G	2	102735435	0.574244	5561	ref1: TG phase3 v5	rs874953	rs874953	Asthma (childhood onset)	""	7e-10	NR	Zhu Z	2019-10-24	31669095
rs1967313:102735435:T:G	2	102735435	0.497416	35847	ref1: TG phase3 v5	rs871656	rs871656	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	1e-09	IL1R1	Ellinghaus D	2016-03-14	26974007
rs1967313:102735435:T:G	2	102735435	0.368665	271	ref1: TG phase3 v5	rs1004548	rs1004548	Nonatopic asthma	""	7e-11	NR	Zhu Z	2019-10-24	31669095
rs34147582:102758667:T:A	2	102758667			LD kl min R2									
rs13001315:102763210:G:A	2	102763210	0.625932	12992	ref1: TG phase3 v5	rs13019803	rs13019803	Serum protein levels (sST2)	""	6e-20	IL1R1	Ho JE	2013-09-03	23999434
rs13001315:102763210:G:A	2	102763210	0.350333	33336	ref2: TG phase1 v3	rs874953	rs874953	Asthma (childhood onset)	""	7e-10	NR	Zhu Z	2019-10-24	31669095
rs3755294:102768376:G:A	2	102768376	0.632577	7826	ref1: TG phase3 v5	rs13019803	rs13019803	Serum protein levels (sST2)	""	6e-20	IL1R1	Ho JE	2013-09-03	23999434
rs3755294:102768376:G:A	2	102768376	0.350333	38502	ref2: TG phase1 v3	rs874953	rs874953	Asthma (childhood onset)	""	7e-10	NR	Zhu Z	2019-10-24	31669095
rs3917335:102771293:C:T	2	102771293			LD kl min R2									
rs3917246:102775164:T:C	2	102775164	0.793051	15871	ref1: TG phase3 v5	rs1800919	rs1800919	C-reactive protein levels	""	4e-18	NR	Han X	2020-01-03	31900758
rs3917246:102775164:T:C	2	102775164	0.330519	48503	ref1: TG phase3 v5	rs12712127	rs12712127	Fibrinogen	(EA)	3e-08	IL1R1, IL1R2	Sabater-Lleal M	2013-08-22	23969696
rs3917246:102775164:T:C	2	102775164	0.328589	43473	ref1: TG phase3 v5	rs1558643	rs1558643	Fibrinogen levels	""	3e-10	IL1R1	de Vries PS	2015-11-10	26561523
rs3917314:102790863:A:C	2	102790863	0.300864	166428	ref2: TG phase1 v3	rs13029918	rs13029918	Serum protein levels (sST2)	""	2e-39	IL1RL1	Ho JE	2013-09-03	23999434
rs72348006:102797407:CTCTT:C	2	102797407	0.474829	159884	ref1: TG phase3 v5	rs13029918	rs13029918	Serum protein levels (sST2)	""	2e-39	IL1RL1	Ho JE	2013-09-03	23999434
rs77435902:102801413:T:G	2	102801413			LD kl min R2									
rs113535067:102813324:A:G	2	102813324			LD kl min R2									
rs17026782:102817077:A:G	2	102817077	0.334287	85481	ref1: TG phase3 v5	rs1007027	rs1007027	Asthma (childhood onset)	""	6e-14	NR	Zhu Z	2019-10-24	31669095
rs1922300:102819594:C:T	2	102819594			LD kl min R2									
rs33983851:102842968:C:A	2	102842968	0.344408	32800	ref1: TG phase3 v5	rs1558648	rs1558648	Serum protein levels (sST2)	""	4e-16	IL1RL2	Ho JE	2013-09-03	23999434
rs33983851:102842968:C:A	2	102842968	0.337548	114323	ref1: TG phase3 v5	rs13029918	rs13029918	Serum protein levels (sST2)	""	2e-39	IL1RL1	Ho JE	2013-09-03	23999434
rs1997502:102844249:A:G	2	102844249	0.731003	2125	ref1: TG phase3 v5	rs2302621	rs2302621	Asthma (childhood onset)	""	1e-19	NR	Zhu Z	2019-10-24	31669095
rs1997502:102844249:A:G	2	102844249	0.517053	8553	ref1: TG phase3 v5	rs10167431	rs10167431	Atopic asthma	""	8e-17	NR	Zhu Z	2019-10-24	31669095
rs1997502:102844249:A:G	2	102844249	0.517053	8553	ref1: TG phase3 v5	rs10167431	rs10167431	Nonatopic asthma	""	4e-18	NR	Zhu Z	2019-10-24	31669095
rs3821205:102852765:C:T	2	102852765	0.580009	37	ref1: TG phase3 v5	rs10167431	rs10167431	Atopic asthma	""	8e-17	NR	Zhu Z	2019-10-24	31669095
rs3821205:102852765:C:T	2	102852765	0.580009	37	ref1: TG phase3 v5	rs10167431	rs10167431	Nonatopic asthma	""	4e-18	NR	Zhu Z	2019-10-24	31669095
rs3821205:102852765:C:T	2	102852765	0.380521	10641	ref1: TG phase3 v5	rs2302621	rs2302621	Asthma (childhood onset)	""	1e-19	NR	Zhu Z	2019-10-24	31669095
rs11692230:102855065:A:G	2	102855065	0.558975	2263	ref1: TG phase3 v5	rs10167431	rs10167431	Atopic asthma	""	8e-17	NR	Zhu Z	2019-10-24	31669095
rs11692230:102855065:A:G	2	102855065	0.558975	2263	ref1: TG phase3 v5	rs10167431	rs10167431	Nonatopic asthma	""	4e-18	NR	Zhu Z	2019-10-24	31669095
rs11692230:102855065:A:G	2	102855065	0.372983	12941	ref1: TG phase3 v5	rs2302621	rs2302621	Asthma (childhood onset)	""	1e-19	NR	Zhu Z	2019-10-24	31669095
rs55871806:102880806:G:C	2	102880806	0.558702	67826	ref1: TG phase3 v5	rs1420103	rs1420103	Serum protein levels (sST2)	""	1e-35	IL1RL1	Ho JE	2013-09-03	23999434
rs55871806:102880806:G:C	2	102880806	0.360367	91059	ref1: TG phase3 v5	rs13015714	rs13015714	Celiac disease	""	4e-09	IL18R1, IL1RL1, SLC9A4, IL18RAP	Hunt KA	2008-03-02	18311140
rs55871806:102880806:G:C	2	102880806	0.360367	91059	ref1: TG phase3 v5	rs13015714	rs13015714	Atopic dermatitis	""	8e-18	IL18R1, IL1RL1, IL18RAP	Hirota T	2012-10-07	23042114
rs55871806:102880806:G:C	2	102880806	0.357715	104618	ref1: TG phase3 v5	rs2058622	rs2058622	Protein quantitative trait loci	(IL-18 Ra)	7e-26	NR	Ruffieux H	2020-06-03	32492067
rs55871806:102880806:G:C	2	102880806	0.357715	126817	ref1: TG phase3 v5	rs3860444	rs3860444	Eczema	""	4e-09	IL18R1	Johansson A	2019-07-30	31361310
rs55871806:102880806:G:C	2	102880806	0.318667	173643	ref1: TG phase3 v5	rs2058660	rs2058660	Crohn's disease	""	2e-12	IL12RL2, IL18R1, IL1RL1, IL18RAP	Franke A	2010-11-21	21102463
rs55871806:102880806:G:C	2	102880806	0.318667	199786	ref1: TG phase3 v5	rs2075184	rs2075184	Pediatric autoimmune diseases	""	9e-08	IL18R1	Li YR	2015-08-24	26301688
rs55871806:102880806:G:C	2	102880806	0.318667	182563	ref1: TG phase3 v5	rs6708413	rs6708413	Inflammatory bowel disease	(EA)	9e-14	NR	Liu JZ	2015-07-20	26192919
rs55871806:102880806:G:C	2	102880806	0.318667	182563	ref1: TG phase3 v5	rs6708413	rs6708413	Crohn's disease	(EA)	3e-16	NR	Liu JZ	2015-07-20	26192919
rs55871806:102880806:G:C	2	102880806	0.318667	189762	ref1: TG phase3 v5	rs917997	rs917997	Celiac disease	""	1e-15	IL18R1, IL1RL1, IL1RL2, IL18RAP	Dubois PC	2010-02-28	20190752
rs55871806:102880806:G:C	2	102880806	0.318667	189762	ref1: TG phase3 v5	rs917997	rs917997	Inflammatory bowel disease	""	3e-20	IL18R1, IL1RL1, IL1R1, IL1RL2, IL18RAP, IL1R2	Jostins L	2012-11-01	23128233
rs113781436:102881527:A:T	2	102881527			LD kl min R2									
rs148900885:102883195:A:G	2	102883195			LD kl min R2									
rs112254084:102885016:C:A	2	102885016			LD kl min R2									
rs181591662:102885986:G:A	2	102885986			LD kl min R2									
rs7560917:102910447:G:A	2	102910447	0.948108	42997	ref1: TG phase3 v5	rs17639215	rs17639215	Serum protein levels (sST2)	""	2e-30	IL1RL1	Ho JE	2013-09-03	23999434
rs1476984:102912269:C:T	2	102912269	0.722999	100633	ref1: TG phase3 v5	rs1420095	rs1420095	Polymyositis	""	6e-06	IL18R1	Rothwell S	2015-09-11	26362759
rs1476984:102912269:C:T	2	102912269	0.338186	102101	ref1: TG phase3 v5	rs1558648	rs1558648	Serum protein levels (sST2)	""	4e-16	IL1RL2	Ho JE	2013-09-03	23999434
rs1476984:102912269:C:T	2	102912269	0.331056	48555	ref1: TG phase3 v5	rs2160203	rs2160203	Allergic sensitization	""	3e-09	IL1RL1	Waage J	2018-07-16	30013184
rs7600901:102915571:A:G	2	102915571	0.366393	29845	ref1: TG phase3 v5	rs76886731	rs76886731	Leprosy	""	2e-23	IL18R1, IL18RAP	Liu H	2015-02-02	25642632
rs77763678:102916749:G:A	2	102916749	0.956697	36695	ref1: TG phase3 v5	rs17639215	rs17639215	Serum protein levels (sST2)	""	2e-30	IL1RL1	Ho JE	2013-09-03	23999434
rs12470864:102926362:G:A	2	102926362	1	0	ref1: TG phase3 v5	rs12470864	rs12470864	Asthma (childhood onset)	""	3e-28	NR	Zhu Z	2019-10-24	31669095
rs12470864:102926362:G:A	2	102926362	1	0	ref1: TG phase3 v5	rs12470864	rs12470864	FEV1	""	3e-06	IL1RL1	Shrine N	2019-02-25	30804560
rs12470864:102926362:G:A	2	102926362	1	22799	ref1: TG phase3 v5	rs12479210	rs12479210	Nonatopic asthma	""	2e-37	NR	Zhu Z	2019-10-24	31669095
rs12470864:102926362:G:A	2	102926362	1	6200	ref1: TG phase3 v5	rs950880	rs950880	Serum protein levels (sST2)	""	7e-94	IL1RL1	Ho JE	2013-09-03	23999434
rs12470864:102926362:G:A	2	102926362	0.9957	5464	ref1: TG phase3 v5	rs13020553	rs13020553	Hay fever and/or eczema	""	2e-33	NR	Johansson A	2019-07-30	31361310
rs12470864:102926362:G:A	2	102926362	0.970208	31354	ref1: TG phase3 v5	rs1420101	rs1420101	Eosinophil counts	(EA)	5e-14	IL1RL1	Gudbjartsson DF	2009-02-08	19198610
rs12470864:102926362:G:A	2	102926362	0.970208	31354	ref1: TG phase3 v5	rs1420101	rs1420101	Blood protein levels in cardiovascular risk	""	6e-254	IL1RL1	Folkersen L	2017-04-03	28369058
rs12470864:102926362:G:A	2	102926362	0.826419	48974	ref1: TG phase3 v5	rs12987977	rs12987977	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	3e-17	IL18R1	Ellinghaus D	2016-03-14	26974007
rs12470864:102926362:G:A	2	102926362	0.826419	57917	ref1: TG phase3 v5	rs1420098	rs1420098	Inflammatory bowel disease	(EA)	2e-20	NR	Liu JZ	2015-07-20	26192919
rs12470864:102926362:G:A	2	102926362	0.82562	38380	ref1: TG phase3 v5	rs13017455	rs13017455	Atopic asthma	""	6e-29	NR	Zhu Z	2019-10-24	31669095
rs12470864:102926362:G:A	2	102926362	0.82562	36710	ref1: TG phase3 v5	rs6543119	rs6543119	Protein quantitative trait loci	(IL-1 R4)	2e-31	NR	Ruffieux H	2020-06-03	32492067
rs12470864:102926362:G:A	2	102926362	0.583332	165178	ref1: TG phase3 v5	rs17027258	rs17027258	White blood cell types	(eosinophil count)	7e-06	SLC9A4	Okada Y	2011-06-30	21738478
rs12470864:102926362:G:A	2	102926362	0.543086	19054	ref1: TG phase3 v5	rs76886731	rs76886731	Leprosy	""	2e-23	IL18R1, IL18RAP	Liu H	2015-02-02	25642632
rs12470864:102926362:G:A	2	102926362	0.301641	44838	ref1: TG phase3 v5	rs9807989	rs9807989	Asthma	""	6e-08	IL18R1, IL1R1	Wan YI	2012-05-05	22561531
rs12470864:102926362:G:A	2	102926362	0.300844	59860	ref1: TG phase3 v5	rs3771166	rs3771166	Asthma	""	3e-09	IL18R1	Moffatt MF	2010-09-23	20860503
rs13001325:102939036:C:T	2	102939036	1	12674	ref1: TG phase3 v5	rs12470864	rs12470864	Asthma (childhood onset)	""	3e-28	NR	Zhu Z	2019-10-24	31669095
rs13001325:102939036:C:T	2	102939036	1	12674	ref1: TG phase3 v5	rs12470864	rs12470864	FEV1	""	3e-06	IL1RL1	Shrine N	2019-02-25	30804560
rs13001325:102939036:C:T	2	102939036	1	10125	ref1: TG phase3 v5	rs12479210	rs12479210	Nonatopic asthma	""	2e-37	NR	Zhu Z	2019-10-24	31669095
rs13001325:102939036:C:T	2	102939036	1	6474	ref1: TG phase3 v5	rs950880	rs950880	Serum protein levels (sST2)	""	7e-94	IL1RL1	Ho JE	2013-09-03	23999434
rs13001325:102939036:C:T	2	102939036	0.9957	7210	ref1: TG phase3 v5	rs13020553	rs13020553	Hay fever and/or eczema	""	2e-33	NR	Johansson A	2019-07-30	31361310
rs13001325:102939036:C:T	2	102939036	0.970208	18680	ref1: TG phase3 v5	rs1420101	rs1420101	Eosinophil counts	(EA)	5e-14	IL1RL1	Gudbjartsson DF	2009-02-08	19198610
rs13001325:102939036:C:T	2	102939036	0.970208	18680	ref1: TG phase3 v5	rs1420101	rs1420101	Blood protein levels in cardiovascular risk	""	6e-254	IL1RL1	Folkersen L	2017-04-03	28369058
rs13001325:102939036:C:T	2	102939036	0.826419	36300	ref1: TG phase3 v5	rs12987977	rs12987977	Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	(subset analysis)	3e-17	IL18R1	Ellinghaus D	2016-03-14	26974007
rs13001325:102939036:C:T	2	102939036	0.826419	45243	ref1: TG phase3 v5	rs1420098	rs1420098	Inflammatory bowel disease	(EA)	2e-20	NR	Liu JZ	2015-07-20	26192919
rs13001325:102939036:C:T	2	102939036	0.82562	25706	ref1: TG phase3 v5	rs13017455	rs13017455	Atopic asthma	""	6e-29	NR	Zhu Z	2019-10-24	31669095
rs13001325:102939036:C:T	2	102939036	0.82562	24036	ref1: TG phase3 v5	rs6543119	rs6543119	Protein quantitative trait loci	(IL-1 R4)	2e-31	NR	Ruffieux H	2020-06-03	32492067
rs13001325:102939036:C:T	2	102939036	0.583332	152504	ref1: TG phase3 v5	rs17027258	rs17027258	White blood cell types	(eosinophil count)	7e-06	SLC9A4	Okada Y	2011-06-30	21738478
rs13001325:102939036:C:T	2	102939036	0.543086	6380	ref1: TG phase3 v5	rs76886731	rs76886731	Leprosy	""	2e-23	IL18R1, IL18RAP	Liu H	2015-02-02	25642632
rs13001325:102939036:C:T	2	102939036	0.301641	32164	ref1: TG phase3 v5	rs9807989	rs9807989	Asthma	""	6e-08	IL18R1, IL1R1	Wan YI	2012-05-05	22561531
rs13001325:102939036:C:T	2	102939036	0.300844	47186	ref1: TG phase3 v5	rs3771166	rs3771166	Asthma	""	3e-09	IL18R1	Moffatt MF	2010-09-23	20860503
rs114879104:102948404:T:C	2	102948404			LD kl min R2									
rs62151723:102949397:G:A	2	102949397			LD kl min R2									
rs1041973:102955468:C:A	2	102955468	0.547294	386	ref1: TG phase3 v5	rs13408661	rs13408661	Asthma	""	1e-09	IL18R1, IL1RL1	Ramasamy A	2012-09-28	23028483
rs1041973:102955468:C:A	2	102955468	0.547294	1851	ref1: TG phase3 v5	rs3771180	rs3771180	Asthma	""	2e-15	IL1RL1	Torgerson DG	2011-07-31	21804549
rs1041973:102955468:C:A	2	102955468	0.542574	11222	ref1: TG phase3 v5	rs59185885	rs59185885	Nonatopic asthma	""	1e-39	NR	Zhu Z	2019-10-24	31669095
rs1041973:102955468:C:A	2	102955468	0.542574	22956	ref1: TG phase3 v5	rs950881	rs950881	Allergic rhinitis	""	2e-30	IL1RL1	Waage J	2018-07-16	30013184
rs1041973:102955468:C:A	2	102955468	0.53478	4742	ref1: TG phase3 v5	rs3771175	rs3771175	Allergic sensitization	""	5e-11	IL18R1, IL1RL1, IL18RAP	Bonnelykke K	2013-06-30	23817571
rs1041973:102955468:C:A	2	102955468	0.53478	4742	ref1: TG phase3 v5	rs3771175	rs3771175	Atopic asthma	""	8e-50	NR	Zhu Z	2019-10-24	31669095
rs1041973:102955468:C:A	2	102955468	0.527721	19309	ref1: TG phase3 v5	rs72823641	rs72823641	Asthma (childhood onset)	""	7e-60	NR	Zhu Z	2019-10-24	31669095
rs1041973:102955468:C:A	2	102955468	0.527721	19309	ref1: TG phase3 v5	rs72823641	rs72823641	Hay fever and/or eczema	""	1e-63	NR	Johansson A	2019-07-30	31361310
rs1041973:102955468:C:A	2	102955468	0.527721	19309	ref1: TG phase3 v5	rs72823641	rs72823641	Allergic rhinitis	""	2e-25	IL1RL1, IL18R1	Johansson A	2019-07-30	31361310
rs1041973:102955468:C:A	2	102955468	0.527721	19309	ref1: TG phase3 v5	rs72823641	rs72823641	Allergic disease (asthma, hay fever or eczema)	""	1e-78	NR	Johansson A	2019-07-30	31361310
rs1041973:102955468:C:A	2	102955468	0.527721	19309	ref1: TG phase3 v5	rs72823641	rs72823641	Asthma	""	4e-61	IL1RL1, IL18R1	Johansson A	2019-07-30	31361310
rs1041973:102955468:C:A	2	102955468	0.520653	11081	ref1: TG phase3 v5	rs10197862	rs10197862	Asthma and hay fever	""	4e-11	IL1RL1	Ferreira MA	2013-12-30	24388013
rs1041973:102955468:C:A	2	102955468	0.436548	76004	ref1: TG phase3 v5	rs10189629	rs10189629	Self-reported allergy	""	2e-16	IL1RL1, IL1RL2	Hinds DA	2013-06-30	23817569
rs1041973:102955468:C:A	2	102955468	0.328991	211563	ref1: TG phase3 v5	rs13008334	rs13008334	Nonatopic asthma	""	2e-09	NR	Zhu Z	2019-10-24	31669095
rs1041973:102955468:C:A	2	102955468	0.305509	297561	ref1: TG phase3 v5	rs67768228	rs67768228	Atopic asthma	""	3e-11	NR	Zhu Z	2019-10-24	31669095
rs13029918:102957291:A:G	2	102957291	1	0	ref1: TG phase3 v5	rs13029918	rs13029918	Serum protein levels (sST2)	""	2e-39	IL1RL1	Ho JE	2013-09-03	23999434
rs186508685:102989580:C:T	2	102989580			LD kl min R2									
rs79196257:102996624:C:CA	2	102996624			LD kl min R2									
rs3771157:103013432:C:A	2	103013432			LD kl min R2									
rs11465677:103035764:G:A	2	103035764			LD kl min R2									
rs148165648:103066346:C:T	2	103066346			LD kl min R2									
rs11465732:103067823:C:T	2	103067823			LD kl min R2									
rs114420077:103074191:A:C	2	103074191			LD kl min R2									
rs79463214:103090575:A:C	2	103090575			LD kl min R2									
rs151254748:103107770:C:T	2	103107770			LD kl min R2									
rs4851609:103128866:T:C	2	103128866	0.71376	53407	ref1: TG phase3 v5	rs12469973	rs12469973	interleukin-18 receptor 1 levels	""	9e-16	NR	Hillary RF	2020-07-08	32641083
rs4851609:103128866:T:C	2	103128866	0.591003	74417	ref1: TG phase3 v5	rs2058660	rs2058660	Crohn's disease	""	2e-12	IL12RL2, IL18R1, IL1RL1, IL18RAP	Franke A	2010-11-21	21102463
rs4851609:103128866:T:C	2	103128866	0.591003	48274	ref1: TG phase3 v5	rs2075184	rs2075184	Pediatric autoimmune diseases	""	9e-08	IL18R1	Li YR	2015-08-24	26301688
rs4851609:103128866:T:C	2	103128866	0.591003	65497	ref1: TG phase3 v5	rs6708413	rs6708413	Inflammatory bowel disease	(EA)	9e-14	NR	Liu JZ	2015-07-20	26192919
rs4851609:103128866:T:C	2	103128866	0.591003	65497	ref1: TG phase3 v5	rs6708413	rs6708413	Crohn's disease	(EA)	3e-16	NR	Liu JZ	2015-07-20	26192919
rs4851609:103128866:T:C	2	103128866	0.591003	58298	ref1: TG phase3 v5	rs917997	rs917997	Celiac disease	""	1e-15	IL18R1, IL1RL1, IL1RL2, IL18RAP	Dubois PC	2010-02-28	20190752
rs4851609:103128866:T:C	2	103128866	0.591003	58298	ref1: TG phase3 v5	rs917997	rs917997	Inflammatory bowel disease	""	3e-20	IL18R1, IL1RL1, IL1R1, IL1RL2, IL18RAP, IL1R2	Jostins L	2012-11-01	23128233
rs4851609:103128866:T:C	2	103128866	0.589997	157001	ref1: TG phase3 v5	rs13015714	rs13015714	Celiac disease	""	4e-09	IL18R1, IL1RL1, SLC9A4, IL18RAP	Hunt KA	2008-03-02	18311140
rs4851609:103128866:T:C	2	103128866	0.589997	157001	ref1: TG phase3 v5	rs13015714	rs13015714	Atopic dermatitis	""	8e-18	IL18R1, IL1RL1, IL18RAP	Hirota T	2012-10-07	23042114
rs4851609:103128866:T:C	2	103128866	0.586035	143442	ref1: TG phase3 v5	rs2058622	rs2058622	Protein quantitative trait loci	(IL-18 Ra)	7e-26	NR	Ruffieux H	2020-06-03	32492067
rs4851609:103128866:T:C	2	103128866	0.586035	121243	ref1: TG phase3 v5	rs3860444	rs3860444	Eczema	""	4e-09	IL18R1	Johansson A	2019-07-30	31361310
rs4851609:103128866:T:C	2	103128866	0.502022	20234	ref1: TG phase3 v5	rs1014286	rs1014286	Serum protein levels (sST2)	""	3e-33	SLC9A4	Ho JE	2013-09-03	23999434
rs4851609:103128866:T:C	2	103128866	0.468006	180234	ref1: TG phase3 v5	rs1420103	rs1420103	Serum protein levels (sST2)	""	1e-35	IL1RL1	Ho JE	2013-09-03	23999434
rs4851609:103128866:T:C	2	103128866	0.32983	30190	ref1: TG phase3 v5	rs2140316	rs2140316	Height	""	6e-19	""	Kichaev G	2018-12-27	30595370
rs2192758:103132269:C:G	2	103132269	0.719622	50004	ref1: TG phase3 v5	rs12469973	rs12469973	interleukin-18 receptor 1 levels	""	9e-16	NR	Hillary RF	2020-07-08	32641083
rs2192758:103132269:C:G	2	103132269	0.58635	77820	ref1: TG phase3 v5	rs2058660	rs2058660	Crohn's disease	""	2e-12	IL12RL2, IL18R1, IL1RL1, IL18RAP	Franke A	2010-11-21	21102463
rs2192758:103132269:C:G	2	103132269	0.58635	51677	ref1: TG phase3 v5	rs2075184	rs2075184	Pediatric autoimmune diseases	""	9e-08	IL18R1	Li YR	2015-08-24	26301688
rs2192758:103132269:C:G	2	103132269	0.58635	68900	ref1: TG phase3 v5	rs6708413	rs6708413	Inflammatory bowel disease	(EA)	9e-14	NR	Liu JZ	2015-07-20	26192919
rs2192758:103132269:C:G	2	103132269	0.58635	68900	ref1: TG phase3 v5	rs6708413	rs6708413	Crohn's disease	(EA)	3e-16	NR	Liu JZ	2015-07-20	26192919
rs2192758:103132269:C:G	2	103132269	0.58635	61701	ref1: TG phase3 v5	rs917997	rs917997	Celiac disease	""	1e-15	IL18R1, IL1RL1, IL1RL2, IL18RAP	Dubois PC	2010-02-28	20190752
rs2192758:103132269:C:G	2	103132269	0.58635	61701	ref1: TG phase3 v5	rs917997	rs917997	Inflammatory bowel disease	""	3e-20	IL18R1, IL1RL1, IL1R1, IL1RL2, IL18RAP, IL1R2	Jostins L	2012-11-01	23128233
rs2192758:103132269:C:G	2	103132269	0.585381	160404	ref1: TG phase3 v5	rs13015714	rs13015714	Celiac disease	""	4e-09	IL18R1, IL1RL1, SLC9A4, IL18RAP	Hunt KA	2008-03-02	18311140
rs2192758:103132269:C:G	2	103132269	0.585381	160404	ref1: TG phase3 v5	rs13015714	rs13015714	Atopic dermatitis	""	8e-18	IL18R1, IL1RL1, IL18RAP	Hirota T	2012-10-07	23042114
rs2192758:103132269:C:G	2	103132269	0.58142	146845	ref1: TG phase3 v5	rs2058622	rs2058622	Protein quantitative trait loci	(IL-18 Ra)	7e-26	NR	Ruffieux H	2020-06-03	32492067
rs2192758:103132269:C:G	2	103132269	0.58142	124646	ref1: TG phase3 v5	rs3860444	rs3860444	Eczema	""	4e-09	IL18R1	Johansson A	2019-07-30	31361310
rs2192758:103132269:C:G	2	103132269	0.511691	16831	ref1: TG phase3 v5	rs1014286	rs1014286	Serum protein levels (sST2)	""	3e-33	SLC9A4	Ho JE	2013-09-03	23999434
rs2192758:103132269:C:G	2	103132269	0.463569	183637	ref1: TG phase3 v5	rs1420103	rs1420103	Serum protein levels (sST2)	""	1e-35	IL1RL1	Ho JE	2013-09-03	23999434
rs2192758:103132269:C:G	2	103132269	0.331015	33593	ref1: TG phase3 v5	rs2140316	rs2140316	Height	""	6e-19	""	Kichaev G	2018-12-27	30595370
rs6712638:103142491:T:C	2	103142491	0.847801	39782	ref1: TG phase3 v5	rs12469973	rs12469973	interleukin-18 receptor 1 levels	""	9e-16	NR	Hillary RF	2020-07-08	32641083
rs6712638:103142491:T:C	2	103142491	0.534814	88042	ref1: TG phase3 v5	rs2058660	rs2058660	Crohn's disease	""	2e-12	IL12RL2, IL18R1, IL1RL1, IL18RAP	Franke A	2010-11-21	21102463
rs6712638:103142491:T:C	2	103142491	0.534814	61899	ref1: TG phase3 v5	rs2075184	rs2075184	Pediatric autoimmune diseases	""	9e-08	IL18R1	Li YR	2015-08-24	26301688
rs6712638:103142491:T:C	2	103142491	0.534814	79122	ref1: TG phase3 v5	rs6708413	rs6708413	Inflammatory bowel disease	(EA)	9e-14	NR	Liu JZ	2015-07-20	26192919
rs6712638:103142491:T:C	2	103142491	0.534814	79122	ref1: TG phase3 v5	rs6708413	rs6708413	Crohn's disease	(EA)	3e-16	NR	Liu JZ	2015-07-20	26192919
rs6712638:103142491:T:C	2	103142491	0.534814	71923	ref1: TG phase3 v5	rs917997	rs917997	Celiac disease	""	1e-15	IL18R1, IL1RL1, IL1RL2, IL18RAP	Dubois PC	2010-02-28	20190752
rs6712638:103142491:T:C	2	103142491	0.534814	71923	ref1: TG phase3 v5	rs917997	rs917997	Inflammatory bowel disease	""	3e-20	IL18R1, IL1RL1, IL1R1, IL1RL2, IL18RAP, IL1R2	Jostins L	2012-11-01	23128233
rs6712638:103142491:T:C	2	103142491	0.532932	170626	ref1: TG phase3 v5	rs13015714	rs13015714	Celiac disease	""	4e-09	IL18R1, IL1RL1, SLC9A4, IL18RAP	Hunt KA	2008-03-02	18311140
rs6712638:103142491:T:C	2	103142491	0.532932	170626	ref1: TG phase3 v5	rs13015714	rs13015714	Atopic dermatitis	""	8e-18	IL18R1, IL1RL1, IL18RAP	Hirota T	2012-10-07	23042114
rs6712638:103142491:T:C	2	103142491	0.529438	157067	ref1: TG phase3 v5	rs2058622	rs2058622	Protein quantitative trait loci	(IL-18 Ra)	7e-26	NR	Ruffieux H	2020-06-03	32492067
rs6712638:103142491:T:C	2	103142491	0.529438	134868	ref1: TG phase3 v5	rs3860444	rs3860444	Eczema	""	4e-09	IL18R1	Johansson A	2019-07-30	31361310
rs6712638:103142491:T:C	2	103142491	0.430516	6609	ref1: TG phase3 v5	rs1014286	rs1014286	Serum protein levels (sST2)	""	3e-33	SLC9A4	Ho JE	2013-09-03	23999434
rs6712638:103142491:T:C	2	103142491	0.429535	193859	ref1: TG phase3 v5	rs1420103	rs1420103	Serum protein levels (sST2)	""	1e-35	IL1RL1	Ho JE	2013-09-03	23999434
rs6712638:103142491:T:C	2	103142491	0.365114	43815	ref1: TG phase3 v5	rs2140316	rs2140316	Height	""	6e-19	""	Kichaev G	2018-12-27	30595370
rs56147623:103170163:G:A	2	103170163	0.950821	43624	ref1: TG phase3 v5	rs11688802	rs11688802	Atopic asthma	""	2e-09	NR	Zhu Z	2019-10-24	31669095
rs10202404:103177414:C:T	2	103177414	0.656834	28314	ref1: TG phase3 v5	rs1014286	rs1014286	Serum protein levels (sST2)	""	3e-33	SLC9A4	Ho JE	2013-09-03	23999434
rs10202404:103177414:C:T	2	103177414	0.433867	78738	ref1: TG phase3 v5	rs2140316	rs2140316	Height	""	6e-19	""	Kichaev G	2018-12-27	30595370
rs6758360:103178988:C:T	2	103178988	0.328977	213596	ref1: TG phase3 v5	rs12999542	rs12999542	Serum protein levels (sST2)	""	2e-27	IL1RL1	Ho JE	2013-09-03	23999434
rs115932256:103181918:G:A	2	103181918			LD kl min R2									
rs74263644:103194558:A:G	2	103194558	1	0	ref1: TG phase3 v5	rs74263644	rs74263644	Nonatopic asthma	""	2e-13	NR	Zhu Z	2019-10-24	31669095
rs74263644:103194558:A:G	2	103194558	0.834736	57369	ref1: TG phase3 v5	rs17775170	rs17775170	Asthma (childhood onset)	""	1e-13	NR	Zhu Z	2019-10-24	31669095
rs74263644:103194558:A:G	2	103194558	0.834736	57369	ref1: TG phase3 v5	rs17775170	rs17775170	Atopic asthma	""	1e-09	NR	Zhu Z	2019-10-24	31669095
rs74263644:103194558:A:G	2	103194558	0.329745	107472	ref1: TG phase3 v5	rs72825929	rs72825929	Asthma (childhood onset)	""	8e-10	NR	Zhu Z	2019-10-24	31669095
rs200128638:103209999:TAAC:T	2	103209999	0.687981	83460	ref1: TG phase3 v5	rs11688802	rs11688802	Atopic asthma	""	2e-09	NR	Zhu Z	2019-10-24	31669095
rs12998183:103257560:C:T	2	103257560	0.491517	47964	ref1: TG phase3 v5	rs10209131	rs10209131	Asthma (childhood onset)	""	3e-12	NR	Zhu Z	2019-10-24	31669095
rs12998183:103257560:C:T	2	103257560	0.491517	47016	ref1: TG phase3 v5	rs2310313	rs2310313	Atopic asthma	""	1e-12	NR	Zhu Z	2019-10-24	31669095
rs12998183:103257560:C:T	2	103257560	0.451297	56255	ref1: TG phase3 v5	rs12712161	rs12712161	Nonatopic asthma	""	2e-10	NR	Zhu Z	2019-10-24	31669095
rs4140834:103268442:T:C	2	103268442			LD kl min R2									
rs4851627:103269873:C:T	2	103269873			LD kl min R2									
rs72828028:103273385:C:T	2	103273385			LD kl min R2									
rs13027243:103309025:C:T	2	103309025			LD kl min R2									
rs33988363:103335512:G:C	2	103335512			LD kl min R2									
rs149342193:187835739:C:T	2	187835739			LD kl min R2									
rs13016281:187843494:G:A	2	187843494			LD kl min R2									
rs62173501:187865727:C:T	2	187865727	0.4635	314682	ref1: TG phase3 v5	rs62174474	rs62174474	Vascular brain injury	""	8e-06	intergenic	Beecham GW	2014-09-04	25188341
rs17754286:187882982:G:C	2	187882982	0.303709	126891	ref2: TG phase1 v3	rs1349520	rs1349520	Waist-to-hip ratio adjusted for BMI	""	3e-09	NR	Zhu Z	2019-10-24	31669095
rs77328207:187949128:C:T	2	187949128	0.335408	40280	ref1: TG phase3 v5	rs62173537	rs62173537	Waist-to-hip ratio adjusted for BMI	""	4e-11	NR	Zhu Z	2019-10-24	31669095
rs17576302:187988788:A:G	2	187988788			LD kl min R2									
rs1487389:187994570:A:T	2	187994570			LD kl min R2									
rs181844741:188031754:A:C	2	188031754			LD kl min R2									
rs114608843:188064723:A:G	2	188064723			LD kl min R2									
rs12987120:188100925:T:A	2	188100925			LD kl min R2									
rs79417739:188115434:A:G	2	188115434			LD kl min R2									
rs62174473:188178995:C:T	2	188178995			LD kl min R2									
rs115467773:188193664:G:T	2	188193664	0.416429	284816	ref1: TG phase3 v5	rs62173537	rs62173537	Waist-to-hip ratio adjusted for BMI	""	4e-11	NR	Zhu Z	2019-10-24	31669095
rs3771074:188285710:T:G	2	188285710			LD kl min R2									
rs78357827:188302216:A:C	2	188302216			LD kl min R2									
rs67492154:188306985:C:A	2	188306985	0.986813	33364	ref1: TG phase3 v5	rs8176547	rs8176547	White matter microstructure (mean diusivities)	(Cingulate gyrus)	7e-09	NR	Zhao B	2019-10-30	31666681
rs67492154:188306985:C:A	2	188306985	0.753934	26079	ref1: TG phase3 v5	rs4140885	rs4140885	Heart rate	""	5e-08	TFPI	den Hoed M	2013-04-14	23583979
rs67492154:188306985:C:A	2	188306985	0.750989	36512	ref1: TG phase3 v5	rs7586970	rs7586970	Coronary heart disease	""	9e-06	intergenic	Coronary Artery Disease (C4D) Genetics Consortium	2011-03-06	21378988
rs67492154:188306985:C:A	2	188306985	0.740105	16326	ref1: TG phase3 v5	rs12987470	rs12987470	Apolipoprotein A1 levels	""	2e-08	TFPI	Richardson TG	2020-03-23	32203549
rs67492154:188306985:C:A	2	188306985	0.66678	28782	ref1: TG phase3 v5	rs17464221	rs17464221	Cortical surface area	(Frontal Pole)	2e-09	NR	Grasby KL	2020-03-01	32193296
rs67492154:188306985:C:A	2	188306985	0.637285	110516	ref1: TG phase3 v5	rs840616	rs840616	Coronary heart disease	""	7e-07	intergenic	Coronary Artery Disease (C4D) Genetics Consortium	2011-03-06	21378988
rs67492154:188306985:C:A	2	188306985	0.62356	223862	ref1: TG phase3 v5	rs13424740	rs13424740	Body mass index	(EA, men)	8e-06	CALCRL	Locke AE	2015-02-12	25673413
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	(EA)	6e-10	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	(women)	2e-06	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	""	3e-10	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-hip ratio	(EA, women)	7e-07	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-hip ratio	(EA)	1e-12	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-hip ratio	(EA, men)	7e-08	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.62356	191587	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	(EA, women)	7e-07	CALCRL	Shungin D	2015-02-12	25673412
rs67492154:188306985:C:A	2	188306985	0.607158	93166	ref1: TG phase3 v5	rs10177093	rs10177093	Waist-to-hip ratio adjusted for BMI	""	5e-29	NR	Zhu Z	2019-10-24	31669095
rs67492154:188306985:C:A	2	188306985	0.52266	72335	ref1: TG phase3 v5	rs35612915	rs35612915	Cortical surface area	(Rostral Middle Frontal)	7e-08	NR	Grasby KL	2020-03-01	32193296
rs67492154:188306985:C:A	2	188306985	0.461249	303867	ref1: TG phase3 v5	rs17576323	rs17576323	White matter hyperintensities	""	3e-08	AC007319.1	Persyn E	2020-05-01	32358547
rs67492154:188306985:C:A	2	188306985	0.45984	141819	ref1: TG phase3 v5	rs17705966	rs17705966	White matter hyperintensity volume	""	3e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	141819	ref1: TG phase3 v5	rs17705966	rs17705966	White matter hyperintensity volume (adjusted for hypertension)	""	1e-09	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	278668	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume x hypertension interaction (2df)	""	2e-09	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	278668	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume x hypertension interaction (2df)	""	2e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	278668	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume	""	4e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	278668	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume (adjusted for hypertension)	""	2e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	278668	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume	""	4e-11	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.45984	278668	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume (adjusted for hypertension)	""	1e-09	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs67492154:188306985:C:A	2	188306985	0.459803	122181	ref1: TG phase3 v5	rs13417165	rs13417165	Heel bone mineral density	""	3e-09	""	Kichaev G	2018-12-27	30595370
rs78761501:188318379:T:C	2	188318379			LD kl min R2									
rs10174735:188326005:A:T	2	188326005	1	17492	ref1: TG phase3 v5	rs7586970	rs7586970	Coronary heart disease	""	9e-06	intergenic	Coronary Artery Disease (C4D) Genetics Consortium	2011-03-06	21378988
rs10174735:188326005:A:T	2	188326005	0.995128	7059	ref1: TG phase3 v5	rs4140885	rs4140885	Heart rate	""	5e-08	TFPI	den Hoed M	2013-04-14	23583979
rs10174735:188326005:A:T	2	188326005	0.985467	2694	ref1: TG phase3 v5	rs12987470	rs12987470	Apolipoprotein A1 levels	""	2e-08	TFPI	Richardson TG	2020-03-23	32203549
rs10174735:188326005:A:T	2	188326005	0.822249	47802	ref1: TG phase3 v5	rs17464221	rs17464221	Cortical surface area	(Frontal Pole)	2e-09	NR	Grasby KL	2020-03-01	32193296
rs10174735:188326005:A:T	2	188326005	0.784862	129536	ref1: TG phase3 v5	rs840616	rs840616	Coronary heart disease	""	7e-07	intergenic	Coronary Artery Disease (C4D) Genetics Consortium	2011-03-06	21378988
rs10174735:188326005:A:T	2	188326005	0.759659	14344	ref1: TG phase3 v5	rs8176547	rs8176547	White matter microstructure (mean diusivities)	(Cingulate gyrus)	7e-09	NR	Zhao B	2019-10-30	31666681
rs10174735:188326005:A:T	2	188326005	0.656539	53315	ref1: TG phase3 v5	rs35612915	rs35612915	Cortical surface area	(Rostral Middle Frontal)	7e-08	NR	Grasby KL	2020-03-01	32193296
rs10174735:188326005:A:T	2	188326005	0.588605	160839	ref1: TG phase3 v5	rs17705966	rs17705966	White matter hyperintensity volume	""	3e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	160839	ref1: TG phase3 v5	rs17705966	rs17705966	White matter hyperintensity volume (adjusted for hypertension)	""	1e-09	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	297688	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume x hypertension interaction (2df)	""	2e-09	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	297688	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume x hypertension interaction (2df)	""	2e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	297688	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume	""	4e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	297688	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume (adjusted for hypertension)	""	2e-10	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	297688	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume	""	4e-11	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.588605	297688	ref1: TG phase3 v5	rs62172472	rs62172472	White matter hyperintensity volume (adjusted for hypertension)	""	1e-09	CALCRL	Sargurupremraj M	2020-12-08	33293549
rs10174735:188326005:A:T	2	188326005	0.583719	141201	ref1: TG phase3 v5	rs13417165	rs13417165	Heel bone mineral density	""	3e-09	""	Kichaev G	2018-12-27	30595370
rs10174735:188326005:A:T	2	188326005	0.58283	322887	ref1: TG phase3 v5	rs17576323	rs17576323	White matter hyperintensities	""	3e-08	AC007319.1	Persyn E	2020-05-01	32358547
rs10174735:188326005:A:T	2	188326005	0.459616	112186	ref1: TG phase3 v5	rs10177093	rs10177093	Waist-to-hip ratio adjusted for BMI	""	5e-29	NR	Zhu Z	2019-10-24	31669095
rs10174735:188326005:A:T	2	188326005	0.453599	242882	ref1: TG phase3 v5	rs13424740	rs13424740	Body mass index	(EA, men)	8e-06	CALCRL	Locke AE	2015-02-12	25673413
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	(EA)	6e-10	CALCRL	Shungin D	2015-02-12	25673412
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	(women)	2e-06	CALCRL	Shungin D	2015-02-12	25673412
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	""	3e-10	CALCRL	Shungin D	2015-02-12	25673412
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-hip ratio	(EA, women)	7e-07	CALCRL	Shungin D	2015-02-12	25673412
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-hip ratio	(EA)	1e-12	CALCRL	Shungin D	2015-02-12	25673412
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-hip ratio	(EA, men)	7e-08	CALCRL	Shungin D	2015-02-12	25673412
rs10174735:188326005:A:T	2	188326005	0.453599	210607	ref1: TG phase3 v5	rs1569135	rs1569135	Waist-to-hip ratio adjusted for body mass index	(EA, women)	7e-07	CALCRL	Shungin D	2015-02-12	25673412
rs5940:188331704:C:T	2	188331704			LD kl min R2									
rs148277153:188341408:A:AT	2	188341408			LD kl min R2									
rs115641298:188386790:C:T	2	188386790			LD kl min R2									
rs75131017:188388417:A:G	2	188388417			LD kl min R2									
rs2192825:188390819:C:T	2	188390819			LD kl min R2									
rs59316390:188411548:CCTGT:C	2	188411548			LD kl min R2									
rs141298400:188462548:C:T	2	188462548			LD kl min R2									
rs34489100:188476109:C:G	2	188476109			LD kl min R2									
rs7586541:188477423:C:G	2	188477423			LD kl min R2									
rs7562407:188483360:A:G	2	188483360			LD kl min R2									
rs2349869:188526925:T:C	2	188526925			LD kl min R2									
rs111714051:188539005:T:G	2	188539005			LD kl min R2									
rs200866107:188541861:ACAAC:A	2	188541861			LD kl min R2									
rs4432415:188545602:T:C	2	188545602			LD kl min R2									
rs1356871:188647821:G:T	2	188647821			LD kl min R2									
rs2067839:188647956:G:A	2	188647956			LD kl min R2									
rs9653308:188662928:G:C	2	188662928			LD kl min R2									
rs5010557:188711522:T:G	2	188711522			LD kl min R2									
rs112578356:188920022:T:TTC	2	188920022			LD kl min R2									
rs9876956:11955108:A:G	3	11955108			LD kl min R2									
rs56296473:11975708:C:T	3	11975708			LD kl min R2									
rs438129:12007910:T:C	3	12007910			LD kl min R2									
rs2600261:12029179:C:T	3	12029179	1	2540	ref1: TG phase3 v5	rs4684833	rs4684833	Worry	""	5e-08	NR	Nagel M	2018-06-25	29942085
rs2600261:12029179:C:T	3	12029179	0.456035	155378	ref1: TG phase3 v5	rs7621569	rs7621569	Circulating leptin levels or type 2 diabetes	""	2e-08	SYN2	Wang X	2020-04-01	32341051
rs139888056:12057734:CT:C	3	12057734			LD kl min R2									
rs61156889:12130162:TAA:T	3	12130162	0.651469	98443	ref1: TG phase3 v5	rs4684833	rs4684833	Worry	""	5e-08	NR	Nagel M	2018-06-25	29942085
rs61156889:12130162:TAA:T	3	12130162	0.431472	13542	ref1: TG phase3 v5	rs308971	rs308971	Fasting blood insulin (BMI interaction)	""	2e-07	SYN2	Manning AK	2012-05-13	22581228
rs61156889:12130162:TAA:T	3	12130162	0.304277	159638	ref1: TG phase3 v5	rs13081389	rs13081389	Type 2 diabetes	""	2e-07	PPARG	Voight BF	2010-06-27	20581827
rs61156889:12130162:TAA:T	3	12130162	0.304277	147683	ref1: TG phase3 v5	rs17036101	rs17036101	Type 2 diabetes	""	2e-07	SYN2, PPARG	Zeggini E	2008-03-30	18372903
rs186273838:12135318:C:T	3	12135318			LD kl min R2									
rs392394:12140087:G:A	3	12140087	0.936355	108368	ref1: TG phase3 v5	rs4684833	rs4684833	Worry	""	5e-08	NR	Nagel M	2018-06-25	29942085
rs392394:12140087:G:A	3	12140087	0.487054	44470	ref1: TG phase3 v5	rs7621569	rs7621569	Circulating leptin levels or type 2 diabetes	""	2e-08	SYN2	Wang X	2020-04-01	32341051
rs11707641:12155888:T:C	3	12155888	1	0	ref1: TG phase3 v5	rs11707641	rs11707641	Chronic obstructive pulmonary disease	(conditional on rs2442776)	3e-06	SYN2	Sakornsakolpat P	2019-02-25	30804561
rs3773364:12189968:A:G	3	12189968	0.972404	34080	ref1: TG phase3 v5	rs11707641	rs11707641	Chronic obstructive pulmonary disease	(conditional on rs2442776)	3e-06	SYN2	Sakornsakolpat P	2019-02-25	30804561
rs111434411:12199906:A:C	3	12199906	0.337342	89894	ref1: TG phase3 v5	rs13081389	rs13081389	Type 2 diabetes	""	2e-07	PPARG	Voight BF	2010-06-27	20581827
rs111434411:12199906:A:C	3	12199906	0.337342	77939	ref1: TG phase3 v5	rs17036101	rs17036101	Type 2 diabetes	""	2e-07	SYN2, PPARG	Zeggini E	2008-03-30	18372903
rs115507561:12251481:G:C	3	12251481			LD kl min R2									
rs114358888:12253307:C:T	3	12253307			LD kl min R2									
rs145410909:12257303:G:C	3	12257303			LD kl min R2									
rs113597482:12273435:A:G	3	12273435			LD kl min R2									
rs310757:12281063:C:T	3	12281063	0.742777	7506	ref1: TG phase3 v5	rs9823123	rs9823123	Heel bone mineral density	""	3e-14	""	Kichaev G	2018-12-27	30595370
rs310757:12281063:C:T	3	12281063	0.59188	7295	ref1: TG phase3 v5	rs310749	rs310749	Total body bone mineral density (MTAG)	""	5e-09	NR	Pei YF	2019-02-28	30690781
rs310757:12281063:C:T	3	12281063	0.59188	7295	ref1: TG phase3 v5	rs310749	rs310749	Heel bone mineral density (MTAG)	""	3e-08	NR	Pei YF	2019-02-28	30690781
rs310757:12281063:C:T	3	12281063	0.451555	43167	ref1: TG phase3 v5	rs2920503	rs2920503	LDL cholesterol	""	3e-10	PPARG	Surakka I	2015-05-11	25961943
rs310757:12281063:C:T	3	12281063	0.385496	35276	ref1: TG phase3 v5	rs2972166	rs2972166	Apolipoprotein A1 levels	""	1e-11	PPARG	Richardson TG	2020-03-23	32203549
rs310757:12281063:C:T	3	12281063	0.371923	169030	ref1: TG phase3 v5	rs1699337	rs1699337	Cholesterol, total	""	9e-12	PPARG	Surakka I	2015-05-11	25961943
rs310757:12281063:C:T	3	12281063	0.350228	12872	ref1: TG phase3 v5	rs9810259	rs9810259	Platelet count	""	1e-28	intergenic	Astle WJ	2016-11-17	27863252
rs310757:12281063:C:T	3	12281063	0.346529	13415	ref1: TG phase3 v5	rs7616006	rs7616006	Platelet count	""	5e-08	SYN2	Gieger C	2011-11-30	22139419
rs9823123:12288569:A:C	3	12288569	1	0	ref1: TG phase3 v5	rs9823123	rs9823123	Heel bone mineral density	""	3e-14	""	Kichaev G	2018-12-27	30595370
rs9823123:12288569:A:C	3	12288569	0.688507	14801	ref1: TG phase3 v5	rs310749	rs310749	Total body bone mineral density (MTAG)	""	5e-09	NR	Pei YF	2019-02-28	30690781
rs9823123:12288569:A:C	3	12288569	0.688507	14801	ref1: TG phase3 v5	rs310749	rs310749	Heel bone mineral density (MTAG)	""	3e-08	NR	Pei YF	2019-02-28	30690781
rs9823123:12288569:A:C	3	12288569	0.542138	20921	ref1: TG phase3 v5	rs7616006	rs7616006	Platelet count	""	5e-08	SYN2	Gieger C	2011-11-30	22139419
rs9823123:12288569:A:C	3	12288569	0.541426	20378	ref1: TG phase3 v5	rs9810259	rs9810259	Platelet count	""	1e-28	intergenic	Astle WJ	2016-11-17	27863252
rs9823123:12288569:A:C	3	12288569	0.46863	21765	ref1: TG phase3 v5	rs1822534	rs1822534	Waist-to-hip ratio adjusted for BMI	""	3e-20	NR	Zhu Z	2019-10-24	31669095
rs9823123:12288569:A:C	3	12288569	0.368055	69661	ref1: TG phase3 v5	rs6442310	rs6442310	Hematocrit	""	3e-11	PPARG	Astle WJ	2016-11-17	27863252
rs9823123:12288569:A:C	3	12288569	0.327393	161524	ref1: TG phase3 v5	rs1699337	rs1699337	Cholesterol, total	""	9e-12	PPARG	Surakka I	2015-05-11	25961943
rs6802898:12391207:C:T	3	12391207	0.990493	5379	ref1: TG phase3 v5	rs11128603	rs11128603	Plasminogen activator inhibitor type 1 levels (PAI-1)	""	9e-08	PPARG	Huang J	2012-09-18	22990020
rs6802898:12391207:C:T	3	12391207	0.990493	723	ref1: TG phase3 v5	rs17036328	rs17036328	Youthful appearance (self-reported)	""	5e-09	PPARG	Roberts V	2020-04-24	32339537
rs6802898:12391207:C:T	3	12391207	0.981039	1918	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	(DGI+FUSION+WTCCC)	2e-06	PPARG	Scott LJ	2007-04-26	17463248
rs6802898:12391207:C:T	3	12391207	0.981039	1918	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	""	2e-06	PPARG	Saxena R	2007-04-26	17463246
rs6802898:12391207:C:T	3	12391207	0.981039	1918	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	(DGI+FUSION+WTCCC)	2e-06	PPARG	Zeggini E	2007-04-26	17463249
rs6802898:12391207:C:T	3	12391207	0.981039	1918	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	""	6e-10	PPARG	Mahajan A	2014-02-09	24509480
rs6802898:12391207:C:T	3	12391207	0.981039	1918	ref1: TG phase3 v5	rs1801282	rs1801282	Fasting blood insulin (BMI interaction)	""	2e-07	PPARG	Manning AK	2012-05-13	22581228
rs6802898:12391207:C:T	3	12391207	0.981039	4870	ref1: TG phase3 v5	rs4684847	rs4684847	Appendicular lean mass	""	4e-19	NR	Hernandez Cordero AI	2019-11-21	31761296
rs6802898:12391207:C:T	3	12391207	0.952564	54700	ref1: TG phase3 v5	rs11709077	rs11709077	Body mass index	(EA)	2e-07	PPARG	Locke AE	2015-02-12	25673413
rs6802898:12391207:C:T	3	12391207	0.617647	5850	ref1: TG phase3 v5	rs3963364	rs3963364	Type 2 diabetes	""	3e-11	PPARG	Spracklen CN	2020-05-06	32499647
rs6802898:12391207:C:T	3	12391207	0.370881	22974	ref1: TG phase3 v5	rs4073770	rs4073770	Hemoglobin levels	""	2e-23	PPARG	Oskarsson GR	2020-04-23	32327693
rs6802898:12391207:C:T	3	12391207	0.367457	4751	ref1: TG phase3 v5	rs7615916	rs7615916	Eosinophil percentage of white cells	""	2e-16	PPARG	Astle WJ	2016-11-17	27863252
rs6802898:12391207:C:T	3	12391207	0.337802	101407	ref1: TG phase3 v5	rs13081389	rs13081389	Type 2 diabetes	""	2e-07	PPARG	Voight BF	2010-06-27	20581827
rs6802898:12391207:C:T	3	12391207	0.337802	113362	ref1: TG phase3 v5	rs17036101	rs17036101	Type 2 diabetes	""	2e-07	SYN2, PPARG	Zeggini E	2008-03-30	18372903
rs6802898:12391207:C:T	3	12391207	0.326761	56855	ref1: TG phase3 v5	rs35958630	rs35958630	Waist-to-hip ratio adjusted for BMI	""	3e-08	NR	Zhu Z	2019-10-24	31669095
rs1899951:12394840:C:T	3	12394840	1	9012	ref1: TG phase3 v5	rs11128603	rs11128603	Plasminogen activator inhibitor type 1 levels (PAI-1)	""	9e-08	PPARG	Huang J	2012-09-18	22990020
rs1899951:12394840:C:T	3	12394840	1	4356	ref1: TG phase3 v5	rs17036328	rs17036328	Youthful appearance (self-reported)	""	5e-09	PPARG	Roberts V	2020-04-24	32339537
rs1899951:12394840:C:T	3	12394840	0.990496	1715	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	(DGI+FUSION+WTCCC)	2e-06	PPARG	Scott LJ	2007-04-26	17463248
rs1899951:12394840:C:T	3	12394840	0.990496	1715	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	""	2e-06	PPARG	Saxena R	2007-04-26	17463246
rs1899951:12394840:C:T	3	12394840	0.990496	1715	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	(DGI+FUSION+WTCCC)	2e-06	PPARG	Zeggini E	2007-04-26	17463249
rs1899951:12394840:C:T	3	12394840	0.990496	1715	ref1: TG phase3 v5	rs1801282	rs1801282	Type 2 diabetes	""	6e-10	PPARG	Mahajan A	2014-02-09	24509480
rs1899951:12394840:C:T	3	12394840	0.990496	1715	ref1: TG phase3 v5	rs1801282	rs1801282	Fasting blood insulin (BMI interaction)	""	2e-07	PPARG	Manning AK	2012-05-13	22581228
rs1899951:12394840:C:T	3	12394840	0.990496	8503	ref1: TG phase3 v5	rs4684847	rs4684847	Appendicular lean mass	""	4e-19	NR	Hernandez Cordero AI	2019-11-21	31761296
rs1899951:12394840:C:T	3	12394840	0.961787	58333	ref1: TG phase3 v5	rs11709077	rs11709077	Body mass index	(EA)	2e-07	PPARG	Locke AE	2015-02-12	25673413
rs1899951:12394840:C:T	3	12394840	0.612049	9483	ref1: TG phase3 v5	rs3963364	rs3963364	Type 2 diabetes	""	3e-11	PPARG	Spracklen CN	2020-05-06	32499647
rs1899951:12394840:C:T	3	12394840	0.377167	26607	ref1: TG phase3 v5	rs4073770	rs4073770	Hemoglobin levels	""	2e-23	PPARG	Oskarsson GR	2020-04-23	32327693
rs1899951:12394840:C:T	3	12394840	0.373752	1118	ref1: TG phase3 v5	rs7615916	rs7615916	Eosinophil percentage of white cells	""	2e-16	PPARG	Astle WJ	2016-11-17	27863252
rs1899951:12394840:C:T	3	12394840	0.340992	105040	ref1: TG phase3 v5	rs13081389	rs13081389	Type 2 diabetes	""	2e-07	PPARG	Voight BF	2010-06-27	20581827
rs1899951:12394840:C:T	3	12394840	0.340992	116995	ref1: TG phase3 v5	rs17036101	rs17036101	Type 2 diabetes	""	2e-07	SYN2, PPARG	Zeggini E	2008-03-30	18372903
rs1899951:12394840:C:T	3	12394840	0.332896	60488	ref1: TG phase3 v5	rs35958630	rs35958630	Waist-to-hip ratio adjusted for BMI	""	3e-08	NR	Zhu Z	2019-10-24	31669095
rs115535070:12397615:G:A	3	12397615			LD kl min R2									
rs2938387:12439387:C:T	3	12439387	0.896283	10706	ref1: TG phase3 v5	rs1699337	rs1699337	Cholesterol, total	""	9e-12	PPARG	Surakka I	2015-05-11	25961943
rs2938387:12439387:C:T	3	12439387	0.435979	171196	ref1: TG phase3 v5	rs9810259	rs9810259	Platelet count	""	1e-28	intergenic	Astle WJ	2016-11-17	27863252
rs2938387:12439387:C:T	3	12439387	0.428241	171739	ref1: TG phase3 v5	rs7616006	rs7616006	Platelet count	""	5e-08	SYN2	Gieger C	2011-11-30	22139419
rs2938387:12439387:C:T	3	12439387	0.376361	81157	ref1: TG phase3 v5	rs6442310	rs6442310	Hematocrit	""	3e-11	PPARG	Astle WJ	2016-11-17	27863252
rs2938387:12439387:C:T	3	12439387	0.354005	172583	ref1: TG phase3 v5	rs1822534	rs1822534	Waist-to-hip ratio adjusted for BMI	""	3e-20	NR	Zhu Z	2019-10-24	31669095
rs2938387:12439387:C:T	3	12439387	0.331263	150818	ref1: TG phase3 v5	rs9823123	rs9823123	Heel bone mineral density	""	3e-14	""	Kichaev G	2018-12-27	30595370
rs13064115:12492949:C:T	3	12492949			LD kl min R2									
rs73029206:12494894:A:G	3	12494894			LD kl min R2									
rs2655268:12503893:C:T	3	12503893	1	0	ref1: TG phase3 v5	rs2655268	rs2655268	Waist-to-hip ratio adjusted for BMI	""	8e-26	NR	Zhu Z	2019-10-24	31669095
rs9869091:12562649:T:C	3	12562649			LD kl min R2									
rs2633444:12577277:T:C	3	12577277			LD kl min R2									
rs13074980:12589241:G:A	3	12589241	0.314392	154712	ref2: TG phase1 v3	rs112126248	rs112126248	Waist-to-hip ratio adjusted for BMI	""	1e-12	NR	Zhu Z	2019-10-24	31669095
rs9288803:105132008:T:C	3	105132008			LD kl min R2									
rs56195827:195552997:A:G	3	195552997			LD kl min R2									
rs889581:195573787:A:C	3	195573787			LD kl min R2									
rs34134349:195602528:CCT:C	3	195602528			LD kl min R2									
rs144687212:195645602:G:T	3	195645602			LD kl min R2									
rs149608438:195684076:G:A	3	195684076			LD kl min R2									
rs72611179:195725157:C:T	3	195725157			LD kl min R2									
rs114658749:195775144:C:T	3	195775144			LD kl min R2									
rs41298107:195778072:G:A	3	195778072			LD kl min R2									
rs142433801:195780772:A:G	3	195780772			LD kl min R2									
rs3804141:195796908:C:T	3	195796908			LD kl min R2									
rs3817672:195800811:C:T	3	195800811	0.826009	264	ref1: TG phase3 v5	rs9859260	rs9859260	Mean corpuscular volume	""	8e-14	TFRC	Ganesh SK	2009-10-11	19862010
rs3817672:195800811:C:T	3	195800811	0.508128	8328	ref1: TG phase3 v5	rs11915082	rs11915082	Mean corpuscular hemoglobin	""	8e-13	TFRC	Ganesh SK	2009-10-11	19862010
rs3817672:195800811:C:T	3	195800811	0.378832	29465	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular volume	""	1e-09	""	Hodonsky CJ	2020-03-14	32171239
rs3817672:195800811:C:T	3	195800811	0.378832	29465	ref1: TG phase3 v5	rs73210009	rs73210009	Red cell distribution width	""	3e-07	""	Hodonsky CJ	2020-03-14	32171239
rs3817672:195800811:C:T	3	195800811	0.378832	29465	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular hemoglobin	""	2e-11	""	Hodonsky CJ	2020-03-14	32171239
rs3817672:195800811:C:T	3	195800811	0.378832	29465	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular hemoglobin concentration	""	5e-06	""	Hodonsky CJ	2020-03-14	32171239
rs3817672:195800811:C:T	3	195800811	0.378832	29465	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular hemoglobin	""	4e-06	""	Hodonsky CJ	2020-03-14	32171239
rs3817672:195800811:C:T	3	195800811	0.378832	29465	ref1: TG phase3 v5	rs73210009	rs73210009	Red cell distribution width	""	3e-07	""	Hodonsky CJ	2020-03-14	32171239
rs3817672:195800811:C:T	3	195800811	0.351218	49181	ref1: TG phase3 v5	rs4927850	rs4927850	Pancreatic cancer	""	2e-07	TFRC	Wu C	2011-12-11	22158540
rs3817672:195800811:C:T	3	195800811	0.302534	65440	ref2: TG phase1 v3	rs2019472	rs2019472	Nonatopic asthma	""	2e-08	NR	Zhu Z	2019-10-24	31669095
rs9870831:195830297:T:C	3	195830297	0.312725	13	ref1: TG phase3 v5	rs9866168	rs9866168	Type 2 diabetes	""	2e-09	TFRC	Spracklen CN	2020-05-06	32499647
rs9867473:195831098:A:C	3	195831098	0.723837	30551	ref1: TG phase3 v5	rs9859260	rs9859260	Mean corpuscular volume	""	8e-14	TFRC	Ganesh SK	2009-10-11	19862010
rs9867473:195831098:A:C	3	195831098	0.455828	21959	ref1: TG phase3 v5	rs11915082	rs11915082	Mean corpuscular hemoglobin	""	8e-13	TFRC	Ganesh SK	2009-10-11	19862010
rs9867473:195831098:A:C	3	195831098	0.372126	79468	ref1: TG phase3 v5	rs4927850	rs4927850	Pancreatic cancer	""	2e-07	TFRC	Wu C	2011-12-11	22158540
rs9867473:195831098:A:C	3	195831098	0.364256	822	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular volume	""	1e-09	""	Hodonsky CJ	2020-03-14	32171239
rs9867473:195831098:A:C	3	195831098	0.364256	822	ref1: TG phase3 v5	rs73210009	rs73210009	Red cell distribution width	""	3e-07	""	Hodonsky CJ	2020-03-14	32171239
rs9867473:195831098:A:C	3	195831098	0.364256	822	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular hemoglobin	""	2e-11	""	Hodonsky CJ	2020-03-14	32171239
rs9867473:195831098:A:C	3	195831098	0.364256	822	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular hemoglobin concentration	""	5e-06	""	Hodonsky CJ	2020-03-14	32171239
rs9867473:195831098:A:C	3	195831098	0.364256	822	ref1: TG phase3 v5	rs73210009	rs73210009	Mean corpuscular hemoglobin	""	4e-06	""	Hodonsky CJ	2020-03-14	32171239
rs9867473:195831098:A:C	3	195831098	0.364256	822	ref1: TG phase3 v5	rs73210009	rs73210009	Red cell distribution width	""	3e-07	""	Hodonsky CJ	2020-03-14	32171239
rs13064333:195841274:C:T	3	195841274			LD kl min R2									
rs11710468:195847906:G:A	3	195847906			LD kl min R2									
rs62408947:195849632:G:A	3	195849632			LD kl min R2									
rs56178612:195850254:G:A	3	195850254			LD kl min R2									
rs7625441:195854279:C:T	3	195854279			LD kl min R2									
rs28651009:195864396:T:C	3	195864396			LD kl min R2									
rs116434121:195943717:C:T	3	195943717			LD kl min R2									
rs115864174:196030272:C:T	3	196030272			LD kl min R2									
rs12631706:196167930:T:C	3	196167930			LD kl min R2									
3:196189807:TAC:T	3	196189807			snp not in any Ref									
rs12636036:196300621:A:G	3	196300621			LD kl min R2									
rs11732521:57685824:T:C	4	57685824			LD kl min R2									
rs201942164:57698059:A:AT	4	57698059			LD kl min R2									
rs71601658:57773601:C:T	4	57773601			LD kl min R2									
rs1713997:57843863:G:C	4	57843863	0.721456	22554	ref1: TG phase3 v5	rs708547	rs708547	Response to bleomycin (chromatid breaks)	""	9e-07	C4orf14, REST	Gu J	2010-11-24	21106707
rs11573086:57922249:C:A	4	57922249			LD kl min R2									
rs7663219:57927690:T:C	4	57927690			LD kl min R2									
rs4596307:57932174:C:T	4	57932174			LD kl min R2									
rs1718871:57938090:A:C	4	57938090	0.43241	10134	ref1: TG phase3 v5	rs1718859	rs1718859	Apolipoprotein A1 levels	""	5e-09	IGFBP7	Richardson TG	2020-03-23	32203549
rs1718871:57938090:A:C	4	57938090	0.405673	228	ref1: TG phase3 v5	rs13141016	rs13141016	Metabolite levels	(pantothenic acid)	8e-07	POLR2B	Rhee EP	2013-07-02	23823483
rs73242636:57939027:C:G	4	57939027			LD kl min R2									
rs1718860:57949517:G:A	4	57949517	0.537016	1293	ref1: TG phase3 v5	rs1718859	rs1718859	Apolipoprotein A1 levels	""	5e-09	IGFBP7	Richardson TG	2020-03-23	32203549
rs1718860:57949517:G:A	4	57949517	0.347016	11655	ref1: TG phase3 v5	rs13141016	rs13141016	Metabolite levels	(pantothenic acid)	8e-07	POLR2B	Rhee EP	2013-07-02	23823483
rs73242648:57961899:A:C	4	57961899	1	0	ref1: TG phase3 v5	rs73242648	rs73242648	Spherical equivalent	""	3e-09	NR	Han X	2020-04-30	32352494
rs35297343:57963121:T:C	4	57963121			LD kl min R2									
rs11573021:57976487:G:A	4	57976487			LD kl min R2									
rs141115061:88406451:C:A	4	88406451			snp not in any Ref									
rs141963650:88666239:G:T	4	88666239			LD kl min R2									
rs10029761:88749845:G:A	4	88749845			LD kl min R2									
rs17013508:88808045:G:T	4	88808045			LD kl min R2									
rs1381949:88832799:G:A	4	88832799	0.329373	57556	ref1: TG phase3 v5	rs1471403	rs1471403	Bone mineral density (hip)	""	8e-07	MEPE	Rivadeneira F	2009-10-04	19801982
rs1381949:88832799:G:A	4	88832799	0.329373	57556	ref1: TG phase3 v5	rs1471403	rs1471403	Bone mineral density (spine)	""	2e-08	MEPE	Rivadeneira F	2009-10-04	19801982
rs1381949:88832799:G:A	4	88832799	0.329373	58950	ref1: TG phase3 v5	rs6532023	rs6532023	Lumbar spine bone mineral density	""	1e-27	MEPE	Estrada K	2012-04-15	22504420
rs1381949:88832799:G:A	4	88832799	0.329373	58950	ref1: TG phase3 v5	rs6532023	rs6532023	Bone mineral density (paediatric, total body less head)	""	3e-06	MEPE	Kemp JP	2014-06-19	24945404
rs62315874:88838388:A:G	4	88838388			LD kl min R2									
rs114363414:88889763:C:T	4	88889763			LD kl min R2									
rs183860561:89074339:G:A	4	89074339			LD kl min R2									
rs62310028:89270472:G:A	4	89270472			LD kl min R2									
rs73011536:185160036:T:G	4	185160036			LD kl min R2									
rs55989033:185313398:A:G	4	185313398			LD kl min R2									
rs3775581:185385392:G:A	4	185385392			LD kl min R2									
rs4647634:185561827:C:T	4	185561827			LD kl min R2									
rs4647603:185569730:C:T	4	185569730			LD kl min R2									
rs13110386:185641568:G:A	4	185641568	0.310168	2399	ref1: TG phase3 v5	rs2130392	rs2130392	Kawasaki disease	""	3e-08	MLF1IP	Onouchi Y	2012-03-25	22446962
rs11933776:185679339:C:T	4	185679339			LD kl min R2									
rs4355430:185885897:C:T	4	185885897			LD kl min R2									
rs112679281:185922828:G:A	4	185922828	0.374977	6663	ref1: TG phase3 v5	rs11730272	rs7432640 x rs11730272	Neuritic plaques (SNP x SNP interaction)	""	2e-09	NR x NR	Wang H	2020-04-29	32450446
rs112679281:185922828:G:A	4	185922828	0.374977	6663	ref1: TG phase3 v5	rs7432640	rs7432640 x rs11730272	Neuritic plaques (SNP x SNP interaction)	""	2e-09	NR x NR	Wang H	2020-04-29	32450446
rs17717320:147205914:C:G	5	147205914			LD kl min R2									
rs75869763:147278281:G:C	5	147278281			LD kl min R2									
rs148217547:40737342:T:C	6	40737342			LD kl min R2									
rs962390:40781420:T:G	6	40781420			LD kl min R2									
rs12203707:40785567:C:T	6	40785567			LD kl min R2									
rs10807251:40931819:G:A	6	40931819			LD kl min R2									
rs79142813:40964484:C:T	6	40964484			LD kl min R2									
rs41273752:41061939:C:T	6	41061939			LD kl min R2									
rs115193711:41070216:G:A	6	41070216			LD kl min R2									
rs77790943:41070941:G:A	6	41070941	0.445973	36941	ref1: TG phase3 v5	rs114812713	rs114812713	Alzheimer's disease (late onset)	""	2e-13	OARD1	Kunkle BW	2019-02-28	30820047
rs78088364:41083075:A:T	6	41083075			LD kl min R2									
rs10456499:41083352:G:A	6	41083352			LD kl min R2									
rs76923011:41087103:A:G	6	41087103			LD kl min R2									
rs13207171:41165819:C:T	6	41165819			LD kl min R2									
rs62396355:41166149:A:G	6	41166149			LD kl min R2									
rs11759347:41167097:C:A	6	41167097			LD kl min R2									
rs2395751:41169428:T:G	6	41169428			LD kl min R2									
rs4711660:41171292:G:C	6	41171292			LD kl min R2									
rs79906444:41200606:A:G	6	41200606			LD kl min R2									
rs12665227:41216385:T:C	6	41216385			LD kl min R2									
rs6906676:41284468:T:C	6	41284468			LD kl min R2									
rs6929418:41307594:A:G	6	41307594			LD kl min R2									
rs2496661:41407801:A:T	6	41407801			LD kl min R2									
rs78740125:54758680:G:A	7	54758680			LD kl min R2									
rs4947976:55182253:C:A	7	55182253			LD kl min R2									
rs6947531:55189190:C:T	7	55189190			LD kl min R2									
rs1815156:55236862:T:C	7	55236862			LD kl min R2									
rs11762702:75171427:C:G	7	75171427			LD kl min R2									
rs1179635:75230264:C:T	7	75230264			LD kl min R2									
rs117762358:75260534:C:T	7	75260534			LD kl min R2									
rs4731229:75264250:A:C	7	75264250	0.459212	9035	ref1: TG phase3 v5	rs1179624	rs1179624	Age-related nuclear cataracts	(Fixed effect)	5e-06	HIP1	Liao J	2014-06-20	24951543
rs56082477:75294545:A:G	7	75294545			LD kl min R2									
rs147981806:75318440:G:A	7	75318440			LD kl min R2									
rs117605738:75319037:G:A	7	75319037			LD kl min R2									
rs4731728:75322959:G:A	7	75322959			LD kl min R2									
rs10954317:75327352:G:T	7	75327352	0.508196	36765	ref2: TG phase1 v3	rs4728351	rs4728351 x rs10112728	Nasopharyngeal carcinoma (SNP x SNP interaction)	""	2e-08	HIP1 x CPA6	Su WH	2013-12-23	24376627
rs10954317:75327352:G:T	7	75327352	0.40347	43794	ref1: TG phase3 v5	rs67999259	rs67999259	Colorectal cancer	(East Asian)	2e-06	""	Lu Y	2019-12-11	31826910
rs1859292:75341135:C:T	7	75341135	0.508196	22982	ref2: TG phase1 v3	rs4728351	rs4728351 x rs10112728	Nasopharyngeal carcinoma (SNP x SNP interaction)	""	2e-08	HIP1 x CPA6	Su WH	2013-12-23	24376627
rs1859292:75341135:C:T	7	75341135	0.40347	30011	ref1: TG phase3 v5	rs67999259	rs67999259	Colorectal cancer	(East Asian)	2e-06	""	Lu Y	2019-12-11	31826910
rs374948961:75346154:A:G	7	75346154			LD kl min R2									
rs62477607:75353658:C:T	7	75353658			LD kl min R2									
rs73145068:75364067:G:A	7	75364067			LD kl min R2									
rs4385416:75369213:A:G	7	75369213	0.411482	1933	ref1: TG phase3 v5	rs67999259	rs67999259	Colorectal cancer	(East Asian)	2e-06	""	Lu Y	2019-12-11	31826910
rs4385416:75369213:A:G	7	75369213	0.332271	5096	ref2: TG phase1 v3	rs4728351	rs4728351 x rs10112728	Nasopharyngeal carcinoma (SNP x SNP interaction)	""	2e-08	HIP1 x CPA6	Su WH	2013-12-23	24376627
rs62475494:75377735:C:T	7	75377735			snp not in any Ref									
rs112059545:75390530:C:A	7	75390530			LD kl min R2									
rs11465320:75403311:G:A	7	75403311			LD kl min R2									
rs187553080:75417730:A:G	7	75417730			LD kl min R2									
rs2302006:75442730:T:G	7	75442730	1	0	ref1: TG phase3 v5	rs2302006	rs2302006	Eosinophil percentage of white cells	""	2e-36	CCL24	Astle WJ	2016-11-17	27863252
rs117315456:75452639:C:A	7	75452639			LD kl min R2									
rs142702069:75456636:C:T	7	75456636			LD kl min R2									
rs117335147:75463606:C:T	7	75463606			LD kl min R2									
rs6966161:75466308:G:A	7	75466308			LD kl min R2									
rs10676679:75484454:A:ACCTT	7	75484454			LD kl min R2									
rs10224179:75491957:T:C	7	75491957			LD kl min R2									
rs34473406:75500398:T:G	7	75500398			LD kl min R2									
rs6969298:75500959:C:T	7	75500959			LD kl min R2									
rs42183:75513062:A:G	7	75513062			LD kl min R2									
rs118140197:75514832:C:G	7	75514832			LD kl min R2									
rs10280802:75529137:C:T	7	75529137	1	0	ref1: TG phase3 v5	rs10280802	rs10280802	Metabolite levels	(citrate)	3e-06	POR	Rhee EP	2013-07-02	23823483
rs28444574:75530376:A:G	7	75530376	0.994545	1239	ref1: TG phase3 v5	rs10280802	rs10280802	Metabolite levels	(citrate)	3e-06	POR	Rhee EP	2013-07-02	23823483
rs73133906:75531810:A:G	7	75531810	0.418093	89516	ref1: TG phase3 v5	rs11465296	rs11465296	Eosinophil percentage of white cells	""	3e-15	CCL24	Astle WJ	2016-11-17	27863252
rs117443688:75573583:A:G	7	75573583			LD kl min R2									
rs76718054:75579715:C:T	7	75579715			LD kl min R2									
rs10954723:75595647:G:A	7	75595647			LD kl min R2									
rs7804806:75595682:A:G	7	75595682			LD kl min R2									
rs72563404:75602561:TG:T	7	75602561			LD kl min R2									
rs1135612:75609677:A:G	7	75609677			LD kl min R2									
rs41299517:75611678:A:G	7	75611678			LD kl min R2									
rs142620045:75631315:G:A	7	75631315			LD kl min R2									
rs62475325:75665987:C:T	7	75665987			LD kl min R2									
rs112691161:75667576:G:A	7	75667576			snp not in any Ref									
rs113082452:75683131:C:T	7	75683131			LD kl min R2									
rs59688557:75715357:G:C	7	75715357			LD kl min R2									
rs118108758:75734498:C:T	7	75734498			LD kl min R2									
rs58762064:75790397:G:A	7	75790397			LD kl min R2									
rs142991792:75798564:G:A	7	75798564			LD kl min R2									
rs141538351:75815027:C:T	7	75815027			LD kl min R2									
rs34606716:75820449:G:A	7	75820449	0.310708	220415	ref2: TG phase1 v3	rs6465122	rs6465122	Parkinson disease and lewy body pathology	""	7e-07	ZP3	Beecham GW	2015-02-06	25663231
rs77644037:75859020:G:T	7	75859020			LD kl min R2									
rs4727116:75869398:C:T	7	75869398	0.923283	9936	ref1: TG phase3 v5	rs11984438	rs11984438	Blood protein levels	(CCL24)	2e-14	NR	Sun W	2016-08-17	27532455
rs4727116:75869398:C:T	7	75869398	0.417187	211548	ref1: TG phase3 v5	rs11983987	rs11983987	Blood protein levels	(CCL24)	7e-09	NR	Sun W	2016-08-17	27532455
rs4727116:75869398:C:T	7	75869398	0.326283	108831	ref1: TG phase3 v5	rs17149161	rs17149161	Multiple sclerosis	(Extreme)	6e-06	YWHAG	Briggs FB	2011-06-09	21654844
rs4727116:75869398:C:T	7	75869398	0.326283	83899	ref1: TG phase3 v5	rs758944	rs758944	Multiple sclerosis	(Continuous)	8e-06	LOC100289506	Briggs FB	2011-06-09	21654844
rs4727116:75869398:C:T	7	75869398	0.326283	106188	ref1: TG phase3 v5	rs7779014	rs7779014	Multiple sclerosis	(Continuous)	8e-06	YWHAG	Briggs FB	2011-06-09	21654844
rs4727116:75869398:C:T	7	75869398	0.326283	81832	ref1: TG phase3 v5	rs7789940	rs7789940	Multiple sclerosis	(Extreme)	6e-06	LOC100289506	Briggs FB	2011-06-09	21654844
rs60576079:75889061:C:A	7	75889061	0.930472	9727	ref1: TG phase3 v5	rs11984438	rs11984438	Blood protein levels	(CCL24)	2e-14	NR	Sun W	2016-08-17	27532455
rs60576079:75889061:C:A	7	75889061	0.3069	231211	ref2: TG phase1 v3	rs11983987	rs11983987	Blood protein levels	(CCL24)	7e-09	NR	Sun W	2016-08-17	27532455
rs57992324:75901613:T:G	7	75901613			LD kl min R2									
rs56176566:75912669:G:T	7	75912669			LD kl min R2									
rs141382786:75930731:G:C	7	75930731			LD kl min R2									
rs2009836:75931160:T:C	7	75931160			LD kl min R2									
rs11769502:75933059:C:T	7	75933059			LD kl min R2									
rs17519444:94603442:G:C	7	94603442			LD kl min R2									
rs739504:94693970:T:C	7	94693970			LD kl min R2									
rs143492924:94702530:G:A	7	94702530			LD kl min R2									
rs145441533:94763850:G:C	7	94763850			LD kl min R2									
rs7802749:94787641:A:G	7	94787641			LD kl min R2									
rs80056489:94896837:T:C	7	94896837			LD kl min R2									
rs854537:94910248:A:G	7	94910248	0.509329	20143	ref1: TG phase3 v5	rs854555	rs854555	Response to TNF antagonist treatment	""	2e-06	PON1	Liu C	2008-07-10	18615156
rs854551:94927677:A:G	7	94927677	0.367214	2714	ref1: TG phase3 v5	rs854555	rs854555	Response to TNF antagonist treatment	""	2e-06	PON1	Liu C	2008-07-10	18615156
rs374148387:94932664:ATGCT:A	7	94932664	0.507821	5593	ref1: TG phase3 v5	rs2057681	rs2057681	Paraoxonase activity	(Serum Paraoxonases activity)	1e-303	PON-1	Tang WH	2012-09-13	22982463
rs374148387:94932664:ATGCT:A	7	94932664	0.507821	5593	ref1: TG phase3 v5	rs2057681	rs2057681	Metabolite levels	(C9H14Ona)	7e-15	PON1	Hong MG	2013-03-01	23281178
rs2299261:94949663:A:G	7	94949663			LD kl min R2									
rs854573:94954863:C:T	7	94954863	0.348397	167	ref1: TG phase3 v5	rs854572	rs854572	Paraoxonase activity	(Serum Arylesterase activity)	5e-116	PON-1	Tang WH	2012-09-13	22982463
rs854573:94954863:C:T	7	94954863	0.303847	968	ref2: TG phase1 v3	rs705379	rs705379	Blood protein levels	(Dual specificity protein phosphatase 13 isoform A, DUSP13.6525.17.3)	1e-29	PON1	Sun BB	2018-06-06	29875488
rs854573:94954863:C:T	7	94954863	0.303847	968	ref2: TG phase1 v3	rs705379	rs705379	Blood protein levels	(Testis-expressed sequence 29 protein, TEX29.10557.6.3)	5e-22	PON1	Sun BB	2018-06-06	29875488
rs757158:94955528:C:T	7	94955528	1	0	ref1: TG phase3 v5	rs757158	rs757158	Protein quantitative trait loci	(paraoxonase 1)	1e-08	NR	Ruffieux H	2020-06-03	32492067
rs757158:94955528:C:T	7	94955528	0.855524	832	ref1: TG phase3 v5	rs854572	rs854572	Paraoxonase activity	(Serum Arylesterase activity)	5e-116	PON-1	Tang WH	2012-09-13	22982463
rs757158:94955528:C:T	7	94955528	0.678698	1633	ref1: TG phase3 v5	rs705379	rs705379	Blood protein levels	(Dual specificity protein phosphatase 13 isoform A, DUSP13.6525.17.3)	1e-29	PON1	Sun BB	2018-06-06	29875488
rs757158:94955528:C:T	7	94955528	0.678698	1633	ref1: TG phase3 v5	rs705379	rs705379	Blood protein levels	(Testis-expressed sequence 29 protein, TEX29.10557.6.3)	5e-22	PON1	Sun BB	2018-06-06	29875488
rs757158:94955528:C:T	7	94955528	0.385419	79247	ref1: TG phase3 v5	rs7493	rs7493	Yu-Zhi constitution type in type 2 diabetes	(Genotype model)	5e-06	PON2	Huang KC	2015-07-14	26169365
rs35715042:94967643:G:A	7	94967643			LD kl min R2									
rs17880824:94979963:C:T	7	94979963			LD kl min R2									
rs10953142:94983354:C:T	7	94983354	0.398092	27826	ref1: TG phase3 v5	rs757158	rs757158	Protein quantitative trait loci	(paraoxonase 1)	1e-08	NR	Ruffieux H	2020-06-03	32492067
rs1003504:95018793:T:C	7	95018793			LD kl min R2									
rs75730309:95024600:T:A	7	95024600			LD kl min R2									
rs149867961:95025744:T:C	7	95025744			LD kl min R2									
rs5885910:95046407:GC:G	7	95046407			LD kl min R2									
rs112227853:95070043:A:G	7	95070043			LD kl min R2									
rs76893606:95073811:A:G	7	95073811			LD kl min R2									
rs43055:95079832:G:A	7	95079832			LD kl min R2									
rs117693635:95092055:A:G	7	95092055	0.425797	49629	ref1: TG phase3 v5	rs186586197	rs186586197	Apolipoprotein A1 levels	""	5e-09	PON2	Richardson TG	2020-03-23	32203549
rs117693635:95092055:A:G	7	95092055	0.361293	80107	ref1: TG phase3 v5	rs183906992	rs183906992	HDL cholesterol levels	""	5e-10	PON1	Richardson TG	2020-03-23	32203549
rs4727314:95095830:A:G	7	95095830			LD kl min R2									
rs150527249:95099972:C:T	7	95099972			LD kl min R2									
rs6973126:95131217:C:T	7	95131217	0.334153	13514	ref1: TG phase3 v5	rs11977715	rs11977715	Middle childhood and early adolescence aggressive behavior	""	8e-06	ASB4	Pappa I	2015-06-18	26087016
rs6975716:95149475:G:T	7	95149475			LD kl min R2									
rs58930216:95157870:C:A	7	95157870	0.399031	297975	ref1: TG phase3 v5	rs3779483	rs3779483	Dementia and core Alzheimer's disease neuropathologic changes	(Primary)	2e-06	DYNC1I1	Beecham GW	2014-09-04	25188341
rs58930216:95157870:C:A	7	95157870	0.399031	297975	ref1: TG phase3 v5	rs3779483	rs3779483	Dementia and core Alzheimer's disease neuropathologic changes	(Complete)	2e-06	DYNC1I1	Beecham GW	2014-09-04	25188341
rs62467701:95171482:T:C	7	95171482			LD kl min R2									
rs77746671:95383210:T:A	7	95383210			LD kl min R2									
rs34802529:95522167:A:AT	7	95522167			LD kl min R2									
rs1476679:100004446:C:T	7	100004446	1	0	ref1: TG phase3 v5	rs1476679	rs1476679	Alzheimer's disease (late onset)	""	6e-10	ZCWPW1	Lambert JC	2013-10-27	24162737
rs1476679:100004446:C:T	7	100004446	0.970948	7888	ref1: TG phase3 v5	rs34919929	rs34919929	Rate of cognitive decline in Alzheimer's disease	(LME model)	7e-07	NR	Sherva R	2020-06-23	32573913
rs1476679:100004446:C:T	7	100004446	0.932541	87349	ref1: TG phase3 v5	rs12539172	rs12539172	Spherical equivalent	""	4e-08	NR	Han X	2020-04-30	32352494
rs144597561:100054937:ATTC:A	7	100054937			LD kl min R2									
rs11768465:100198386:C:T	7	100198386	0.494012	15629	ref1: TG phase3 v5	rs7786877	rs7786877	Mean corpuscular volume	""	3e-11	TFR2	Ganesh SK	2009-10-11	19862010
rs11768465:100198386:C:T	7	100198386	0.475193	146720	ref1: TG phase3 v5	rs2075671	rs2075671	Other erythrocyte phenotypes	(RBC)	1e-09	EPO	Ganesh SK	2009-10-11	19862010
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Hematological parameters	(RBC)	5e-10	TFR2	Soranzo N	2009-10-11	19820697
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Hematocrit	""	4e-10	TFR2	Ganesh SK	2009-10-11	19862010
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Iron status biomarkers	(iron)	7e-08	TFR2	Pichler I	2011-01-04	21208937
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Mean corpuscular volume	""	9e-85	TFR2	Astle WJ	2016-11-17	27863252
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Iron status biomarkers (transferrin saturation)	""	6e-12	TFR2	Benyamin B	2014-10-29	25352340
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Iron status biomarkers (iron levels)	""	1e-18	TFR2	Benyamin B	2014-10-29	25352340
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Red blood cell count	""	7e-16	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Hemoglobin concentration	""	3e-06	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Hematocrit	""	2e-10	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Red blood cell count	""	3e-09	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Red blood cell count	""	7e-09	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Mean corpuscular volume	""	2e-11	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Mean corpuscular volume	""	1e-09	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Mean corpuscular hemoglobin	""	1e-14	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Mean corpuscular hemoglobin	""	3e-10	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.326904	37584	ref2: TG phase1 v3	rs7385804	rs7385804	Hematocrit	""	1e-06	""	Hodonsky CJ	2020-03-14	32171239
rs11768465:100198386:C:T	7	100198386	0.316125	41910	ref2: TG phase1 v3	rs2075672	rs2075672	Platelet count	""	2e-13	TFR2	Astle WJ	2016-11-17	27863252
rs11768465:100198386:C:T	7	100198386	0.316125	41910	ref2: TG phase1 v3	rs2075672	rs2075672	Red blood cell traits	(EA, RBCC)	2e-20	ACTL6B, TFR2	van der Harst P	2012-12-05	23222517
rs4434553:100240191:A:G	7	100240191	0.549778	105	ref1: TG phase3 v5	rs2075672	rs2075672	Platelet count	""	2e-13	TFR2	Astle WJ	2016-11-17	27863252
rs4434553:100240191:A:G	7	100240191	0.549778	105	ref1: TG phase3 v5	rs2075672	rs2075672	Red blood cell traits	(EA, RBCC)	2e-20	ACTL6B, TFR2	van der Harst P	2012-12-05	23222517
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Hematological parameters	(RBC)	5e-10	TFR2	Soranzo N	2009-10-11	19820697
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Hematocrit	""	4e-10	TFR2	Ganesh SK	2009-10-11	19862010
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Iron status biomarkers	(iron)	7e-08	TFR2	Pichler I	2011-01-04	21208937
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Mean corpuscular volume	""	9e-85	TFR2	Astle WJ	2016-11-17	27863252
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Iron status biomarkers (transferrin saturation)	""	6e-12	TFR2	Benyamin B	2014-10-29	25352340
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Iron status biomarkers (iron levels)	""	1e-18	TFR2	Benyamin B	2014-10-29	25352340
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Red blood cell count	""	7e-16	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Hemoglobin concentration	""	3e-06	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Hematocrit	""	2e-10	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Red blood cell count	""	3e-09	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Red blood cell count	""	7e-09	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Mean corpuscular volume	""	2e-11	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Mean corpuscular volume	""	1e-09	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Mean corpuscular hemoglobin	""	1e-14	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Mean corpuscular hemoglobin	""	3e-10	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.547854	4221	ref1: TG phase3 v5	rs7385804	rs7385804	Hematocrit	""	1e-06	""	Hodonsky CJ	2020-03-14	32171239
rs4434553:100240191:A:G	7	100240191	0.344741	81337	ref1: TG phase3 v5	rs551238	rs551238	Hematocrit	""	4e-32	EPO	Astle WJ	2016-11-17	27863252
rs4434553:100240191:A:G	7	100240191	0.322196	26176	ref1: TG phase3 v5	rs7786877	rs7786877	Mean corpuscular volume	""	3e-11	TFR2	Ganesh SK	2009-10-11	19862010
rs221811:100359117:C:T	7	100359117	0.392698	94091	ref1: TG phase3 v5	rs314370	rs314370	Resting heart rate	""	6e-10	SLC12A9	Eijgelsheim M	2010-07-16	20639392
rs221811:100359117:C:T	7	100359117	0.343374	127637	ref1: TG phase3 v5	rs12666989	rs12666989	Resting heart rate	""	2e-08	UFSP1	Eijgelsheim M	2010-07-16	20639392
rs221811:100359117:C:T	7	100359117	0.328612	64248	ref1: TG phase3 v5	rs314313	rs314313	Inflammatory bowel disease	(EA)	4e-10	NR	Liu JZ	2015-07-20	26192919
rs221811:100359117:C:T	7	100359117	0.328612	64248	ref1: TG phase3 v5	rs314313	rs314313	Ulcerative colitis	(EA)	4e-06	NR	Liu JZ	2015-07-20	26192919
rs221811:100359117:C:T	7	100359117	0.328612	64248	ref1: TG phase3 v5	rs314313	rs314313	Crohn's disease	(EA)	3e-08	NR	Liu JZ	2015-07-20	26192919
rs221811:100359117:C:T	7	100359117	0.314807	138014	ref1: TG phase3 v5	rs13245899	rs13245899	Heart rate	""	8e-27	ACHE	den Hoed M	2013-04-14	23583979
rs314295:100369045:G:A	7	100369045			LD kl min R2									
rs146191724:100384029:CTTGT:C	7	100384029	0.308745	98497	ref1: TG phase3 v5	rs6942607	rs6942607	Hemoglobin levels	""	1e-09	ACHE, SRRT	Oskarsson GR	2020-04-23	32327693
rs146191724:100384029:CTTGT:C	7	100384029	0.303727	128090	ref2: TG phase1 v3	rs6976053	rs6976053	Plasminogen activator inhibitor type 1 levels (PAI-1)	""	6e-13	UFSP1, SLC12A9, TRIP6, SRRT, EPHB4, ACHE, MUC3	Huang J	2012-09-18	22990020
rs2553022:100401862:A:G	7	100401862			LD kl min R2									
rs79570624:100660113:G:C	7	100660113			LD kl min R2									
rs965634:100823775:A:G	7	100823775			LD kl min R2									
rs35802177:130003958:T:G	7	130003958			LD kl min R2									
rs35454128:130013574:G:C	7	130013574			LD kl min R2									
rs2074699:149547703:T:C	7	149547703			LD kl min R2									
rs11766288:150002815:T:A	7	150002815	0.833285	42487	ref1: TG phase3 v5	rs10282458	rs10282458	Protein levels in obesity	(TIG2)	2e-10	NR	Carayol J	2017-12-12	29234017
rs11766288:150002815:T:A	7	150002815	0.618101	53824	ref1: TG phase3 v5	rs114190730	rs114190730	Protein quantitative trait loci	(TIG2)	5e-10	NR	Ruffieux H	2020-06-03	32492067
rs73170174:150016523:T:C	7	150016523	0.814468	28779	ref1: TG phase3 v5	rs10282458	rs10282458	Protein levels in obesity	(TIG2)	2e-10	NR	Carayol J	2017-12-12	29234017
rs73170174:150016523:T:C	7	150016523	0.625669	40116	ref1: TG phase3 v5	rs114190730	rs114190730	Protein quantitative trait loci	(TIG2)	5e-10	NR	Ruffieux H	2020-06-03	32492067
rs2159236:150017214:A:G	7	150017214	0.818822	28088	ref1: TG phase3 v5	rs10282458	rs10282458	Protein levels in obesity	(TIG2)	2e-10	NR	Carayol J	2017-12-12	29234017
rs2159236:150017214:A:G	7	150017214	0.629893	39425	ref1: TG phase3 v5	rs114190730	rs114190730	Protein quantitative trait loci	(TIG2)	5e-10	NR	Ruffieux H	2020-06-03	32492067
rs79741600:150051282:C:T	7	150051282			LD kl min R2									
rs111727757:150125374:C:T	7	150125374			LD kl min R2									
rs67791511:22906641:A:G	8	22906641			LD kl min R2									
rs4871845:22927696:T:C	8	22927696	0.41405	29307	ref1: TG phase3 v5	rs12545733	rs12545733	Eosinophil percentage of white cells	""	2e-10	TNFRSF10C	Astle WJ	2016-11-17	27863252
rs10110028:22957419:A:G	8	22957419	0.317064	4929	ref2: TG phase1 v3	rs4077341	rs4077341	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	""	8e-06	NR	Ma Y	2015-08-05	26242244
rs6988487:22985276:G:A	8	22985276			LD kl min R2									
rs10448069:23229763:C:G	8	23229763	0.975107	1135	ref1: TG phase3 v5	rs6557662	rs6557662	Blood protein levels in cardiovascular risk	""	1e-08	intergenic	Folkersen L	2017-04-03	28369058
rs7001838:23339389:C:T	8	23339389			LD kl min R2									
rs13279189:23472044:G:A	8	23472044	0.640223	48375	ref1: TG phase3 v5	rs2942194	rs2942194	Mean corpuscular volume	""	8e-18	SLC25A37	Astle WJ	2016-11-17	27863252
rs13279189:23472044:G:A	8	23472044	0.337087	33069	ref1: TG phase3 v5	rs2928679	rs2928679	Prostate cancer	""	2e-11	NR	Schumacher FR	2018-06-11	29892016
rs75795539:82269332:G:A	8	82269332			LD kl min R2									
rs76370550:82280532:T:C	8	82280532			LD kl min R2									
rs76370550:82280532:T:C	8	82280532			LD kl min R2									
rs4876843:119464353:G:A	8	119464353			LD kl min R2									
rs76536382:119491284:A:T	8	119491284			LD kl min R2									
rs3866487:119596914:C:T	8	119596914			LD kl min R2									
rs1389542:119758261:G:A	8	119758261			LD kl min R2									
rs7821263:119760957:G:T	8	119760957			LD kl min R2									
rs5894453:119802878:T:TAGAG	8	119802878			LD kl min R2									
rs1353171:119872998:G:C	8	119872998	0.301208	134422	ref1: TG phase3 v5	rs2062377	rs2062377	Bone mineral density (spine)	""	4e-16	TNFRSF11B	Rivadeneira F	2009-10-04	19801982
rs1353171:119872998:G:C	8	119872998	0.301208	134422	ref1: TG phase3 v5	rs2062377	rs2062377	Bone mineral density	(Cortical vBMD)	1e-07	TNFRSF11B	Paternoster L	2013-02-21	23437003
rs1353171:119872998:G:C	8	119872998	0.301208	134422	ref1: TG phase3 v5	rs2062377	rs2062377	Lumbar spine bone mineral density	""	3e-39	TNFRSF11B	Estrada K	2012-04-15	22504420
rs3103991:119886091:A:G	8	119886091			LD kl min R2									
rs2465383:120079748:A:G	8	120079748	0.849686	43596	ref1: TG phase3 v5	rs6469811	rs6469811	Blood protein levels in cardiovascular risk	""	3e-13	TNFRSF11B	Folkersen L	2017-04-03	28369058
rs2465383:120079748:A:G	8	120079748	0.849686	44074	ref1: TG phase3 v5	rs7813952	rs7813952	Blood protein levels in cardiovascular risk	""	1e-21	TNFRSF11B	Folkersen L	2017-04-03	28369058
rs2450081:120084408:T:C	8	120084408	0.658037	116294	ref1: TG phase3 v5	rs2468186	rs2468186	Osteoprotegerin levels	(Female-specific)	8e-09	COLEC10, MAL2, TNFRSF11B	Kwan JS	2014-07-30	25080503
rs2450081:120084408:T:C	8	120084408	0.643889	128582	ref1: TG phase3 v5	rs1425053	rs1425053	Osteoprotegerin levels	(Sex-combined)	8e-15	COLEC10, MAL2, TNFRSF11B	Kwan JS	2014-07-30	25080503
rs2450081:120084408:T:C	8	120084408	0.341019	38936	ref1: TG phase3 v5	rs6469811	rs6469811	Blood protein levels in cardiovascular risk	""	3e-13	TNFRSF11B	Folkersen L	2017-04-03	28369058
rs2450081:120084408:T:C	8	120084408	0.341019	39414	ref1: TG phase3 v5	rs7813952	rs7813952	Blood protein levels in cardiovascular risk	""	1e-21	TNFRSF11B	Folkersen L	2017-04-03	28369058
rs11300005:120101198:CT:C	8	120101198	0.887353	22146	ref1: TG phase3 v5	rs6469811	rs6469811	Blood protein levels in cardiovascular risk	""	3e-13	TNFRSF11B	Folkersen L	2017-04-03	28369058
rs11300005:120101198:CT:C	8	120101198	0.887353	22624	ref1: TG phase3 v5	rs7813952	rs7813952	Blood protein levels in cardiovascular risk	""	1e-21	TNFRSF11B	Folkersen L	2017-04-03	28369058
rs143957798:120209022:C:T	8	120209022			LD kl min R2									
rs75134351:120228450:A:G	8	120228450			LD kl min R2									
rs2970398:120353062:G:T	8	120353062	0.350269	162286	ref1: TG phase3 v5	rs28575764	rs28575764	Heel bone mineral density	""	5e-08	""	Kichaev G	2018-12-27	30595370
rs2970398:120353062:G:T	8	120353062	0.303248	203512	ref2: TG phase1 v3	rs10102546	rs10102546	Smoking cessation	""	7e-06	NR	Argos M	2014-03-24	24665060
rs73606786:5627659:C:A	10	5627659			LD kl min R2									
rs17143154:5787230:A:G	10	5787230			LD kl min R2									
rs3136614:6005674:G:A	10	6005674			LD kl min R2									
rs7913599:6022562:C:T	10	6022562			LD kl min R2									
rs6602360:6029726:G:A	10	6029726			LD kl min R2									
rs10795738:6049417:T:C	10	6049417	0.512985	20476	ref1: TG phase3 v5	rs12722561	rs12722561	Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis	""	6e-08	IL2RA	Zhou Y	2016-01-27	26819262
rs10795738:6049417:T:C	10	6049417	0.504139	20856	ref1: TG phase3 v5	rs12722559	rs12722559	Multiple sclerosis	""	2e-15	IL2RA	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs10795738:6049417:T:C	10	6049417	0.485568	40905	ref1: TG phase3 v5	rs791590	rs791590	Soluble interleukin-2 receptor subunit alpha	(EA, conditioned on rs7911500)	7e-35	IL2RA	Durda P	2015-08-20	26293465
rs10795738:6049417:T:C	10	6049417	0.482247	31813	ref1: TG phase3 v5	rs12722515	rs12722515	Inflammatory bowel disease	(EA)	5e-12	NR	Liu JZ	2015-07-20	26192919
rs10795738:6049417:T:C	10	6049417	0.482247	31813	ref1: TG phase3 v5	rs12722515	rs12722515	Crohn's disease	(EA)	8e-13	NR	Liu JZ	2015-07-20	26192919
rs10795738:6049417:T:C	10	6049417	0.482247	31813	ref1: TG phase3 v5	rs12722515	rs12722515	Inflammatory bowel disease	""	4e-10	IL2RA, IL15RA	Jostins L	2012-11-01	23128233
rs10795738:6049417:T:C	10	6049417	0.474417	52595	ref1: TG phase3 v5	rs12722489	rs12722489	Multiple sclerosis	""	4e-08	IL2RA	Patsopoulos NA	2011-12-01	22190364
rs10795738:6049417:T:C	10	6049417	0.474417	52595	ref1: TG phase3 v5	rs12722489	rs12722489	Multiple sclerosis	""	3e-08	IL2RA	Hafler DA	2007-07-29	17660530
rs10795738:6049417:T:C	10	6049417	0.474417	52595	ref1: TG phase3 v5	rs12722489	rs12722489	Crohn's disease	""	3e-09	IL2RA	Franke A	2010-11-21	21102463
rs10795738:6049417:T:C	10	6049417	0.474417	52595	ref1: TG phase3 v5	rs12722489	rs12722489	Blood protein levels	(IL2RA)	3e-20	NR	Sun W	2016-08-17	27532455
rs12722600:6054765:C:T	10	6054765	0.316521	48997	ref2: TG phase1 v3	rs12722486	rs12722486	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)	(EA)	2e-09	IL2RA	Leger PD	2014-02-20	24554482
rs12722600:6054765:C:T	10	6054765	0.309278	69856	ref2: TG phase1 v3	rs41295115	rs41295115	Asthma and hay fever	""	5e-07	RBM17, IL2RA	Ferreira MA	2013-12-30	24388013
rs12722588:6060433:C:T	10	6060433	0.762665	9460	ref1: TG phase3 v5	rs12722561	rs12722561	Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis	""	6e-08	IL2RA	Zhou Y	2016-01-27	26819262
rs12722588:6060433:C:T	10	6060433	0.754064	9840	ref1: TG phase3 v5	rs12722559	rs12722559	Multiple sclerosis	""	2e-15	IL2RA	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs12722588:6060433:C:T	10	6060433	0.720973	29889	ref1: TG phase3 v5	rs791590	rs791590	Soluble interleukin-2 receptor subunit alpha	(EA, conditioned on rs7911500)	7e-35	IL2RA	Durda P	2015-08-20	26293465
rs12722588:6060433:C:T	10	6060433	0.715294	20797	ref1: TG phase3 v5	rs12722515	rs12722515	Inflammatory bowel disease	(EA)	5e-12	NR	Liu JZ	2015-07-20	26192919
rs12722588:6060433:C:T	10	6060433	0.715294	20797	ref1: TG phase3 v5	rs12722515	rs12722515	Crohn's disease	(EA)	8e-13	NR	Liu JZ	2015-07-20	26192919
rs12722588:6060433:C:T	10	6060433	0.715294	20797	ref1: TG phase3 v5	rs12722515	rs12722515	Inflammatory bowel disease	""	4e-10	IL2RA, IL15RA	Jostins L	2012-11-01	23128233
rs12722588:6060433:C:T	10	6060433	0.672142	41579	ref1: TG phase3 v5	rs12722489	rs12722489	Multiple sclerosis	""	4e-08	IL2RA	Patsopoulos NA	2011-12-01	22190364
rs12722588:6060433:C:T	10	6060433	0.672142	41579	ref1: TG phase3 v5	rs12722489	rs12722489	Multiple sclerosis	""	3e-08	IL2RA	Hafler DA	2007-07-29	17660530
rs12722588:6060433:C:T	10	6060433	0.672142	41579	ref1: TG phase3 v5	rs12722489	rs12722489	Crohn's disease	""	3e-09	IL2RA	Franke A	2010-11-21	21102463
rs12722588:6060433:C:T	10	6060433	0.672142	41579	ref1: TG phase3 v5	rs12722489	rs12722489	Blood protein levels	(IL2RA)	3e-20	NR	Sun W	2016-08-17	27532455
rs12722588:6060433:C:T	10	6060433	0.37172	38612	ref1: TG phase3 v5	rs2104286	rs2104286	Multiple sclerosis	""	9e-08	IL2RA	De Jager PL	2009-06-14	19525953
rs12722588:6060433:C:T	10	6060433	0.37172	38612	ref1: TG phase3 v5	rs2104286	rs2104286	Multiple sclerosis	""	7e-06	IL2RA	Bahlo M	2009-06-14	19525955
rs10752175:6061781:T:C	10	6061781			LD kl min R2									
rs12722497:6095928:C:A	10	6095928	0.626656	58202	ref1: TG phase3 v5	rs7911500	rs7911500	Inflammatory biomarkers	(hsCRP-IL6 pattern prefenofibrate)	5e-09	IL2RA	Aslibekyan S	2012-01-05	22228203
rs12722497:6095928:C:A	10	6095928	0.626656	58202	ref1: TG phase3 v5	rs7911500	rs7911500	Soluble interleukin-2 receptor subunit alpha	(EA)	1e-100	IL2RA, IL15RA, RMB17	Durda P	2015-08-20	26293465
rs12722497:6095928:C:A	10	6095928	0.510834	42765	ref1: TG phase3 v5	rs12722605	rs12722605	Inflammatory biomarkers	(MCP1-TNF-a pattern postfenofibrate)	3e-07	IL2RA	Aslibekyan S	2012-01-05	22228203
rs12722497:6095928:C:A	10	6095928	0.30765	77765	ref1: TG phase3 v5	rs7924005	rs7924005	Soluble interleukin-2 receptor subunit alpha	(EA, conditioned on on rs7911500, rs791590, rs8177757 and rs10905716)	4e-10	LOC101928080, RBM17	Durda P	2015-08-20	26293465
rs2182410:6122669:T:C	10	6122669	0.642621	5347	ref1: TG phase3 v5	rs11256593	rs11256593	Multiple sclerosis	""	3e-65	IL2RA	International Multiple Sclerosis Genetics Consortium	2019-09-01	31604244
rs2182410:6122669:T:C	10	6122669	0.428903	23624	ref1: TG phase3 v5	rs2104286	rs2104286	Multiple sclerosis	""	9e-08	IL2RA	De Jager PL	2009-06-14	19525953
rs2182410:6122669:T:C	10	6122669	0.428903	23624	ref1: TG phase3 v5	rs2104286	rs2104286	Multiple sclerosis	""	7e-06	IL2RA	Bahlo M	2009-06-14	19525955
rs2182410:6122669:T:C	10	6122669	0.316329	20657	ref1: TG phase3 v5	rs12722489	rs12722489	Multiple sclerosis	""	4e-08	IL2RA	Patsopoulos NA	2011-12-01	22190364
rs2182410:6122669:T:C	10	6122669	0.316329	20657	ref1: TG phase3 v5	rs12722489	rs12722489	Multiple sclerosis	""	3e-08	IL2RA	Hafler DA	2007-07-29	17660530
rs2182410:6122669:T:C	10	6122669	0.316329	20657	ref1: TG phase3 v5	rs12722489	rs12722489	Crohn's disease	""	3e-09	IL2RA	Franke A	2010-11-21	21102463
rs2182410:6122669:T:C	10	6122669	0.316329	20657	ref1: TG phase3 v5	rs12722489	rs12722489	Blood protein levels	(IL2RA)	3e-20	NR	Sun W	2016-08-17	27532455
rs2182410:6122669:T:C	10	6122669	0.308046	32347	ref1: TG phase3 v5	rs791590	rs791590	Soluble interleukin-2 receptor subunit alpha	(EA, conditioned on rs7911500)	7e-35	IL2RA	Durda P	2015-08-20	26293465
rs2182410:6122669:T:C	10	6122669	0.307127	41439	ref1: TG phase3 v5	rs12722515	rs12722515	Inflammatory bowel disease	(EA)	5e-12	NR	Liu JZ	2015-07-20	26192919
rs2182410:6122669:T:C	10	6122669	0.307127	41439	ref1: TG phase3 v5	rs12722515	rs12722515	Crohn's disease	(EA)	8e-13	NR	Liu JZ	2015-07-20	26192919
rs2182410:6122669:T:C	10	6122669	0.307127	41439	ref1: TG phase3 v5	rs12722515	rs12722515	Inflammatory bowel disease	""	4e-10	IL2RA, IL15RA	Jostins L	2012-11-01	23128233
rs62626327:6127668:G:C	10	6127668			LD kl min R2									
rs7902931:6141942:A:G	10	6141942	0.307136	31751	ref2: TG phase1 v3	rs7924005	rs7924005	Soluble interleukin-2 receptor subunit alpha	(EA, conditioned on on rs7911500, rs791590, rs8177757 and rs10905716)	4e-10	LOC101928080, RBM17	Durda P	2015-08-20	26293465
rs7477416:6171779:G:A	10	6171779			LD kl min R2									
rs56716256:6177463:GCTGGGA:G	10	6177463			LD kl min R2									
rs10905897:6185667:G:A	10	6185667			LD kl min R2									
rs12783932:6187621:G:T	10	6187621			LD kl min R2									
rs4747891:6188119:G:C	10	6188119			LD kl min R2									
rs12771615:6196110:G:A	10	6196110			LD kl min R2									
rs11257019:6199228:T:C	10	6199228			LD kl min R2									
rs10905924:6204266:C:G	10	6204266			LD kl min R2									
rs1341926:6294444:G:A	10	6294444			LD kl min R2									
rs9633784:6453002:C:T	10	6453002			LD kl min R2									
rs10906559:6475947:C:T	10	6475947			LD kl min R2									
rs527611:6533625:T:A	10	6533625			LD kl min R2									
rs3815975:6533877:A:G	10	6533877			LD kl min R2									
rs74668157:75336978:C:T	10	75336978			LD kl min R2									
rs11000834:75747319:G:C	10	75747319			LD kl min R2									
rs2279648:75867193:G:T	10	75867193	0.939014	85477	ref1: TG phase3 v5	rs12220238	rs12220238	Soluble interleukin-2 receptor subunit alpha	(AA)	8e-06	ADK	Durda P	2015-08-20	26293465
rs57559820:81200234:G:C	10	81200234			LD kl min R2									
rs6480942:81201306:G:A	10	81201306			LD kl min R2									
rs7909837:81228041:T:C	10	81228041			LD kl min R2									
rs142606783:81247780:G:A	10	81247780			LD kl min R2									
rs17880822:81323663:T:C	10	81323663			LD kl min R2									
rs1713334:81393809:T:C	10	81393809			LD kl min R2									
rs2475755:81651522:C:G	10	81651522	0.585967	54802	ref1: TG phase3 v5	rs721917	rs721917	Chronic obstructive pulmonary disease	""	2e-08	SFTPD	Sakornsakolpat P	2019-02-25	30804561
rs2475755:81651522:C:G	10	81651522	0.528397	43428	ref1: TG phase3 v5	rs1923539	rs1923539	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	5e-09	RP11-479O17.4	Kim DK	2012-11-09	23144326
rs11199934:81670280:A:G	10	81670280			LD kl min R2									
rs17886252:81693613:C:T	10	81693613			LD kl min R2									
rs721917:81706324:A:G	10	81706324	1	0	ref1: TG phase3 v5	rs721917	rs721917	Chronic obstructive pulmonary disease	""	2e-08	SFTPD	Sakornsakolpat P	2019-02-25	30804561
rs721917:81706324:A:G	10	81706324	0.379534	11374	ref1: TG phase3 v5	rs1923539	rs1923539	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	5e-09	RP11-479O17.4	Kim DK	2012-11-09	23144326
rs726287:81706793:A:T	10	81706793	0.992977	1360	ref1: TG phase3 v5	rs7078012	rs7078012	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	5e-09	SFTPD	Kim DK	2012-11-09	23144326
rs7074156:81707371:G:A	10	81707371	0.520109	1938	ref1: TG phase3 v5	rs7078012	rs7078012	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	5e-09	SFTPD	Kim DK	2012-11-09	23144326
rs7072378:81711067:C:G	10	81711067	0.550079	4671	ref1: TG phase3 v5	rs2146192	rs2146192	Blood protein levels	(SFTPD)	2e-37	NR	Sun W	2016-08-17	27532455
rs7072378:81711067:C:G	10	81711067	0.33333	4743	ref1: TG phase3 v5	rs721917	rs721917	Chronic obstructive pulmonary disease	""	2e-08	SFTPD	Sakornsakolpat P	2019-02-25	30804561
rs10887238:81716268:C:A	10	81716268	0.556395	19713	ref1: TG phase3 v5	rs3923564	rs3923564	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	2e-27	SFTPD	Kim DK	2012-11-09	23144326
rs10887238:81716268:C:A	10	81716268	0.556395	9295	ref1: TG phase3 v5	rs726288	rs726288	Rheumatoid arthritis	(East Asian)	9e-09	SFTPD	Okada Y	2013-12-25	24390342
rs61860410:81726640:A:G	10	81726640	0.825292	121274	ref1: TG phase3 v5	rs728616	rs728616	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	2e-12	RP11-369J21.2	Kim DK	2012-11-09	23144326
rs61860410:81726640:A:G	10	81726640	0.660897	10902	ref1: TG phase3 v5	rs2146192	rs2146192	Blood protein levels	(SFTPD)	2e-37	NR	Sun W	2016-08-17	27532455
rs61860410:81726640:A:G	10	81726640	0.568034	207108	ref1: TG phase3 v5	rs6585424	rs6585424	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	1e-10	ANXA11	Kim DK	2012-11-09	23144326
rs80327717:81728105:T:C	10	81728105			LD kl min R2									
rs11201062:81750894:C:T	10	81750894	0.433396	14913	ref1: TG phase3 v5	rs3923564	rs3923564	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	2e-27	SFTPD	Kim DK	2012-11-09	23144326
rs11201062:81750894:C:T	10	81750894	0.433396	43921	ref1: TG phase3 v5	rs726288	rs726288	Rheumatoid arthritis	(East Asian)	9e-09	SFTPD	Okada Y	2013-12-25	24390342
rs79406594:81755744:T:A	10	81755744			LD kl min R2									
rs78943967:81765322:A:T	10	81765322			LD kl min R2									
rs10788351:81765642:G:T	10	81765642			LD kl min R2									
rs10887353:81773731:C:T	10	81773731			LD kl min R2									
rs75173027:81789578:C:G	10	81789578	0.615282	1474	ref1: TG phase3 v5	rs12220777	rs12220777	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	7e-11	RP11-369J21.6, RP11-369J21.5	Kim DK	2012-11-09	23144326
rs140210911:81809355:C:T	10	81809355			LD kl min R2									
rs149072974:81815094:G:A	10	81815094	0.350919	26990	ref1: TG phase3 v5	rs12220777	rs12220777	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	7e-11	RP11-369J21.6, RP11-369J21.5	Kim DK	2012-11-09	23144326
rs2342609:81853055:T:G	10	81853055			LD kl min R2									
rs12763926:81858677:G:A	10	81858677			LD kl min R2									
rs11201719:81867682:A:G	10	81867682	0.490082	19768	ref1: TG phase3 v5	rs728616	rs728616	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	2e-12	RP11-369J21.2	Kim DK	2012-11-09	23144326
10:81869514:T:TA	10	81869514			LD kl min R2									
rs7923669:81870713:G:A	10	81870713			LD kl min R2									
rs7920526:81885236:C:T	10	81885236	0.461755	21272	ref1: TG phase3 v5	rs7905482	rs7905482	Blood protein levels	(SFTPD)	2e-16	NR	Sun W	2016-08-17	27532455
rs7920526:81885236:C:T	10	81885236	0.340682	2866	ref1: TG phase3 v5	rs3851050	rs3851050	Chronic obstructive pulmonary disease-related biomarkers	(SP-D)	1e-11	RP11-369J21.4	Kim DK	2012-11-09	23144326
rs12249449:81885500:G:T	10	81885500			LD kl min R2									
rs2573361:81890982:A:G	10	81890982	0.431307	20743	ref1: TG phase3 v5	rs1953600	rs1953600	Sarcoidosis	(Chronic)	1e-06	ANXA11	Hofmann S	2012-08-30	22936702
rs11201833:81895031:G:A	10	81895031	0.403941	16694	ref1: TG phase3 v5	rs1953600	rs1953600	Sarcoidosis	(Chronic)	1e-06	ANXA11	Hofmann S	2012-08-30	22936702
rs2789698:81895970:A:G	10	81895970	0.445942	15755	ref1: TG phase3 v5	rs1953600	rs1953600	Sarcoidosis	(Chronic)	1e-06	ANXA11	Hofmann S	2012-08-30	22936702
rs34378235:81897257:A:T	10	81897257			LD kl min R2									
rs3838346:81927935:CAACCCTGGAGGAACTGCCAACATTCTCCCTACCCAAAGGGA:C	10	81927935	0.375996	243624	ref1: TG phase3 v5	rs6585986	rs6585986	Intraocular pressure	""	1e-09	FAM213A	Khawaja AP	2018-05-21	29785010
rs116959116:81950007:G:A	10	81950007			LD kl min R2									
rs11202256:81993489:C:T	10	81993489			LD kl min R2									
rs111682778:82012432:G:A	10	82012432			LD kl min R2									
rs12773664:82012954:A:G	10	82012954			LD kl min R2									
rs2993763:82033594:G:A	10	82033594	0.620822	20460	ref1: TG phase3 v5	rs1298908	rs1298908	Diabetic kidney disease	(AA, dominant )	9e-07	MAT1A, ANXA11	Iyengar SK	2015-08-25	26305897
rs2993763:82033594:G:A	10	82033594	0.31723	137965	ref1: TG phase3 v5	rs6585986	rs6585986	Intraocular pressure	""	1e-09	FAM213A	Khawaja AP	2018-05-21	29785010
rs4934028:82038779:G:A	10	82038779	0.534369	25645	ref1: TG phase3 v5	rs1298908	rs1298908	Diabetic kidney disease	(AA, dominant )	9e-07	MAT1A, ANXA11	Iyengar SK	2015-08-25	26305897
rs143396142:82050967:T:C	10	82050967			LD kl min R2									
rs7099331:82086406:C:T	10	82086406	0.343725	131700	ref1: TG phase3 v5	rs1902661	rs1902661	Chronic obstructive pulmonary disease	(conditional on rs721917)	4e-08	TSPAN14	Sakornsakolpat P	2019-02-25	30804561
rs7099331:82086406:C:T	10	82086406	0.318123	85153	ref1: TG phase3 v5	rs6585986	rs6585986	Intraocular pressure	""	1e-09	FAM213A	Khawaja AP	2018-05-21	29785010
rs145865540:82146569:G:A	10	82146569			LD kl min R2									
rs10466236:82149717:T:C	10	82149717	0.562503	68389	ref1: TG phase3 v5	rs1902661	rs1902661	Chronic obstructive pulmonary disease	(conditional on rs721917)	4e-08	TSPAN14	Sakornsakolpat P	2019-02-25	30804561
rs10466236:82149717:T:C	10	82149717	0.468052	21842	ref1: TG phase3 v5	rs6585986	rs6585986	Intraocular pressure	""	1e-09	FAM213A	Khawaja AP	2018-05-21	29785010
rs75841224:82160038:A:G	10	82160038			LD kl min R2									
rs35117401:82171687:A:T	10	82171687			LD kl min R2									
rs17105302:82189772:A:G	10	82189772			LD kl min R2									
rs7904935:82202803:G:A	10	82202803			LD kl min R2									
rs117150063:82203932:G:A	10	82203932			LD kl min R2									
rs60366349:82217874:C:T	10	82217874			LD kl min R2									
rs72819575:82223939:C:T	10	82223939			LD kl min R2									
rs55897874:82226375:A:C	10	82226375			LD kl min R2									
rs140920426:82231085:GT:G	10	82231085			LD kl min R2									
rs9665678:82233542:C:G	10	82233542			LD kl min R2									
rs74837002:82237921:T:C	10	82237921			LD kl min R2									
rs188572:90574813:G:A	10	90574813			LD kl min R2									
rs17096285:90676246:T:C	10	90676246			LD kl min R2									
rs12761227:90748594:C:T	10	90748594			LD kl min R2									
rs2031612:90766980:T:C	10	90766980	0.452089	16955	ref1: TG phase3 v5	rs7089946	rs7089946	Blood protein levels	(Tumor necrosis factor receptor superfamily member 6, FAS.5392.73.2)	2e-16	NR	Sun BB	2018-06-06	29875488
rs2031612:90766980:T:C	10	90766980	0.452089	16955	ref1: TG phase3 v5	rs7089946	rs7089946	Blood protein levels	(Tumor necrosis factor receptor superfamily member 6, FAS.9459.7.3)	6e-17	NR	Sun BB	2018-06-06	29875488
rs2031612:90766980:T:C	10	90766980	0.451937	7256	ref1: TG phase3 v5	rs4406737	rs4406737	Chronic lymphocytic leukemia	""	9e-14	ACTA2, FAS	Berndt SI	2016-03-09	26956414
rs2031612:90766980:T:C	10	90766980	0.451937	7256	ref1: TG phase3 v5	rs4406737	rs4406737	Chronic lymphocytic leukemia	""	1e-14	ACTA2, FAS	Berndt SI	2013-06-16	23770605
rs7910435:90768240:T:C	10	90768240	0.450803	15695	ref1: TG phase3 v5	rs7089946	rs7089946	Blood protein levels	(Tumor necrosis factor receptor superfamily member 6, FAS.5392.73.2)	2e-16	NR	Sun BB	2018-06-06	29875488
rs7910435:90768240:T:C	10	90768240	0.450803	15695	ref1: TG phase3 v5	rs7089946	rs7089946	Blood protein levels	(Tumor necrosis factor receptor superfamily member 6, FAS.9459.7.3)	6e-17	NR	Sun BB	2018-06-06	29875488
rs7910435:90768240:T:C	10	90768240	0.439981	8516	ref1: TG phase3 v5	rs4406737	rs4406737	Chronic lymphocytic leukemia	""	9e-14	ACTA2, FAS	Berndt SI	2016-03-09	26956414
rs7910435:90768240:T:C	10	90768240	0.439981	8516	ref1: TG phase3 v5	rs4406737	rs4406737	Chronic lymphocytic leukemia	""	1e-14	ACTA2, FAS	Berndt SI	2013-06-16	23770605
rs11202932:90787881:A:C	10	90787881	0.373847	38898	ref1: TG phase3 v5	rs1937332	rs1937332	Atrioventricular conduction	""	7e-07	CH25H, FAS	Denny JC	2010-11-01	21041692
rs11202932:90787881:A:C	10	90787881	0.359255	30496	ref1: TG phase3 v5	rs7920888	rs7920888	Obesity-related traits	(Weight z-score )	7e-06	FAS	Comuzzie AG	2012-12-04	23251661
rs11202932:90787881:A:C	10	90787881	0.359255	30496	ref1: TG phase3 v5	rs7920888	rs7920888	Obesity-related traits	(BMI z-score )	5e-06	FAS	Comuzzie AG	2012-12-04	23251661
rs11202932:90787881:A:C	10	90787881	0.359255	30496	ref1: TG phase3 v5	rs7920888	rs7920888	Obesity-related traits	(WC )	9e-06	FAS	Comuzzie AG	2012-12-04	23251661
rs11202932:90787881:A:C	10	90787881	0.359255	30496	ref1: TG phase3 v5	rs7920888	rs7920888	Obesity-related traits	(Hip circumference )	7e-06	FAS	Comuzzie AG	2012-12-04	23251661
rs12792005:1630177:G:A	11	1630177			LD kl min R2									
rs1021344:1650079:C:T	11	1650079			LD kl min R2									
rs117997371:1724442:C:T	11	1724442			LD kl min R2									
rs78353932:1744139:G:A	11	1744139			LD kl min R2									
rs72850947:1746010:G:A	11	1746010			LD kl min R2									
rs17834326:1751986:G:A	11	1751986			LD kl min R2									
rs4752755:1756848:C:T	11	1756848	0.418989	13376	ref1: TG phase3 v5	rs111693235	rs111693235	Blood protein levels in cardiovascular risk	""	1e-41	CTSD	Folkersen L	2017-04-03	28369058
rs201488097:1769831:CCACCGCGGGCTG:C	11	1769831			LD kl min R2									
rs78735768:1775385:C:T	11	1775385			LD kl min R2									
rs2334407:1826391:G:C	11	1826391			LD kl min R2									
rs72851023:2130620:C:T	11	2130620			LD kl min R2									
rs11022863:13539344:C:T	11	13539344			LD kl min R2									
rs75691776:13573682:C:T	11	13573682			LD kl min R2									
rs146848365:13623698:CCT:C	11	13623698	0.347175	3526	ref1: TG phase3 v5	rs9630182	rs9630182	Bone mineral density	""	4e-07	PTH	Guo Y	2009-10-29	19874204
rs10832087:13629018:A:G	11	13629018	0.634502	8846	ref1: TG phase3 v5	rs9630182	rs9630182	Bone mineral density	""	4e-07	PTH	Guo Y	2009-10-29	19874204
rs182021960:13683448:C:T	11	13683448			LD kl min R2									
rs78325759:13756664:TAGG:T	11	13756664			LD kl min R2									
rs12416997:13925137:G:A	11	13925137			LD kl min R2									
rs16913462:13952585:A:G	11	13952585			LD kl min R2									
rs72871487:13970894:G:T	11	13970894			LD kl min R2									
rs56406826:13975016:G:A	11	13975016	0.474392	21139	ref1: TG phase3 v5	rs1819084	rs1819084	Tuberculosis	""	9e-06	SPON1	Chimusa ER	2013-09-18	24057671
rs7116230:14035580:G:A	11	14035580	0.815843	13941	ref1: TG phase3 v5	rs2618516	rs2618516	Brain connectivity	(connectivity pattern)	6e-10	SPON1	Jahanshad N	2013-03-05	23471985
rs7116230:14035580:G:A	11	14035580	0.606641	3041	ref1: TG phase3 v5	rs1969539	rs1969539	Blood protein levels in cardiovascular risk	""	8e-34	SPON1	Folkersen L	2017-04-03	28369058
rs7116230:14035580:G:A	11	14035580	0.488932	5726	ref1: TG phase3 v5	rs1919309	rs1919309	Apolipoprotein A1 levels	""	3e-09	RRAS2	Richardson TG	2020-03-23	32203549
rs10832164:14048480:C:T	11	14048480	1	9859	ref1: TG phase3 v5	rs1969539	rs1969539	Blood protein levels in cardiovascular risk	""	8e-34	SPON1	Folkersen L	2017-04-03	28369058
rs10832164:14048480:C:T	11	14048480	0.808891	18626	ref1: TG phase3 v5	rs1919309	rs1919309	Apolipoprotein A1 levels	""	3e-09	RRAS2	Richardson TG	2020-03-23	32203549
rs10832164:14048480:C:T	11	14048480	0.468669	26841	ref1: TG phase3 v5	rs2618516	rs2618516	Brain connectivity	(connectivity pattern)	6e-10	SPON1	Jahanshad N	2013-03-05	23471985
rs200445583:14151007:TC:T	11	14151007			LD kl min R2									
rs6416164:14158703:T:C	11	14158703			LD kl min R2									
rs11023122:14191282:A:C	11	14191282			LD kl min R2									
rs7112362:14231260:A:G	11	14231260			LD kl min R2									
rs147131410:14260935:T:C	11	14260935			LD kl min R2									
rs12807052:14267467:G:A	11	14267467			LD kl min R2									
rs11023175:14302533:C:T	11	14302533			LD kl min R2									
rs377362208:14652634:G:C	11	14652634			LD kl min R2									
rs117494483:14787110:G:C	11	14787110			LD kl min R2									
rs117189349:102231873:G:A	11	102231873			LD kl min R2									
rs76638843:102259607:A:G	11	102259607			LD kl min R2									
rs74666402:102264678:C:G	11	102264678			LD kl min R2									
rs117462234:102295352:G:A	11	102295352	0.537488	14601	ref1: TG phase3 v5	rs11225247	rs11225247	Vein graft stenosis in coronary artery bypass grafting	""	8e-06	TMEM123	Shah AA	2015-02-27	25881214
rs138361977:102328345:C:T	11	102328345			LD kl min R2									
rs72982103:102372269:T:A	11	102372269			LD kl min R2									
rs17882041:102390343:G:A	11	102390343	1	0	ref1: TG phase3 v5	rs17882041	rs17882041	Narcolepsy with cataplexy	""	1e-06	NR	Ouyang H	2020-05-01	32358372
rs17878383:102399596:C:G	11	102399596			LD kl min R2									
rs11225328:102441916:A:G	11	102441916			LD kl min R2									
rs6590973:102447053:A:G	11	102447053			LD kl min R2									
rs139008575:102449041:AC:A	11	102449041			LD kl min R2									
rs2509014:102454640:C:T	11	102454640			LD kl min R2									
rs7950388:102467147:G:C	11	102467147			LD kl min R2									
rs2701985:102516208:A:C	11	102516208	0.541908	1347	ref1: TG phase3 v5	rs4433535	rs4433535	Blood protein levels	(MMP3)	7e-07	NR	Sun W	2016-08-17	27532455
rs139968397:102561791:A:C	11	102561791			LD kl min R2									
rs4121366:102570760:T:G	11	102570760	0.69959	55899	ref1: TG phase3 v5	rs4433535	rs4433535	Blood protein levels	(MMP3)	7e-07	NR	Sun W	2016-08-17	27532455
rs1939015:102576375:G:A	11	102576375			LD kl min R2									
rs12794384:102588985:T:C	11	102588985			LD kl min R2									
rs34341556:102590852:A:G	11	102590852			LD kl min R2									
rs3758861:102598600:G:A	11	102598600			LD kl min R2									
rs12272341:102644601:G:A	11	102644601			LD kl min R2									
rs486055:102650424:C:T	11	102650424	1	0	ref1: TG phase3 v5	rs486055	rs486055	Matrix metalloproteinase-10 levels	""	2e-11	NR	Hillary RF	2020-07-08	32641083
rs17860938:102652744:T:C	11	102652744			LD kl min R2									
rs145242717:102655808:C:T	11	102655808	0.389091	74225	ref1: TG phase3 v5	rs72983521	rs72983521	Post bronchodilator FEV1/FVC ratio	""	6e-08	Intergenic	Lutz SM	2015-12-03	26634245
rs145242717:102655808:C:T	11	102655808	0.383005	96792	ref1: TG phase3 v5	rs17368890	rs17368890	Post bronchodilator FEV1/FVC ratio	""	9e-09	Intergenic	Lutz SM	2015-12-03	26634245
rs145242717:102655808:C:T	11	102655808	0.371241	99060	ref1: TG phase3 v5	rs61493282	rs61493282	Post bronchodilator FEV1/FVC ratio	""	8e-08	Intergenic	Lutz SM	2015-12-03	26634245
rs145242717:102655808:C:T	11	102655808	0.349224	144470	ref1: TG phase3 v5	rs72985562	rs72985562	Post bronchodilator FEV1/FVC ratio	""	1e-06	Intergenic	Lutz SM	2015-12-03	26634245
rs521898:102657908:C:A	11	102657908			LD kl min R2									
rs17878905:102661757:G:A	11	102661757			LD kl min R2									
rs11225426:102664591:C:T	11	102664591			LD kl min R2									
rs514921:102669230:A:G	11	102669230			LD kl min R2									
rs498186:102669645:A:C	11	102669645			LD kl min R2									
rs504875:102678441:G:A	11	102678441	0.410328	6954	ref1: TG phase3 v5	rs470292	rs470292	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.410328	6939	ref1: TG phase3 v5	rs470928	rs470928	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.410328	23705	ref1: TG phase3 v5	rs525119	rs525119	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.410328	22935	ref1: TG phase3 v5	rs553542	rs553542	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.410328	28925	ref1: TG phase3 v5	rs563096	rs563096	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.410328	16027	ref1: TG phase3 v5	rs611705	rs611705	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.410328	24837	ref1: TG phase3 v5	rs646760	rs646760	Post bronchodilator FEV1/FVC ratio	""	2e-07	LOC100288077	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.40088	33140	ref1: TG phase3 v5	rs680753	rs680753	Post bronchodilator FEV1/FVC ratio	""	2e-07	MMP3	Lutz SM	2015-12-03	26634245
rs504875:102678441:G:A	11	102678441	0.395774	39200	ref1: TG phase3 v5	rs116187470	rs116187470	Post bronchodilator FEV1/FVC ratio	""	2e-08	Intergenic	Lutz SM	2015-12-03	26634245
rs17360292:102683288:C:T	11	102683288			LD kl min R2									
rs111501139:102689389:C:T	11	102689389			LD kl min R2									
rs147606771:102689960:G:A	11	102689960			LD kl min R2									
rs116896243:102690381:T:C	11	102690381			LD kl min R2									
rs113006933:102690600:GC:G	11	102690600	0.971707	882	ref1: TG phase3 v5	rs11225434	rs11225434	Matrix metalloproteinase levels	""	9e-29	MMP-1	Cheng YC	2009-08-01	20031604
rs113006933:102690600:GC:G	11	102690600	0.944361	8860	ref1: TG phase3 v5	rs7946057	rs7946057	Blood protein levels in cardiovascular risk	""	5e-160	MMP3	Folkersen L	2017-04-03	28369058
rs113006933:102690600:GC:G	11	102690600	0.932431	25721	ref1: TG phase3 v5	rs645419	rs645419	Blood protein levels	(MMP3)	1e-46	NR	Sun W	2016-08-17	27532455
rs113006933:102690600:GC:G	11	102690600	0.571532	18903	ref1: TG phase3 v5	rs534191	rs534191	Matrix metalloproteinase levels	""	6e-16	NR	Hillary RF	2020-07-08	32641083
rs113006933:102690600:GC:G	11	102690600	0.521559	7131	ref1: TG phase3 v5	rs471994	rs471994	Blood protein levels in cardiovascular risk	""	2e-82	MMP1	Folkersen L	2017-04-03	28369058
rs113006933:102690600:GC:G	11	102690600	0.367027	4508	ref1: TG phase3 v5	rs495366	rs495366	Matrix metalloproteinase levels	""	6e-34	MMP	Cheng YC	2009-08-01	20031604
rs72979581:102691534:C:A	11	102691534			LD kl min R2									
rs142225998:102695271:A:C	11	102695271			LD kl min R2									
rs111961940:102710318:G:A	11	102710318			LD kl min R2									
rs3025066:102710483:T:C	11	102710483			LD kl min R2									
rs591058:102711338:T:C	11	102711338	0.995983	4983	ref1: TG phase3 v5	rs645419	rs645419	Blood protein levels	(MMP3)	1e-46	NR	Sun W	2016-08-17	27532455
rs591058:102711338:T:C	11	102711338	0.992018	11878	ref1: TG phase3 v5	rs7946057	rs7946057	Blood protein levels in cardiovascular risk	""	5e-160	MMP3	Folkersen L	2017-04-03	28369058
rs591058:102711338:T:C	11	102711338	0.964573	19856	ref1: TG phase3 v5	rs11225434	rs11225434	Matrix metalloproteinase levels	""	9e-29	MMP-1	Cheng YC	2009-08-01	20031604
rs591058:102711338:T:C	11	102711338	0.558134	13607	ref1: TG phase3 v5	rs471994	rs471994	Blood protein levels in cardiovascular risk	""	2e-82	MMP1	Folkersen L	2017-04-03	28369058
rs591058:102711338:T:C	11	102711338	0.556776	39641	ref1: TG phase3 v5	rs534191	rs534191	Matrix metalloproteinase levels	""	6e-16	NR	Hillary RF	2020-07-08	32641083
rs591058:102711338:T:C	11	102711338	0.356516	16230	ref1: TG phase3 v5	rs495366	rs495366	Matrix metalloproteinase levels	""	6e-34	MMP	Cheng YC	2009-08-01	20031604
rs147857116:102724216:T:G	11	102724216			LD kl min R2									
rs144494196:102727510:CAA:C	11	102727510			LD kl min R2									
rs78406549:102732526:T:G	11	102732526			LD kl min R2									
rs28381675:102740976:T:C	11	102740976	0.3571	7813	ref1: TG phase3 v5	rs12808148	rs12808148	Alzheimer's disease	""	1e-06	MMP3, MMP12	Kamboh MI	2012-05-15	22832961
rs12786343:102743156:C:T	11	102743156			LD kl min R2									
rs144897250:102750264:C:A	11	102750264			LD kl min R2									
rs11225455:102763081:G:A	11	102763081			LD kl min R2									
11:102767811:G:A	11	102767811			LD kl min R2									
rs12798926:102769817:C:A	11	102769817	0.652888	36654	ref1: TG phase3 v5	rs12808148	rs12808148	Alzheimer's disease	""	1e-06	MMP3, MMP12	Kamboh MI	2012-05-15	22832961
rs182844815:102776502:A:G	11	102776502			LD kl min R2									
rs146660141:102792179:G:T	11	102792179			LD kl min R2									
rs6590997:102793854:T:C	11	102793854			LD kl min R2									
rs12792356:102799120:C:T	11	102799120			LD kl min R2									
rs660161:102807159:T:A	11	102807159	0.395675	22296	ref1: TG phase3 v5	rs671188	rs671188	Blood protein levels	(MMP3)	3e-09	NR	Sun W	2016-08-17	27532455
rs1042840:102814110:T:C	11	102814110	0.439463	15345	ref1: TG phase3 v5	rs671188	rs671188	Blood protein levels	(MMP3)	3e-09	NR	Sun W	2016-08-17	27532455
rs1042840:102814110:T:C	11	102814110	0.358104	20930	ref1: TG phase3 v5	rs72987535	rs72987535	Post bronchodilator FEV1/FVC ratio	""	3e-06	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.342405	36807	ref1: TG phase3 v5	rs150986675	rs150986675	Post bronchodilator FEV1/FVC ratio	""	6e-08	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	94576	ref2: TG phase1 v3	rs114176245	rs114176245	Post bronchodilator FEV1/FVC ratio	""	7e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	71349	ref2: TG phase1 v3	rs17368659	rs17368659	Post bronchodilator FEV1/FVC ratio	""	6e-10	MMP12	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	71349	ref2: TG phase1 v3	rs17368659	rs17368659	Local histogram emphysema pattern	(normal)	1e-08	MMP12	Castaldi PJ	2014-07-09	25006744
rs1042840:102814110:T:C	11	102814110	0.324957	71349	ref2: TG phase1 v3	rs17368659	rs17368659	Local histogram emphysema pattern	(normal, EA)	2e-07	MMP12	Castaldi PJ	2014-07-09	25006744
rs1042840:102814110:T:C	11	102814110	0.324957	71349	ref2: TG phase1 v3	rs17368659	rs17368659	Blood protein levels in cardiovascular risk	""	3e-171	MMP12	Folkersen L	2017-04-03	28369058
rs1042840:102814110:T:C	11	102814110	0.324957	65415	ref2: TG phase1 v3	rs17368814	rs17368814	Post bronchodilator FEV1/FVC ratio	""	2e-09	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	76918	ref2: TG phase1 v3	rs28381684	rs28381684	Post bronchodilator FEV1/FVC ratio	""	5e-10	MMP12	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	76918	ref2: TG phase1 v3	rs28381684	rs28381684	Blood protein levels	(Macrophage metalloelastase, MMP12.4496.60.2)	5e-111	MMP12	Sun BB	2018-06-06	29875488
rs1042840:102814110:T:C	11	102814110	0.324957	92859	ref2: TG phase1 v3	rs72981675	rs72981675	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	92251	ref2: TG phase1 v3	rs72981680	rs72981680	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	89899	ref2: TG phase1 v3	rs72981684	rs72981684	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	87570	ref2: TG phase1 v3	rs72981698	rs72981698	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	86701	ref2: TG phase1 v3	rs72983508	rs72983508	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.324957	87968	ref2: TG phase1 v3	rs737693	rs737693	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.322085	22370	ref1: TG phase3 v5	rs72987546	rs72987546	Post bronchodilator FEV1/FVC ratio	""	2e-06	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.31371	76035	ref2: TG phase1 v3	rs17368582	rs17368582	Post bronchodilator FEV1/FVC ratio	""	8e-10	MMP12	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.31371	76035	ref2: TG phase1 v3	rs17368582	rs17368582	Local histogram emphysema pattern	(Moderate Centrilobular)	3e-09	MMP12	Castaldi PJ	2014-07-09	25006744
rs1042840:102814110:T:C	11	102814110	0.31371	76035	ref2: TG phase1 v3	rs17368582	rs17368582	Local histogram emphysema pattern	(Moderate Centrilobular, EA)	7e-09	MMP12	Castaldi PJ	2014-07-09	25006744
rs1042840:102814110:T:C	11	102814110	0.31371	68319	ref2: TG phase1 v3	rs2276109	rs2276109	Post bronchodilator FEV1/FVC ratio	""	7e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.307109	91496	ref2: TG phase1 v3	rs72981683	rs72981683	Post bronchodilator FEV1/FVC ratio	""	6e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.307109	85125	ref2: TG phase1 v3	rs72983513	rs72983513	Post bronchodilator FEV1/FVC ratio	""	5e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs1042840:102814110:T:C	11	102814110	0.30639	93766	ref2: TG phase1 v3	rs17361668	rs17361668	Post bronchodilator FEV1/FVC ratio	""	4e-10	Intergenic	Lutz SM	2015-12-03	26634245
rs17860575:102817262:C:T	11	102817262			LD kl min R2									
rs10895372:102819574:T:C	11	102819574			LD kl min R2									
rs17099788:102822169:A:G	11	102822169			LD kl min R2									
rs66805544:102833916:ATAAAGT:A	11	102833916			LD kl min R2									
rs72987546:102836480:T:C	11	102836480	1	0	ref1: TG phase3 v5	rs72987546	rs72987546	Post bronchodilator FEV1/FVC ratio	""	2e-06	Intergenic	Lutz SM	2015-12-03	26634245
rs72987546:102836480:T:C	11	102836480	0.833956	1440	ref1: TG phase3 v5	rs72987535	rs72987535	Post bronchodilator FEV1/FVC ratio	""	3e-06	Intergenic	Lutz SM	2015-12-03	26634245
rs72987546:102836480:T:C	11	102836480	0.317564	59177	ref2: TG phase1 v3	rs150986675	rs150986675	Post bronchodilator FEV1/FVC ratio	""	6e-08	Intergenic	Lutz SM	2015-12-03	26634245
rs11225514:102877513:A:G	11	102877513	0.325341	9716	ref1: TG phase3 v5	rs74380195	rs74380195	Diisocyanate-induced asthma	""	1e-09	MMP13, DCUN1D5	Yucesoy B	2015-04-26	25918132
rs2509113:102888594:A:G	11	102888594			LD kl min R2									
rs137916984:102919290:A:T	11	102919290			LD kl min R2									
rs12577612:102996987:A:G	11	102996987			LD kl min R2									
rs201028912:103009520:C:T	11	103009520			LD kl min R2									
rs148490414:103011562:C:T	11	103011562			LD kl min R2									
rs150786504:103018629:T:C	11	103018629			LD kl min R2									
rs641823:103066027:G:A	11	103066027	0.461597	15999	ref1: TG phase3 v5	rs632672	rs632672	Intraocular pressure	""	3e-08	NR	Han X	2020-04-30	32352494
rs641823:103066027:G:A	11	103066027	0.442851	49834	ref1: TG phase3 v5	rs11225569	rs11225569	Diisocyanate-induced asthma	""	2e-06	DYNC2H1, DCUN1D5, PDGFD	Yucesoy B	2015-04-26	25918132
rs188664797:103093428:G:T	11	103093428			LD kl min R2									
rs17396421:103180445:C:T	11	103180445			LD kl min R2									
rs313405:103192402:T:G	11	103192402	0.481652	17582	ref1: TG phase3 v5	rs313426	rs313426	Toenail selenium levels	""	2e-06	DYNC2H1, DCUN1D5, PDGFD	Cornelis MC	2014-10-24	25343990
rs138328932:103201031:TTA:T	11	103201031			LD kl min R2									
rs61100530:103214228:G:A	11	103214228	0.435974	188458	ref1: TG phase3 v5	rs17101053	rs17101053	Metabolite levels	(CE 16:0)	8e-06	PDGFD	Rhee EP	2013-07-02	23823483
rs11064074:6281039:C:T	12	6281039	0.783261	13696	ref1: TG phase3 v5	rs34667100	rs34667100	Platelet count	""	2e-36	intergenic	Astle WJ	2016-11-17	27863252
rs11064074:6281039:C:T	12	6281039	0.579865	10054	ref1: TG phase3 v5	rs7342306	rs7342306	Platelet count	""	2e-07	VWF, CD9	Schick UM	2016-01-21	26805783
rs11064074:6281039:C:T	12	6281039	0.579865	10054	ref1: TG phase3 v5	rs7342306	rs7342306	Platelet count	""	4e-11	CD9, VWF	Gieger C	2011-11-30	22139419
rs11064074:6281039:C:T	12	6281039	0.56672	8180	ref1: TG phase3 v5	rs1558324	rs1558324	Mean platelet volume	""	2e-21	CD9, VWF	Gieger C	2011-11-30	22139419
rs11832287:6291307:A:G	12	6291307	0.960272	3428	ref1: TG phase3 v5	rs34667100	rs34667100	Platelet count	""	2e-36	intergenic	Astle WJ	2016-11-17	27863252
rs11832287:6291307:A:G	12	6291307	0.701149	214	ref1: TG phase3 v5	rs7342306	rs7342306	Platelet count	""	2e-07	VWF, CD9	Schick UM	2016-01-21	26805783
rs11832287:6291307:A:G	12	6291307	0.701149	214	ref1: TG phase3 v5	rs7342306	rs7342306	Platelet count	""	4e-11	CD9, VWF	Gieger C	2011-11-30	22139419
rs11832287:6291307:A:G	12	6291307	0.654836	2088	ref1: TG phase3 v5	rs1558324	rs1558324	Mean platelet volume	""	2e-21	CD9, VWF	Gieger C	2011-11-30	22139419
rs36205633:6453212:G:A	12	6453212			LD kl min R2									
rs2364480:6495275:C:A	12	6495275			LD kl min R2									
rs10849449:6498662:A:G	12	6498662	0.310133	4080	ref1: TG phase3 v5	rs11616188	rs11616188	Ankylosing spondylitis	""	4e-12	LTBR-TNFRSF1A	Evans DM	2011-07-10	21743469
rs138944463:6551165:C:T	12	6551165			LD kl min R2									
rs61753197:6604331:G:T	12	6604331			LD kl min R2									
rs7302581:6842902:G:C	12	6842902			LD kl min R2									
rs11054527:7725583:A:G	12	7725583			LD kl min R2									
rs12369506:8008179:C:T	12	8008179			LD kl min R2									
rs10878340:40695095:G:A	12	40695095			LD kl min R2									
rs3958417:40828435:T:C	12	40828435			LD kl min R2									
rs11564228:40837331:G:A	12	40837331			LD kl min R2									
rs66971097:40838704:CAT:C	12	40838704			LD kl min R2									
rs201439981:41030159:TA:T	12	41030159			LD kl min R2									
rs10878949:41036856:A:C	12	41036856			LD kl min R2									
rs74078529:41054980:C:G	12	41054980			LD kl min R2									
rs56260639:41122583:G:A	12	41122583			LD kl min R2									
rs1992605:41131647:G:T	12	41131647			LD kl min R2									
rs10879122:41139235:C:T	12	41139235			LD kl min R2									
rs7297165:41164522:C:T	12	41164522			LD kl min R2									
rs3904168:41176322:C:T	12	41176322			LD kl min R2									
rs1596519:41198114:T:A	12	41198114			LD kl min R2									
rs12821990:41301834:T:G	12	41301834			LD kl min R2									
rs148113566:41406840:G:A	12	41406840			LD kl min R2									
rs11179509:41412531:T:C	12	41412531			LD kl min R2									
rs7301688:41519500:C:T	12	41519500			LD kl min R2									
rs10879789:41557906:A:C	12	41557906			LD kl min R2									
rs80247949:41559450:G:A	12	41559450			LD kl min R2									
rs142781285:41723982:GACAAAGT:G	12	41723982			LD kl min R2									
rs10880051:41740196:G:A	12	41740196	0.313366	181469	ref1: TG phase3 v5	rs285575	rs285575	Body mass index	(EA)	6e-07	PDZRN4	Locke AE	2015-02-12	25673413
rs10880051:41740196:G:A	12	41740196	0.313366	181469	ref1: TG phase3 v5	rs285575	rs285575	Body mass index	""	7e-07	PDZRN4	Locke AE	2015-02-12	25673413
rs10880051:41740196:G:A	12	41740196	0.313366	181469	ref1: TG phase3 v5	rs285575	rs285575	Body mass index	(EA, men)	7e-06	PDZRN4	Locke AE	2015-02-12	25673413
rs12874628:108872153:G:A	13	108872153			LD kl min R2									
rs111727450:108915394:C:T	13	108915394			LD kl min R2									
rs16972217:108935447:C:T	13	108935447			LD kl min R2									
rs7995847:108936262:T:C	13	108936262			LD kl min R2									
rs374039502:108960385:T:A	13	108960385	1	0	ref1: TG phase3 v5	rs374039502	rs374039502	Apolipoprotein A1 levels	""	1e-09	TNFSF13B	Richardson TG	2020-03-23	32203549
rs8011374:55124327:T:C	14	55124327			LD kl min R2									
rs911621:55125716:T:C	14	55125716			LD kl min R2									
rs11623013:55151580:G:A	14	55151580			LD kl min R2									
rs17729919:55166774:G:A	14	55166774			LD kl min R2									
rs1957364:55182407:G:A	14	55182407			LD kl min R2									
rs17127871:55212029:G:A	14	55212029			LD kl min R2									
rs7150566:55230513:G:A	14	55230513			LD kl min R2									
rs1885397:55233098:A:C	14	55233098			LD kl min R2									
rs4898851:55233594:C:T	14	55233594			LD kl min R2									
rs7155922:55238309:G:A	14	55238309			LD kl min R2									
rs34752928:55243698:A:ATCAG	14	55243698			LD kl min R2									
rs17738594:55269778:G:A	14	55269778			LD kl min R2									
rs11158024:55276391:T:C	14	55276391			LD kl min R2									
rs111743415:55284854:T:A	14	55284854			LD kl min R2									
rs72713460:55297043:G:T	14	55297043	0.494092	51826	ref1: TG phase3 v5	rs11158026	rs11158026	Parkinson's disease	""	6e-11	GCH1	Nalls MA	2014-07-27	25064009
rs1952437:55323450:C:T	14	55323450			LD kl min R2									
rs150825385:55330064:C:T	14	55330064	0.389439	18805	ref1: TG phase3 v5	rs11158026	rs11158026	Parkinson's disease	""	6e-11	GCH1	Nalls MA	2014-07-27	25064009
rs118105307:55398674:C:T	14	55398674			LD kl min R2									
rs1187886:55449775:G:C	14	55449775			LD kl min R2									
rs117316271:55486603:G:A	14	55486603			LD kl min R2									
rs17128136:55510110:G:A	14	55510110			LD kl min R2									
rs117957450:55520865:G:C	14	55520865			LD kl min R2									
rs140427123:55526381:A:G	14	55526381			LD kl min R2									
rs79940222:55542852:G:A	14	55542852			LD kl min R2									
rs117786119:55544723:C:T	14	55544723			LD kl min R2									
rs61975407:55568276:C:T	14	55568276	0.587353	46360	ref1: TG phase3 v5	rs2274273	rs2274273	Protein biomarker	(Galectin-3)	2e-188	LGALS3, DLGAP5	de Boer RA	2012-10-09	23056639
rs2340930:55586286:C:T	14	55586286	0.671901	215401	ref1: TG phase3 v5	rs9323280	rs9323280	Blood protein levels in cardiovascular risk	""	7e-94	LGALS3	Folkersen L	2017-04-03	28369058
rs142112604:55586819:GC:G	14	55586819	0.834554	214868	ref1: TG phase3 v5	rs9323280	rs9323280	Blood protein levels in cardiovascular risk	""	7e-94	LGALS3	Folkersen L	2017-04-03	28369058
rs61508494:55587297:T:C	14	55587297	0.939169	27339	ref1: TG phase3 v5	rs2274273	rs2274273	Protein biomarker	(Galectin-3)	2e-188	LGALS3, DLGAP5	de Boer RA	2012-10-09	23056639
rs10140881:55633527:T:C	14	55633527	0.923209	168160	ref1: TG phase3 v5	rs9323280	rs9323280	Blood protein levels in cardiovascular risk	""	7e-94	LGALS3	Folkersen L	2017-04-03	28369058
rs75811768:55659031:C:T	14	55659031			LD kl min R2									
rs116848050:55751814:G:A	14	55751814			LD kl min R2									
rs144221070:55792539:A:C	14	55792539			LD kl min R2									
rs144265380:55859786:C:T	14	55859786			LD kl min R2									
rs61975446:55871532:G:A	14	55871532			LD kl min R2									
rs11627272:55890387:A:G	14	55890387			LD kl min R2									
rs6573026:55892017:C:T	14	55892017			LD kl min R2									
rs56409894:55920284:G:A	14	55920284			LD kl min R2									
rs1890255:55920781:T:C	14	55920781			LD kl min R2									
rs75527499:55921067:C:T	14	55921067			LD kl min R2									
rs12431984:55940818:C:T	14	55940818	0.62581	625	ref1: TG phase3 v5	rs7144510	rs7144510	Brain region volumes	(right putamen)	1e-08	NR	Zhao B	2019-11-01	31676860
rs12432729:55941431:A:G	14	55941431	0.620202	1238	ref1: TG phase3 v5	rs7144510	rs7144510	Brain region volumes	(right putamen)	1e-08	NR	Zhao B	2019-11-01	31676860
rs7492880:55947784:T:C	14	55947784	0.683252	17940	ref1: TG phase3 v5	rs7146055	rs7146055	Brain region volumes	(right putamen)	2e-10	NR	Zhao B	2019-11-01	31676860
rs7492880:55947784:T:C	14	55947784	0.509191	26223	ref1: TG phase3 v5	rs11851435	rs11851435	Brain region volumes	(right putamen)	9e-09	NR	Zhao B	2019-11-01	31676860
rs7492880:55947784:T:C	14	55947784	0.359213	188778	ref1: TG phase3 v5	rs3783654	rs3783654	Brain region volumes	(right putamen)	2e-14	NR	Zhao B	2019-11-01	31676860
rs10139709:55955515:C:G	14	55955515	0.521642	10209	ref1: TG phase3 v5	rs7146055	rs7146055	Brain region volumes	(right putamen)	2e-10	NR	Zhao B	2019-11-01	31676860
rs10139709:55955515:C:G	14	55955515	0.307171	181047	ref2: TG phase1 v3	rs3783654	rs3783654	Brain region volumes	(right putamen)	2e-14	NR	Zhao B	2019-11-01	31676860
rs113607710:55961660:T:C	14	55961660			LD kl min R2									
rs77139386:55968436:T:G	14	55968436			LD kl min R2									
rs10130266:55980471:C:G	14	55980471			LD kl min R2									
rs45565035:56043123:C:A	14	56043123			LD kl min R2									
rs72719457:56049483:C:T	14	56049483			LD kl min R2									
rs75317742:56069499:A:G	14	56069499			LD kl min R2									
rs61976631:56098619:C:A	14	56098619	0.322051	82899	ref1: TG phase3 v5	rs10130783	rs10130783	Brain region volumes	(right putamen)	2e-10	NR	Zhao B	2019-11-01	31676860
rs17653848:101102059:A:T	14	101102059			LD kl min R2									
rs1467537:101121274:T:C	14	101121274			LD kl min R2									
rs12881545:101176212:G:C	14	101176212	0.958638	6258	ref1: TG phase3 v5	rs7141210	rs7141210	Menarche (age at onset)	""	6e-09	DLK1	Perry JR	2014-07-23	25231870
rs12881545:101176212:G:C	14	101176212	0.654926	557	ref1: TG phase3 v5	rs1555405	rs1555405	Platelet count	""	9e-33	intergenic	Astle WJ	2016-11-17	27863252
rs12881545:101176212:G:C	14	101176212	0.546253	22140	ref1: TG phase3 v5	rs4905994	rs4905994	Magnesium levels	""	4e-06	NR	Chang X	2015-04-17	25886283
rs12881545:101176212:G:C	14	101176212	0.546253	22140	ref1: TG phase3 v5	rs4905994	rs4905994	Magnesium levels	(EA)	7e-06	NR	Chang X	2015-04-17	25886283
rs12881545:101176212:G:C	14	101176212	0.482354	16796	ref1: TG phase3 v5	rs7149242	rs7149242	Platelet count	""	3e-08	C14orf70, DLK1	Gieger C	2011-11-30	22139419
rs118122626:101201630:C:T	14	101201630			LD kl min R2									
rs2104071:101215409:A:G	14	101215409			LD kl min R2									
rs72698743:101215540:G:A	14	101215540			LD kl min R2									
rs8017361:101218652:G:A	14	101218652			LD kl min R2									
rs11625568:101230886:A:G	14	101230886			LD kl min R2									
rs76006621:101235455:C:T	14	101235455			LD kl min R2									
rs187787744:101239264:A:T	14	101239264			LD kl min R2									
rs35937723:101248038:T:TA	14	101248038	0.803535	3951	ref1: TG phase3 v5	rs1884537	rs1884537	Optic nerve measurement (disc area)	""	2e-06	MEG3	Macgregor S	2010-04-15	20395239
rs17236115:90164910:C:G	15	90164910			LD kl min R2									
rs72750756:90195536:G:C	15	90195536			LD kl min R2									
rs12905150:90221576:G:A	15	90221576			LD kl min R2									
rs11073885:90232730:C:A	15	90232730			LD kl min R2									
rs78155399:90264358:C:T	15	90264358			LD kl min R2									
rs79781638:90269505:T:C	15	90269505			LD kl min R2									
rs112424763:90308415:G:A	15	90308415			LD kl min R2									
rs62024162:90309154:C:A	15	90309154			LD kl min R2									
rs28698386:90327226:C:T	15	90327226			LD kl min R2									
rs8030846:90330530:C:A	15	90330530			LD kl min R2									
rs2007084:90345335:G:A	15	90345335	1	0	ref1: TG phase3 v5	rs2007084	rs2007084	Blood metabolite levels	(HWESASXX)	2e-12	ANPEP	Shin SY	2014-05-11	24816252
rs17240240:90347783:C:T	15	90347783	0.841101	2448	ref1: TG phase3 v5	rs2007084	rs2007084	Blood metabolite levels	(HWESASXX)	2e-12	ANPEP	Shin SY	2014-05-11	24816252
rs11637384:90363099:C:T	15	90363099	0.357979	84847	ref1: TG phase3 v5	rs7178909	rs7178909	Common traits (Other)	(optimism)	5e-07	NR	Eriksson N	2010-06-24	20585627
rs9920762:90368171:T:C	15	90368171	0.954523	6086	ref1: TG phase3 v5	rs2028299	rs2028299	Type 2 diabetes	""	5e-07	AP3S2	Mahajan A	2014-02-09	24509480
rs9920762:90368171:T:C	15	90368171	0.954523	6086	ref1: TG phase3 v5	rs2028299	rs2028299	Type 2 diabetes	""	2e-11	AP3S2	Kooner JS	2011-08-28	21874001
rs9920762:90368171:T:C	15	90368171	0.954523	6086	ref1: TG phase3 v5	rs2028299	rs2028299	Type 2 diabetes	""	3e-06	AP3S2	Hara K	2013-08-14	23945395
rs9920762:90368171:T:C	15	90368171	0.885049	60723	ref1: TG phase3 v5	rs10852123	rs10852123	Type 2 diabetes	""	8e-13	AP3S2	Spracklen CN	2020-05-06	32499647
rs7183842:90400030:G:A	15	90400030	0.944186	25773	ref1: TG phase3 v5	rs2028299	rs2028299	Type 2 diabetes	""	5e-07	AP3S2	Mahajan A	2014-02-09	24509480
rs7183842:90400030:G:A	15	90400030	0.944186	25773	ref1: TG phase3 v5	rs2028299	rs2028299	Type 2 diabetes	""	2e-11	AP3S2	Kooner JS	2011-08-28	21874001
rs7183842:90400030:G:A	15	90400030	0.944186	25773	ref1: TG phase3 v5	rs2028299	rs2028299	Type 2 diabetes	""	3e-06	AP3S2	Hara K	2013-08-14	23945395
rs7183842:90400030:G:A	15	90400030	0.914613	28864	ref1: TG phase3 v5	rs10852123	rs10852123	Type 2 diabetes	""	8e-13	AP3S2	Spracklen CN	2020-05-06	32499647
rs55736028:90409418:C:T	15	90409418	0.383369	38528	ref1: TG phase3 v5	rs7178909	rs7178909	Common traits (Other)	(optimism)	5e-07	NR	Eriksson N	2010-06-24	20585627
rs376625010:90455079:GAC:G	15	90455079			LD kl min R2									
rs6496617:90579578:T:C	15	90579578			LD kl min R2									
rs16956504:66432381:T:C	16	66432381			LD kl min R2									
rs56749851:4478174:T:TC	17	4478174			LD kl min R2									
rs77627231:4551122:C:T	17	4551122			LD kl min R2									
rs72824951:4588500:G:C	17	4588500	0.711165	37392	ref1: TG phase3 v5	rs35186877	rs35186877	Blood protein levels in cardiovascular risk	""	3e-13	CXCL16	Folkersen L	2017-04-03	28369058
rs2304970:4642787:C:A	17	4642787			LD kl min R2									
rs12451720:4646480:C:T	17	4646480			LD kl min R2									
rs8080014:4671566:T:C	17	4671566	0.354662	13662	ref1: TG phase3 v5	rs34460487	rs34460487	Blood protein levels	(Glycolipid transfer protein domain-containing protein 2, GLTPD2.7948.129.3)	7e-25	GLTPD2	Sun BB	2018-06-06	29875488
rs7224718:4672763:C:T	17	4672763			LD kl min R2									
rs2617864:28078558:A:C	17	28078558			LD kl min R2									
rs143794512:28092924:G:A	17	28092924			LD kl min R2									
rs9905634:28157002:T:C	17	28157002			LD kl min R2									
rs139373365:28158277:AC:A	17	28158277			LD kl min R2									
rs4795524:28320248:T:A	17	28320248			LD kl min R2									
rs35421305:28371588:G:A	17	28371588			LD kl min R2									
rs9900546:28380655:G:T	17	28380655			LD kl min R2									
rs4436830:28383709:A:G	17	28383709	0.624312	29420	ref1: TG phase3 v5	rs8080772	rs8080772	Brain region volumes	(right precuneus)	6e-10	NR	Zhao B	2019-11-01	31676860
rs4436830:28383709:A:G	17	28383709	0.624312	29420	ref1: TG phase3 v5	rs8080772	rs8080772	Chronic obstructive pulmonary disease	""	1e-08	EFCAB5	Sakornsakolpat P	2019-02-25	30804561
rs4436830:28383709:A:G	17	28383709	0.301252	70716	ref1: TG phase3 v5	rs55866125	rs55866125	PR interval	""	3e-11	EFCAB5	Ntalla I	2020-05-21	32439900
rs4436830:28383709:A:G	17	28383709	0.301252	87382	ref1: TG phase3 v5	rs9897794	rs9897794	Hemoglobin levels	""	3e-08	EFCAB5	Oskarsson GR	2020-04-23	32327693
rs144773328:28409827:G:A	17	28409827			LD kl min R2									
17:28429406:A:G	17	28429406			LD kl min R2									
rs138099271:28434389:AAC:A	17	28434389			LD kl min R2									
rs6355:28548810:C:G	17	28548810			LD kl min R2									
rs117390397:28561092:A:T	17	28561092			LD kl min R2									
rs25533:28562892:A:G	17	28562892			LD kl min R2									
rs59701878:28569375:C:CCTCACCCTTGACGTCT	17	28569375	0.59439	113078	ref1: TG phase3 v5	rs9916613	rs9916613	Apolipoprotein A1 levels	""	3e-17	TMIGD1	Richardson TG	2020-03-23	32203549
rs7214248:28574177:G:A	17	28574177	0.456426	108276	ref1: TG phase3 v5	rs9916613	rs9916613	Apolipoprotein A1 levels	""	3e-17	TMIGD1	Richardson TG	2020-03-23	32203549
rs7214248:28574177:G:A	17	28574177	0.304164	42919	ref1: TG phase3 v5	rs3794809	rs3794809	PR interval	""	3e-11	EFCAB5	Ntalla I	2020-05-21	32439900
rs2129785:28590530:T:C	17	28590530			LD kl min R2									
rs11871567:28642141:C:T	17	28642141	0.610976	330196	ref1: TG phase3 v5	rs141020954	rs141020954	General cognitive ability	""	3e-06	NR	Davies G	2018-05-29	29844566
rs140849286:28644743:A:G	17	28644743			LD kl min R2									
rs146631372:28671514:A:AT	17	28671514	0.372945	719157	ref1: TG phase3 v5	rs60642411	rs60642411	Worry	""	5e-08	NR	Nagel M	2018-06-25	29942085
rs7221691:28723619:C:T	17	28723619	0.318271	539154	ref1: TG phase3 v5	rs7208859	rs7208859	Mean corpuscular volume	""	1e-19	ADAP2	Astle WJ	2016-11-17	27863252
rs142292749:28733862:T:G	17	28733862	0.351869	656809	ref1: TG phase3 v5	rs60642411	rs60642411	Worry	""	5e-08	NR	Nagel M	2018-06-25	29942085
rs141167135:28736104:A:C	17	28736104			LD kl min R2									
rs117173344:28801401:C:T	17	28801401			LD kl min R2									
rs180988152:28806662:G:A	17	28806662			LD kl min R2									
rs139342538:28846791:C:T	17	28846791			LD kl min R2									
rs78190160:28847605:C:T	17	28847605			LD kl min R2									
rs72809843:28861134:A:G	17	28861134	0.307086	529537	ref1: TG phase3 v5	rs60642411	rs60642411	Worry	""	5e-08	NR	Nagel M	2018-06-25	29942085
rs17669329:28869877:T:C	17	28869877	0.33032	29737	ref1: TG phase3 v5	rs17669584	rs17669584	Insomnia symptoms (never/rarely vs. usually)	""	5e-08	LOC729704	Lane JM	2019-02-25	30804566
rs17669329:28869877:T:C	17	28869877	0.33032	29737	ref1: TG phase3 v5	rs17669584	rs17669584	Insomnia symptoms (never/rarely vs. sometimes/usually)	""	4e-08	LOC729704	Lane JM	2019-02-25	30804566
rs201566030:28888825:A:G	17	28888825	0.495867	10789	ref1: TG phase3 v5	rs17669584	rs17669584	Insomnia symptoms (never/rarely vs. usually)	""	5e-08	LOC729704	Lane JM	2019-02-25	30804566
rs201566030:28888825:A:G	17	28888825	0.495867	10789	ref1: TG phase3 v5	rs17669584	rs17669584	Insomnia symptoms (never/rarely vs. sometimes/usually)	""	4e-08	LOC729704	Lane JM	2019-02-25	30804566
rs201566030:28888825:A:G	17	28888825	0.329322	206372	ref1: TG phase3 v5	rs9916613	rs9916613	Apolipoprotein A1 levels	""	3e-17	TMIGD1	Richardson TG	2020-03-23	32203549
rs148291572:28978168:C:T	17	28978168	0.496327	78554	ref1: TG phase3 v5	rs17669584	rs17669584	Insomnia symptoms (never/rarely vs. usually)	""	5e-08	LOC729704	Lane JM	2019-02-25	30804566
rs148291572:28978168:C:T	17	28978168	0.496327	78554	ref1: TG phase3 v5	rs17669584	rs17669584	Insomnia symptoms (never/rarely vs. sometimes/usually)	""	4e-08	LOC729704	Lane JM	2019-02-25	30804566
rs62078152:33813786:T:C	17	33813786			LD kl min R2									
rs60487474:33823391:T:C	17	33823391	0.418282	20121	ref1: TG phase3 v5	rs8070473	rs8070473	Depression (quantitative trait)	""	2e-06	SLFN12L	Terracciano A	2010-08-25	20800221
rs41324748:33825403:A:G	17	33825403			LD kl min R2									
rs35042707:33861639:G:A	17	33861639			LD kl min R2									
rs11654357:33867369:A:C	17	33867369	0.609301	22714	ref1: TG phase3 v5	rs9908158	rs9908158	Platelet count	""	4e-16	RP11-1094M14.14, SLFN14, RP11-1094M14.1	Astle WJ	2016-11-17	27863252
rs11654357:33867369:A:C	17	33867369	0.571473	24699	ref1: TG phase3 v5	rs2840044	rs2840044	Response to radiotherapy in cancer (late toxicity)	(Breast cancer, overal toxicity, multivariable analysis)	8e-06	SLFN14	Barnett GC	2014-04-28	24785509
rs11654357:33867369:A:C	17	33867369	0.457623	7893	ref1: TG phase3 v5	rs8073060	rs8073060	Platelet count	""	9e-14	SLFN14	Astle WJ	2016-11-17	27863252
rs116169465:33881017:T:C	17	33881017			LD kl min R2									
rs16971207:33941744:A:T	17	33941744			LD kl min R2									
rs112098280:34057413:A:G	17	34057413			LD kl min R2									
rs117253863:34067786:G:C	17	34067786			LD kl min R2									
rs117695737:34070289:C:T	17	34070289	0.805609	4386	ref1: TG phase3 v5	rs73990293	rs73990293	Clopidogrel active metabolite levels	""	7e-07	NR	Backman JD	2017-04-01	28207573
rs145033564:34091340:G:C	17	34091340			LD kl min R2									
rs117940183:34101375:G:A	17	34101375			LD kl min R2									
rs4796107:34102775:G:A	17	34102775			LD kl min R2									
rs4795088:34113210:G:A	17	34113210			LD kl min R2									
rs147259602:34125172:G:A	17	34125172			LD kl min R2									
rs12453047:34130013:T:C	17	34130013			LD kl min R2									
rs62078172:34134560:G:A	17	34134560			LD kl min R2									
rs76610863:34139854:G:A	17	34139854			LD kl min R2									
rs4251726:34144511:G:A	17	34144511			LD kl min R2									
rs4293433:34157655:A:G	17	34157655			LD kl min R2									
rs3817655:34199641:A:T	17	34199641			LD kl min R2									
rs1800825:34207486:A:G	17	34207486			LD kl min R2									
rs4239253:34208190:C:T	17	34208190			LD kl min R2									
rs74939478:34283306:T:C	17	34283306			LD kl min R2									
rs60764079:34287643:T:A	17	34287643			LD kl min R2									
rs854649:34293866:A:C	17	34293866			LD kl min R2									
rs1635281:34296012:A:G	17	34296012			LD kl min R2									
rs1635282:34296059:G:A	17	34296059			LD kl min R2									
rs1719189:34296925:T:C	17	34296925			LD kl min R2									
rs1734968:34302127:C:T	17	34302127			LD kl min R2									
rs80329614:34303312:T:C	17	34303312	0.985415	1852	ref1: TG phase3 v5	rs11080369	rs11080369	Protein levels in obesity	(HCC-4)	2e-30	NR	Carayol J	2017-12-12	29234017
rs80329614:34303312:T:C	17	34303312	0.985415	1852	ref1: TG phase3 v5	rs11080369	rs11080369	Blood protein levels	(HGF)	2e-06	NR	Sun W	2016-08-17	27532455
rs80329614:34303312:T:C	17	34303312	0.985415	1852	ref1: TG phase3 v5	rs11080369	rs11080369	Blood protein levels	(CCL16)	8e-68	NR	Sun W	2016-08-17	27532455
rs150951362:34304264:G:A	17	34304264	0.813514	900	ref1: TG phase3 v5	rs11080369	rs11080369	Protein levels in obesity	(HCC-4)	2e-30	NR	Carayol J	2017-12-12	29234017
rs150951362:34304264:G:A	17	34304264	0.813514	900	ref1: TG phase3 v5	rs11080369	rs11080369	Blood protein levels	(HGF)	2e-06	NR	Sun W	2016-08-17	27532455
rs150951362:34304264:G:A	17	34304264	0.813514	900	ref1: TG phase3 v5	rs11080369	rs11080369	Blood protein levels	(CCL16)	8e-68	NR	Sun W	2016-08-17	27532455
rs10445391:34306106:A:G	17	34306106	0.69951	942	ref1: TG phase3 v5	rs11080369	rs11080369	Protein levels in obesity	(HCC-4)	2e-30	NR	Carayol J	2017-12-12	29234017
rs10445391:34306106:A:G	17	34306106	0.69951	942	ref1: TG phase3 v5	rs11080369	rs11080369	Blood protein levels	(HGF)	2e-06	NR	Sun W	2016-08-17	27532455
rs10445391:34306106:A:G	17	34306106	0.69951	942	ref1: TG phase3 v5	rs11080369	rs11080369	Blood protein levels	(CCL16)	8e-68	NR	Sun W	2016-08-17	27532455
rs12953144:34318759:C:G	17	34318759	0.355135	7456	ref1: TG phase3 v5	rs712048	rs712048	Blood protein levels	(Ck-beta-8-1, CCL23.3028.36.2)	2e-94	CCL23	Sun BB	2018-06-06	29875488
rs854686:34319442:T:C	17	34319442	0.823835	19441	ref1: TG phase3 v5	rs1617208	rs1617208	Blood protein levels	(CCL23)	6e-29	NR	Sun W	2016-08-17	27532455
rs854686:34319442:T:C	17	34319442	0.503676	6773	ref1: TG phase3 v5	rs712048	rs712048	Blood protein levels	(Ck-beta-8-1, CCL23.3028.36.2)	2e-94	CCL23	Sun BB	2018-06-06	29875488
rs34571766:34321162:GT:G	17	34321162	0.44025	5053	ref1: TG phase3 v5	rs712048	rs712048	Blood protein levels	(Ck-beta-8-1, CCL23.3028.36.2)	2e-94	CCL23	Sun BB	2018-06-06	29875488
rs2075746:34325532:T:C	17	34325532			LD kl min R2									
rs41436444:34328646:CAGGGCAG:C	17	34328646	0.532026	185	ref1: TG phase3 v5	rs854625	rs854625	CCL23 levels	""	6e-15	NR	Hillary RF	2020-07-08	32641083
rs41436444:34328646:CAGGGCAG:C	17	34328646	0.477112	2431	ref1: TG phase3 v5	rs712048	rs712048	Blood protein levels	(Ck-beta-8-1, CCL23.3028.36.2)	2e-94	CCL23	Sun BB	2018-06-06	29875488
rs41436444:34328646:CAGGGCAG:C	17	34328646	0.307547	10237	ref2: TG phase1 v3	rs1617208	rs1617208	Blood protein levels	(CCL23)	6e-29	NR	Sun W	2016-08-17	27532455
rs7209212:34329227:A:T	17	34329227	0.408543	3012	ref1: TG phase3 v5	rs712048	rs712048	Blood protein levels	(Ck-beta-8-1, CCL23.3028.36.2)	2e-94	CCL23	Sun BB	2018-06-06	29875488
rs7209212:34329227:A:T	17	34329227	0.347755	766	ref1: TG phase3 v5	rs854625	rs854625	CCL23 levels	""	6e-15	NR	Hillary RF	2020-07-08	32641083
rs7222922:34335694:C:T	17	34335694	0.581341	3189	ref1: TG phase3 v5	rs1617208	rs1617208	Blood protein levels	(CCL23)	6e-29	NR	Sun W	2016-08-17	27532455
rs7222922:34335694:C:T	17	34335694	0.532685	23113	ref1: TG phase3 v5	rs72830000	rs72830000	Blood protein levels	(C-C motif chemokine 23, CCL23.2913.1.2)	1e-89	CCL23	Sun BB	2018-06-06	29875488
rs1005107:34340592:C:T	17	34340592			LD kl min R2									
rs11657605:34340834:G:A	17	34340834			LD kl min R2									
rs7222703:34341195:A:G	17	34341195	0.744133	2312	ref1: TG phase3 v5	rs1617208	rs1617208	Blood protein levels	(CCL23)	6e-29	NR	Sun W	2016-08-17	27532455
rs7222703:34341195:A:G	17	34341195	0.407912	28614	ref1: TG phase3 v5	rs72830000	rs72830000	Blood protein levels	(C-C motif chemokine 23, CCL23.2913.1.2)	1e-89	CCL23	Sun BB	2018-06-06	29875488
rs117230744:34341558:A:G	17	34341558			LD kl min R2									
rs6505500:34346783:C:A	17	34346783	0.737604	7900	ref1: TG phase3 v5	rs1617208	rs1617208	Blood protein levels	(CCL23)	6e-29	NR	Sun W	2016-08-17	27532455
rs6505500:34346783:C:A	17	34346783	0.404979	34202	ref1: TG phase3 v5	rs72830000	rs72830000	Blood protein levels	(C-C motif chemokine 23, CCL23.2913.1.2)	1e-89	CCL23	Sun BB	2018-06-06	29875488
rs12603273:34352415:C:T	17	34352415			LD kl min R2									
rs77867003:34352836:A:T	17	34352836			LD kl min R2									
rs12951688:34353992:A:G	17	34353992			LD kl min R2									
rs117759380:34357194:A:G	17	34357194			LD kl min R2									
rs2735835:34393296:A:G	17	34393296			LD kl min R2									
rs1634492:34411839:A:C	17	34411839			LD kl min R2									
rs1634506:34425363:T:C	17	34425363			LD kl min R2									
rs4795108:34442887:A:G	17	34442887	0.455569	28251	ref1: TG phase3 v5	rs2188974	rs2188974	Blood protein levels in cardiovascular risk	""	8e-35	CCL3	Folkersen L	2017-04-03	28369058
rs112119017:34443446:T:C	17	34443446			LD kl min R2									
rs17617750:34445545:C:T	17	34445545			LD kl min R2									
rs118052308:34824886:C:T	17	34824886			LD kl min R2									
rs2277662:34849697:C:G	17	34849697	0.34188	29947	ref1: TG phase3 v5	rs8064426	rs8064426	Blood protein levels	(CCL4)	7e-15	NR	Sun W	2016-08-17	27532455
rs2277662:34849697:C:G	17	34849697	0.31408	30561	ref2: TG phase1 v3	rs6607368	rs6607368	Blood protein levels in cardiovascular risk	""	2e-47	CCL4	Folkersen L	2017-04-03	28369058
rs117017546:42000044:C:A	17	42000044			LD kl min R2									
rs5848:42430244:C:T	17	42430244	0.613724	12100	ref1: TG phase3 v5	rs708382	rs708382	Platelet count	""	2e-08	FAM171A2, ITGA2B	Gieger C	2011-11-30	22139419
rs936018:42475962:A:C	17	42475962			LD kl min R2									
rs117964596:42541156:T:C	17	42541156	0.531686	344692	ref1: TG phase3 v5	rs79343067	rs79343067	Rate of cognitive decline in Alzheimer's disease	(GEE model)	4e-06	NR	Sherva R	2020-06-23	32573913
rs117964596:42541156:T:C	17	42541156	0.497991	197455	ref1: TG phase3 v5	rs45445495	rs45445495	Appendicular lean mass	""	1e-08	NR	Hernandez Cordero AI	2019-11-21	31761296
17:42605605:C:T	17	42605605	0.921197	10850	ref1: TG phase3 v5	rs150568286	rs150568286	Platelet count	""	4e-18	intergenic	Astle WJ	2016-11-17	27863252
rs34721364:42628735:C:T	17	42628735			LD kl min R2									
rs11373641:42637733:C:CA	17	42637733			LD kl min R2									
rs56240010:42656954:G:GTTTA	17	42656954			LD kl min R2									
rs2231650:42927723:G:A	17	42927723			LD kl min R2									
rs11656659:55847884:G:A	17	55847884			LD kl min R2									
rs12953049:56046783:G:A	17	56046783			LD kl min R2									
rs9892354:56228795:G:A	17	56228795			LD kl min R2									
rs1075009:56230863:A:G	17	56230863			LD kl min R2									
rs34523089:56436109:C:T	17	56436109	1	0	ref1: TG phase3 v5	rs34523089	rs34523089	Mean corpuscular volume	""	2e-11	RNF43	Astle WJ	2016-11-17	27863252
rs34523089:56436109:C:T	17	56436109	1	0	ref1: TG phase3 v5	rs34523089	rs34523089	Hemoglobin levels	""	2e-10	RNF43	Oskarsson GR	2020-04-23	32327693
rs150454583:56669751:A:G	17	56669751	0.721133	311322	ref1: TG phase3 v5	rs34097845	rs34097845	Blood protein levels	(Myeloperoxidase, MPO.2580.83.2)	9e-31	MPO	Sun BB	2018-06-06	29875488
rs142735413:56772612:T:TGTACTATCG	17	56772612			LD kl min R2									
rs3745368:7735297:G:A	19	7735297	0.60012	1621	ref1: TG phase3 v5	rs34124816	rs34124816	Blood protein levels	(Resistin, RETN.3046.31.1)	4e-21	RETN	Sun BB	2018-06-06	29875488
rs143343619:11427632:G:A	19	11427632			LD kl min R2									
rs11085784:11647141:C:T	19	11647141			LD kl min R2									
rs10417525:11662542:C:G	19	11662542			LD kl min R2									
rs11881637:11670232:G:A	19	11670232			LD kl min R2									
rs2229531:11687195:C:T	19	11687195			LD kl min R2									
rs2071485:11688200:G:A	19	11688200			LD kl min R2									
rs149147675:11690676:T:C	19	11690676			LD kl min R2									
rs79320712:11696949:G:A	19	11696949	0.497252	37677	ref1: TG phase3 v5	rs187568415	rs187568415	3-hydroxypropylmercapturic acid levels in smokers	(Japanese)	2e-08	NR	Park SL	2015-06-08	26053186
rs10409242:11706373:T:C	19	11706373			LD kl min R2									
rs4804617:11739548:C:T	19	11739548			LD kl min R2									
rs412088:11812009:A:G	19	11812009			LD kl min R2									
rs9749384:11834721:T:C	19	11834721			LD kl min R2									
rs74181615:11944989:T:A	19	11944989			LD kl min R2									
rs8103160:15238415:G:T	19	15238415			LD kl min R2									
rs57419676:18487479:C:T	19	18487479			LD kl min R2									
rs12979706:18495424:G:A	19	18495424			LD kl min R2									
rs2303040:39138608:T:C	19	39138608	0.945572	49504	ref1: TG phase3 v5	rs11083475	rs11083475	Heart rate	""	2e-06	ACTN4	den Hoed M	2013-04-14	23583979
rs146861953:39176299:A:G	19	39176299			LD kl min R2									
rs13343794:39179271:G:A	19	39179271	0.980332	8841	ref1: TG phase3 v5	rs11083475	rs11083475	Heart rate	""	2e-06	ACTN4	den Hoed M	2013-04-14	23583979
rs28593196:41632107:G:A	19	41632107			LD kl min R2									
rs186373920:41643515:G:A	19	41643515			LD kl min R2									
rs116841703:41663711:A:T	19	41663711			LD kl min R2									
rs12984631:41718575:G:T	19	41718575	0.709768	5312	ref1: TG phase3 v5	rs8101017	rs8101017	Blood protein levels	(AXL)	5e-07	NR	Sun W	2016-08-17	27532455
rs12984631:41718575:G:T	19	41718575	0.698997	6310	ref1: TG phase3 v5	rs28364580	rs28364580	Heel bone mineral density	""	9e-30	AXL	Morris JA	2018-12-31	30598549
rs12984631:41718575:G:T	19	41718575	0.698997	6310	ref1: TG phase3 v5	rs28364580	rs28364580	Heel bone mineral density	""	7e-23	""	Kichaev G	2018-12-27	30595370
rs8107802:41722613:A:G	19	41722613	0.994513	1274	ref1: TG phase3 v5	rs8101017	rs8101017	Blood protein levels	(AXL)	5e-07	NR	Sun W	2016-08-17	27532455
rs8107802:41722613:A:G	19	41722613	0.978296	2272	ref1: TG phase3 v5	rs28364580	rs28364580	Heel bone mineral density	""	9e-30	AXL	Morris JA	2018-12-31	30598549
rs8107802:41722613:A:G	19	41722613	0.978296	2272	ref1: TG phase3 v5	rs28364580	rs28364580	Heel bone mineral density	""	7e-23	""	Kichaev G	2018-12-27	30595370
rs66841352:41739180:G:C	19	41739180	0.700081	5121	ref1: TG phase3 v5	rs4802111	rs4802111	Heel bone mineral density	""	1e-21	AXL	Morris JA	2018-12-31	30598549
rs7256873:41742308:G:A	19	41742308	0.312573	8249	ref1: TG phase3 v5	rs4802111	rs4802111	Heel bone mineral density	""	1e-21	AXL	Morris JA	2018-12-31	30598549
rs12972779:41752127:C:A	19	41752127	0.312707	18068	ref1: TG phase3 v5	rs4802111	rs4802111	Heel bone mineral density	""	1e-21	AXL	Morris JA	2018-12-31	30598549
rs3213315:44066858:C:T	19	44066858			LD kl min R2									
rs79528728:44093789:T:C	19	44093789			LD kl min R2									
rs73038875:44142882:T:C	19	44142882			LD kl min R2									
rs346055:44203408:T:A	19	44203408			LD kl min R2									
rs2072563:46526648:G:A	19	46526648			LD kl min R2									
rs12982683:46534284:G:A	19	46534284			LD kl min R2									
rs11667193:46682663:A:G	19	46682663			LD kl min R2									
rs8106623:46813461:A:G	19	46813461			LD kl min R2									
rs76811578:55058135:G:A	19	55058135			LD kl min R2									
rs775902:55496995:A:G	19	55496995			LD kl min R2									
rs1613662:55536595:G:A	19	55536595	0.837084	10250	ref1: TG phase3 v5	rs1671152	rs1671152	Platelet aggregation	(collagen)	8e-14	GP6	Johnson AD	2010-06-06	20526338
rs12609715:55545139:A:G	19	55545139			LD kl min R2									
rs1671169:55573633:G:A	19	55573633			LD kl min R2									
rs2384692:55806445:C:T	19	55806445			LD kl min R2									
rs78022814:1428407:T:G	20	1428407			LD kl min R2									
rs2263653:1507608:A:T	20	1507608			LD kl min R2									
rs11474004:1510966:C:CTA	20	1510966			LD kl min R2									
rs140285112:1538279:T:A	20	1538279			LD kl min R2									
rs16995228:1545857:C:T	20	1545857			LD kl min R2									
rs41297640:1551564:T:C	20	1551564			LD kl min R2									
rs2746603:1559259:C:T	20	1559259			LD kl min R2									
rs73080723:1594702:T:C	20	1594702			LD kl min R2									
rs2209313:1599142:C:T	20	1599142			LD kl min R2									
rs2224878:1602704:T:C	20	1602704			LD kl min R2									
rs6105433:1608108:T:G	20	1608108			LD kl min R2									
rs112927380:1608630:G:A	20	1608630			LD kl min R2									
rs2281808:1610551:T:C	20	1610551	1	0	ref1: TG phase3 v5	rs2281808	rs2281808	Type 1 diabetes	""	1e-11	intergenic	Barrett JC	2009-05-10	19430480
rs2147336:1612279:G:A	20	1612279	0.985759	1728	ref1: TG phase3 v5	rs2281808	rs2281808	Type 1 diabetes	""	1e-11	intergenic	Barrett JC	2009-05-10	19430480
rs117314329:1624913:G:A	20	1624913	0.464004	59739	ref1: TG phase3 v5	rs1595459	rs1595459	Adolescent idiopathic scoliosis	""	6e-07	NR	Liu J	2018-07-17	30019117
rs11696836:1630860:C:T	20	1630860	0.875411	18942	ref1: TG phase3 v5	rs56040592	rs56040592	Intracranial aneurysm	(French Canadians)	2e-06	SIRPG	Zhou S	2018-03-12	29531279
rs11696836:1630860:C:T	20	1630860	0.355529	53792	ref1: TG phase3 v5	rs1595459	rs1595459	Adolescent idiopathic scoliosis	""	6e-07	NR	Liu J	2018-07-17	30019117
rs117366411:1643254:C:T	20	1643254			LD kl min R2									
rs2023563:1652664:A:G	20	1652664			LD kl min R2									
rs117460513:1658662:A:G	20	1658662			LD kl min R2									
rs202522:1674490:A:G	20	1674490			LD kl min R2									
rs11699191:1692185:C:A	20	1692185	0.752248	80267	ref1: TG phase3 v5	rs56040592	rs56040592	Intracranial aneurysm	(French Canadians)	2e-06	SIRPG	Zhou S	2018-03-12	29531279
rs11699191:1692185:C:A	20	1692185	0.440422	7533	ref1: TG phase3 v5	rs1595459	rs1595459	Adolescent idiopathic scoliosis	""	6e-07	NR	Liu J	2018-07-17	30019117
rs4814498:1698013:G:A	20	1698013			LD kl min R2									
rs202470:1719557:G:C	20	1719557			LD kl min R2									
rs73077378:1734358:G:A	20	1734358			LD kl min R2									
rs142300341:1735223:G:C	20	1735223			LD kl min R2									
rs200873:1782667:C:T	20	1782667			LD kl min R2									
rs200889:1794342:G:A	20	1794342			LD kl min R2									
rs200888:1796461:G:T	20	1796461			LD kl min R2									
rs6044870:1806234:C:A	20	1806234			LD kl min R2									
rs148541653:1817507:G:A	20	1817507			LD kl min R2									
rs156357:1819295:C:T	20	1819295			LD kl min R2									
rs635290:1841245:G:A	20	1841245			LD kl min R2									
rs59679691:1850876:T:C	20	1850876			LD kl min R2									
rs272902:1858019:G:C	20	1858019			LD kl min R2									
rs6105870:1861230:T:A	20	1861230			LD kl min R2									
rs6136317:1870069:G:A	20	1870069	0.315105	3424	ref1: TG phase3 v5	rs6111858	rs6111858	Metabolite levels	(UDP glucose; UDP galactose)	5e-06	PDYN	Rhee EP	2013-07-02	23823483
rs6136322:1870755:T:C	20	1870755	0.316608	4110	ref2: TG phase1 v3	rs6111858	rs6111858	Metabolite levels	(UDP glucose; UDP galactose)	5e-06	PDYN	Rhee EP	2013-07-02	23823483
rs6034990:1872088:T:C	20	1872088			LD kl min R2									
rs6075314:1883939:T:C	20	1883939			LD kl min R2									
rs6075316:1884126:C:A	20	1884126			LD kl min R2									
rs59317774:1888865:A:G	20	1888865			LD kl min R2									
rs77892370:1891261:T:A	20	1891261			LD kl min R2									
rs28546378:1893570:G:A	20	1893570			LD kl min R2									
rs6045464:1907716:T:C	20	1907716			LD kl min R2									
rs75657737:1910094:C:A	20	1910094			LD kl min R2									
rs56901296:1910440:T:A	20	1910440			LD kl min R2									
rs141654671:1912065:AC:A	20	1912065			LD kl min R2									
rs144842110:1916456:G:A	20	1916456			LD kl min R2									
rs181600116:1918556:C:A	20	1918556			LD kl min R2									
rs6045554:1919427:T:C	20	1919427			LD kl min R2									
rs76551759:1929509:C:T	20	1929509			LD kl min R2									
rs6045677:1941488:A:G	20	1941488	0.46593	317	ref2: TG phase1 v3	rs6045676	rs6045676	Aortic root size	""	3e-08	PDYN, SIRPA	Wineinger NE	2011-01-11	21223598
rs869220:2033627:T:C	20	2033627			LD kl min R2									
rs181022566:2040402:G:A	20	2040402			LD kl min R2									
rs117706619:2040813:C:A	20	2040813			LD kl min R2									
rs77851109:2119246:C:T	20	2119246			LD kl min R2									
rs139522076:2162283:T:G	20	2162283			LD kl min R2									
rs726403:2206591:G:T	20	2206591			LD kl min R2									
rs76223888:43441307:C:T	20	43441307			LD kl min R2									
rs6124664:43470481:C:T	20	43470481			LD kl min R2									
rs112231070:43488505:T:A	20	43488505			LD kl min R2									
rs2425688:43551620:G:A	20	43551620			LD kl min R2									
rs75978388:43596712:G:A	20	43596712			LD kl min R2									
rs6017452:43604003:C:T	20	43604003	0.49142	65638	ref1: TG phase3 v5	rs6065777	rs6065777	Schizophrenia	""	2e-06	NR	Goes FS	2015-07-21	26198764
rs6017452:43604003:C:T	20	43604003	0.308563	117490	ref1: TG phase3 v5	rs6124684	rs6124684	Bipolar disorder	(NSM vs. Control)	9e-06	SERINC3	Lee HJ	2012-08-25	22925353
rs117850822:43689763:A:C	20	43689763			LD kl min R2									
rs62206429:43730333:A:G	20	43730333	0.957564	8786	ref1: TG phase3 v5	rs17422688	rs17422688	Eye color (hue)	""	2e-08	WFDC5	Adhikari K	2019-01-21	30664655
rs916311:43736533:T:G	20	43736533			LD kl min R2									
rs35227660:43756697:C:G	20	43756697	0.905829	17578	ref1: TG phase3 v5	rs17422688	rs17422688	Eye color (hue)	""	2e-08	WFDC5	Adhikari K	2019-01-21	30664655
rs41282752:43803606:G:A	20	43803606			LD kl min R2									
rs62208422:43808762:G:A	20	43808762			LD kl min R2									
rs140222503:43844653:G:A	20	43844653			LD kl min R2									
rs72432601:43937317:CTCTGG:C	20	43937317			LD kl min R2									
rs6073708:43952877:A:G	20	43952877			LD kl min R2									
rs720063:43953076:T:G	20	43953076			LD kl min R2									
rs2235224:43956527:G:A	20	43956527			LD kl min R2									
rs11469243:43988640:GGTA:G	20	43988640	0.437616	7914	ref1: TG phase3 v5	rs1008953	rs1008953	Psoriasis	""	1e-07	SDC4	Stuart PE	2010-10-17	20953189
rs6104154:44055963:G:A	20	44055963			LD kl min R2									
rs16990132:44057848:C:T	20	44057848			LD kl min R2									
rs2743294:44059501:A:G	20	44059501			LD kl min R2									
rs2272955:44184498:A:G	20	44184498			LD kl min R2									
rs62205622:44186027:G:A	20	44186027			LD kl min R2									
rs6065913:44635103:C:T	20	44635103	0.608418	3807	ref2: TG phase1 v3	rs8121146	rs8121146	Heel bone mineral density	""	3e-09	MMP9	Morris JA	2018-12-31	30598549
rs6065913:44635103:C:T	20	44635103	0.333916	4450	ref1: TG phase3 v5	rs6073984	rs6073984	Reaction time	""	2e-06	NR	Davies G	2018-05-29	29844566
rs35079426:43263742:G:A	21	43263742			LD kl min R2									
rs6586293:43438874:A:G	21	43438874			LD kl min R2									
rs117044715:43735183:A:G	21	43735183			LD kl min R2									
rs9978991:43781594:T:C	21	43781594	0.614509	2699	ref1: TG phase3 v5	rs1547374	rs1547374	Pancreatic cancer	""	4e-13	TFF1	Wu C	2011-12-11	22158540
rs2839493:43795697:G:A	21	43795697			LD kl min R2									
rs7275642:43799567:T:C	21	43799567			LD kl min R2									
rs9980705:44717291:T:A	21	44717291			LD kl min R2									
rs117616810:45027872:G:A	21	45027872			LD kl min R2									
rs77003306:45119034:C:T	21	45119034			LD kl min R2									
rs79268608:45128449:A:G	21	45128449			LD kl min R2									
rs114593958:45163714:T:G	21	45163714			LD kl min R2									
rs117331444:45198009:C:G	21	45198009			LD kl min R2									
rs35285321:45201832:G:A	21	45201832	1	0	ref1: TG phase3 v5	rs35285321	rs35285321	Blood protein levels in cardiovascular risk	""	8e-57	CSTB	Folkersen L	2017-04-03	28369058
rs35285321:45201832:G:A	21	45201832	0.666418	4523	ref1: TG phase3 v5	rs1041456	rs1041456	Blood protein levels	(CSTB)	2e-41	NR	Sun W	2016-08-17	27532455
rs139464933:45206041:G:A	21	45206041			LD kl min R2									
rs968578:45224328:T:C	21	45224328	0.312707	17973	ref1: TG phase3 v5	rs1041456	rs1041456	Blood protein levels	(CSTB)	2e-41	NR	Sun W	2016-08-17	27532455
rs75162335:45227150:T:G	21	45227150			LD kl min R2									
rs73224975:45230152:C:T	21	45230152			LD kl min R2									
rs79772272:45232514:C:T	21	45232514			LD kl min R2									
rs13046671:45248114:A:G	21	45248114			LD kl min R2									
rs13051408:45248455:C:T	21	45248455			LD kl min R2									
rs144976938:45261428:C:T	21	45261428			LD kl min R2									
rs189476900:45261761:C:A	21	45261761			LD kl min R2									
rs118167506:45267881:A:G	21	45267881			LD kl min R2									
rs2014085:45283214:T:C	21	45283214			LD kl min R2									
rs117184761:45326609:C:T	21	45326609			LD kl min R2									
rs14151:45406095:C:G	21	45406095	0.317254	1757	ref1: TG phase3 v5	rs7435	rs7435	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	""	2e-07	AGPAT3	Lemaitre RN	2011-07-28	21829377
rs7277731:45416486:C:T	21	45416486			LD kl min R2									
rs9984123:45515347:T:G	21	45515347			LD kl min R2									
rs9606012:17104369:T:C	22	17104369			LD kl min R2									
rs13056782:17130657:C:T	22	17130657			LD kl min R2									
rs2529893:17208726:C:T	22	17208726			LD kl min R2									
rs5994021:17282665:T:C	22	17282665			LD kl min R2									
rs2110438:17294042:C:T	22	17294042			LD kl min R2									
rs175147:17309362:G:T	22	17309362			LD kl min R2									
rs16981741:17309881:A:G	22	17309881			LD kl min R2									
rs5994048:17344949:C:G	22	17344949			LD kl min R2									
rs118103800:17419726:C:A	22	17419726			LD kl min R2									
rs118003938:17421074:T:C	22	17421074			LD kl min R2									
rs117511368:17424860:C:T	22	17424860			LD kl min R2									
rs5748765:17445502:A:C	22	17445502			LD kl min R2									
rs78175391:17472134:T:C	22	17472134			LD kl min R2									
rs5994129:17492203:G:A	22	17492203			LD kl min R2									
rs2192155:17492533:A:G	22	17492533			LD kl min R2									
rs62237429:17492987:G:T	22	17492987			LD kl min R2									
rs118145395:17508946:C:G	22	17508946			LD kl min R2									
rs5994143:17516126:G:C	22	17516126			LD kl min R2									
22:17528433:C:CTT	22	17528433			LD kl min R2									
rs145865055:17562831:T:C	22	17562831			LD kl min R2									
rs1990502:17573272:A:G	22	17573272			LD kl min R2									
rs2241047:17586583:C:G	22	17586583			LD kl min R2									
rs879576:17589246:G:A	22	17589246			LD kl min R2									
rs9606621:17603153:C:G	22	17603153			LD kl min R2									
rs5748883:17611515:T:C	22	17611515			LD kl min R2									
rs73149858:17632133:C:T	22	17632133			LD kl min R2									
rs113824702:17638316:T:C	22	17638316			LD kl min R2									
rs7287672:17640045:G:A	22	17640045			LD kl min R2									
rs113527030:17648717:CTG:C	22	17648717			LD kl min R2									
rs1544504:17670256:C:T	22	17670256			LD kl min R2									
rs5994195:17678667:G:A	22	17678667			LD kl min R2									
rs11704386:17685818:T:G	22	17685818			LD kl min R2									
rs362047:17687609:G:C	22	17687609			LD kl min R2									
rs150574678:17735346:G:A	22	17735346			LD kl min R2									
rs114035176:17735864:C:T	22	17735864			LD kl min R2									
rs16982258:17747195:A:C	22	17747195			LD kl min R2									
rs1989564:17995759:G:A	22	17995759			LD kl min R2									
